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Background: Despite a recent decline in the annual incidence of tuberculosis (TB) in the UK, rates remain
higher than in most Western European countries. The detection and treatment of latent TB infection (LTBI)
is an essential component of the UK TB control programme.
Objectives: To assess the prognostic value and cost-effectiveness of the current two interferon gamma
release assays (IGRAs) compared with the standard tuberculin skin test (TST) for predicting active TB
among untreated individuals at increased risk of TB: (1) contacts of active TB cases and (2) new entrants
to the UK from high-TB-burden countries.
Design: A prospective cohort study and economic analysis.
Participants and setting: Participants were recruited in TB clinics, general practices and community
settings. Contacts of active TB cases and migrants who were born in high-TB-burden countries arriving in
the UK were eligible to take part if they were aged ≥ 16 years.
Main outcome measures: Outcomes include incidence rate ratios comparing the incidence of active TB
in those participants with a positive test result and those with a negative test result for each assay, and
combination of tests and the cost per quality-adjusted life-year (QALY) for each screening strategy.
Results: A total of 10,045 participants were recruited between May 2010 and July 2015. Among 9610
evaluable participants, 97 (1.0%) developed active TB. For the primary analysis, all test data were available for
6380 participants, with 77 participants developing active TB. A positive result for TSTa (positive if induration is
≥ 5 mm) was a significantly poorer predictor of progression to active TB than a positive result for any of the
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other tests. Compared with TSTb [positive if induration is ≥ 6 mm without prior bacillus Calmette–Guérin
(BCG) alone, T-SPOT®.TB (Oxford Immunotec Ltd, Oxford, UK), TSTa + T-SPOT.TB, TSTa + IGRA and the three
combination strategies including TSTb were significantly superior predictors of progression. Compared with
the T-SPOT.TB test alone, TSTa + T-SPOT.TB, TSTb +QuantiFERON® TB Gold In-Tube (QFT-GIT; QIAGEN GmbH,
Hilden, Germany) and TSTb + IGRA were significantly superior predictors of progression and, compared with
QFT-GIT alone, T-SPOT.TB, TSTa + T-SPOT.TB, TSTa +QFT-GIT, TSTa + IGRA, TSTb + T-SPOT.TB, TSTb +QFT-GIT
and TSTb + IGRA were significantly superior predictors of progression. When evaluating the negative
predictive performance of tests and strategies, negative results for TSTa +QFT-GIT were significantly poorer
predictors of non-progression than negative results for TSTa, T-SPOT.TB and TSTa + IGRA. The most
cost-effective LTBI testing strategies are the dual-testing strategies. The cost and QALY differences between
the LTBI testing strategies were small; in particular, QFT-GIT, TSTb + T-SPOT.TB and TSTb +QFT-GIT had very
similar incremental net benefit estimates.
Conclusion: This study found modest differences between tests, or combinations of tests, in identifying
individuals who would go on to develop active TB. However, a two-step approach that combined TSTb
with an IGRA was the most cost-effective testing option.
Implications for practice and future research: The two-step TSTb strategy, which stratified the TST
by prior BCG vaccination followed by an IGRA, was the most cost-effective approach. The limited ability
of current tests to predict who will progress limits the clinical utility of tests. The implications of these
results for the NHS England/Public Health England national TB screening programme for migrants should
be investigated.
Study registration: This study is registered as NCT01162265.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
People can be infected with the bacteria that cause tuberculosis (TB) without having symptoms. Theyare then said to have latent TB infection (LTBI). For a small proportion of people, the bacteria can later
‘reactivate’ to cause TB disease. To avoid reactivation, people with LTBI may be offered treatment to clear
the infection before they become ill. Ideally, treatment would be given only to people who are at the
highest risk of progressing to active disease. However, at the moment, we cannot accurately predict
people’s risk of progressing.
This study was designed to determine how well new blood tests, called interferon gamma release assays
(IGRAs), can predict who will develop active TB compared with an older test [tuberculin skin test (TST)].
It also assessed how cost-effective the new tests are on their own or in combination with other tests.
The study recruited 6386 participants who had a test result for all three LTBI tests (the TST and two
different IGRAs), of whom 97 developed TB disease. When we compared the three different tests and
combinations of these tests, none appeared to be better than the others for predicting who would
develop TB disease. The approach with the best value from a health systems perspective is to combine the
skin test with either of the blood tests. However, there were only small differences in cost-effectiveness
between the different testing strategies.
This study concluded that no particular test or combination of tests was statistically superior to other
approaches at predicting who would develop TB disease. However, a two-step approach that combined
the skin test with either of the blood tests and took into account people’s previous vaccination against
TB provided the most benefit, taking into account the cost. Skin testing that did not account for previous
vaccination was worse than other test options.
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Scientific summary
Background
Although there has been a decline in the incidence of tuberculosis (TB) in the UK over the past few years,
rates remain higher than in most Western European countries. This study has investigated the predictive
values and cost-effectiveness of different combinations of the tuberculin skin test (TST) and two interferon
gamma release assays (IGRAs) in contacts (of people with TB) and new entrants to the UK.
Objectives
1. To assess the prognostic value of the two current IGRAs compared with the standard Mantoux test for
predicting active TB among untreated individuals at increased risk of latent TB infection (LTBI), among
contacts of active TB cases and among new entrants to the UK from high-TB-burden countries.
2. To assess the cost-effectiveness of various screening strategies [including the two-step approach
recommended by the National Institute for Health and Care Excellence (NICE)] using IGRAs and/or
TST in defined patient groups (contacts and new entrants to the UK stratified by age and risk).
Methods
A prospective cohort design was used to investigate the predictive value of the two commercial IGRAs and
the tuberculin Mantoux skin test. Participants were recruited in TB clinics, general practices and community
settings. Contacts of active TB cases, migrants who were born in high-TB-burden countries but had arrived
in the UK within the previous 5 years or those who had travelled frequently in the previous 5 years were
eligible to take part if they were aged ≥ 16 years. Outcomes include incidence rate ratios comparing the
incidence of active TB in those with a positive test result compared with those with a negative result for
each assay and combination of assays, positive and negative predictive values and cost per quality-adjusted
life-year (QALY) for each screening strategy.
Results
The study recruited 10,045 participants between May 2010 and July 2015. A total of 175 participants had
active TB at baseline (diagnosed or treated < 21 days after being recruited) and another 260 were treated
for LTBI, leaving 9610 evaluable participants, of whom 97 (1.0%) developed active TB. For the primary
analyses, data for the 6386 participants with all test data (including 77 participants who developed active TB)
were used.
A positive result for TSTa (a skin induration of ≥ 5 mm) was a significantly poorer predictor of progression
to active TB than positive results for all other tests. Compared with TSTb alone [positive if (1) there is a skin
induration of ≥ 6 mm following the standard TST and the participant was not known to have had a bacillus
Calmette–Guérin (BCG) vaccination or (2) there is a skin induration of ≥ 15mm for those known to have had
a BCG vaccination], T-SPOT®.TB (Oxford Immunotec Ltd, Oxford, UK), TSTa + T-SPOT.TB, TSTa + IGRA and the
three combination strategies including TSTb were significantly superior predictors of progression. Compared
with the T-SPOT.TB test alone, TSTa + T-SPOT.TB, TSTb +QuantiFERON® TB Gold In-Tube (QFT-GIT; Cellestis
International Pty Ltd, Chadstone, VIC, Australia) and TSTb + IGRA were significantly superior predictors of
progression and, compared with QFT-GIT alone, T-SPOT.TB, TSTa + T-SPOT.TB, TSTa +QFT-GIT, TSTa + IGRA,
TSTb + T-SPOT.TB, TSTb +QFT-GIT and TSTb + IGRA were significantly superior predictors of progression.
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When evaluating the negative predictive performance of tests and strategies, negative results for
TSTa + QFT-GIT were significantly poorer predictors of non-progression than negative results for TSTa,
T-SPOT.TB and TSTa + IGRA. Negative results for TSTb +QFT-GIT were significantly poorer predictors of
non-progression than negative results for TSTa, TSTb, T-SPOT.TB, TSTa + T-SPOT.TB, TSTa + IGRA, TSTb +
T-SPOT.TB and TSTb + IGRA, which all performed better.
The most cost-effective LTBI testing strategy is TSTb +QFT-GIT. However, the estimated cost and QALY
differences between the LTBI testing strategies were small, in particular QFT-GIT, TSTb + T-SPOT.TB and
TSTb + QFT-GIT gave very similar incremental net benefit estimates.
Conclusion
This study investigated the optimal screening strategy for LTBI, based on existing technologies. It did
not find evidence that any particular test or combination of tests was superior to other approaches in
identifying individuals who would go on to develop active TB. However, a two-step approach that
combined TSTb with an IGRA was the most cost-effective testing option.
Implications for health care
The current recommendation by NICE for contacts is to offer the Mantoux test using a 5-mm threshold
(the more cost-effective option), and consider IGRAs if TST is not available. Our results demonstrate that a
two-step process using the more nuanced TSTb strategy, which stratified the TST by prior BCG vaccination,
followed by an IGRA, was the most cost-effective approach.
Implications for future research
Further research to develop new markers with better predictive ability utilising transcriptomics, new
antigens and cytokines, metabolomics and proteomics is ongoing. Ongoing work with the Prognostic
Evaluation of Diagnostic IGRAs ConsorTium (PREDICT) biobank is likely to result in better biomarkers for
progression and the development of new assays. The cost-effectiveness of these new assays, using
progression data from this study, should be assessed.
The limited ability of current tests to predict who will progress to active TB limits the utility of latent TB
detection and treatment. The widespread treatment of groups who may have a positive IGRA or TST result
is unlikely to be cost-effective; the most cost-effective delivery of treatment is likely to be focused on the
highest-risk groups. Further research should investigate the implications of these results on the NHS England/
Public Health England national TB screening programme for migrants from high-TB-burden countries.
Study registration
This study is registered as NCT01162265.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background, aims and objectives
Background
Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. In 2015, an estimated 9 million
cases occurred globally and > 1.5 million people died of TB.1 The UK has seen a resurgence of TB since the
late 1980s, and there are currently > 7000 new cases each year.2 Although there has been a decline over
the last few years, levels remain higher than in most Western European countries. Most cases in the UK
occur in major cities, particularly London, and two-thirds of TB patients were born abroad. There are
also high rates among those with social risk factors such as homelessness and/or drug/alcohol misuse.
Control measures have traditionally relied on the prompt diagnosis of active TB and ensuring that patients
completed their treatment. More recently, the collaborative TB strategy for England has initiated a
programme of latent TB screening of migrants entering the UK from countries with a high TB burden.3
The majority of TB cases in the UK are a result of reactivation of latent infection.2 Among migrant groups, the
infection is likely to have been acquired abroad whereas, among the elderly UK-born population, the infection
is likely to represent acquisition several decades ago when TB was highly prevalent in the UK. The policy of
targeting active TB cases for treatment alone will therefore not be sufficient to control and eventually eliminate
TB in the UK. The identification and treatment of individuals with latent TB infection (LTBI) who are at high risk
of developing active TB may therefore be an essential additional measure provided that (1) true LTBI can be
identified [and distinguished from prior bacillus Calmette–Guérin (BCG) vaccination], (2) the probability of
developing active TB in people with untreated LTBI can be determined and (3) the intervention strategy
available (treatment of latent infection) is effective and can be successfully implemented.
Identification of latent tuberculosis infection
It is estimated that between one-quarter and one-third of the world’s population is latently infected with
the tubercle bacterium4,5 and it is widely accepted that, among those with LTBI, there is approximately a
10% lifetime chance of progression to active TB. Until recently, the tuberculin skin test (TST) was the only
tool for the diagnosis of LTBI. TST assesses the delayed-type hypersensitivity response to a purified protein
derivative, which contains antigens shared by several mycobacteria and Mycobacterium bovis BCG, by
measuring the size of the skin induration following the injection of the antigen. Limitations to the validity
(sensitivity and specificity) of TST as a measure of latent infection have been recognised for many years.
These are partly attributable to variability in the quality of the administration and interpretation of the test,
as well as the state of host immunity.
Interferon gamma release assays
Interferon gamma release assays (IGRAs) are based on the detection of Mycobacterium tuberculosis
complex specific region of difference 1 (RD1) antigens such as early secretory antigenic target 6 (ESAT-6),
culture filtrate protein 10 (CFP-10) and other TB-specific antigens. Two commercial assays have been
developed using these M. tuberculosis antigens: (1) QuantiFERON® TB Gold In-Tube (QFT-GIT; Cellestis
International Pty Ltd, Chadstone, VIC, Australia), which uses an enzyme-linked immunosorbent assay
(ELISA) format; and (2) the T-SPOT®.TB test (Oxford Immunotec Ltd, Oxford, UK), which is an enzyme-
linked immunospot (ELISPOT)-based assay.
Predictive value studies of interferon gamma release assays
Early systematic reviews6 of the role of IGRAs in the diagnosis of latent infection with M. tuberculosis
concluded that they have several advantages over the TST, including higher specificity (less cross-reactivity
with BCG vaccine and environmental mycobacteria) and better correlation with exposure to M. tuberculosis.
In the absence of a gold standard for the diagnosis of LTBI, all of the studies in these reviews have used other
proxy measures to estimate the sensitivity and specificity of IGRAs for latent infection. These measures
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include ‘degree of contact with a case of TB’ and the use of ‘active TB disease’ as an indicator of a true
positive result and ‘low prevalence of infection in the test population’ to estimate true negative results.4
The majority of the studies included in these reviews were conducted in high-incidence countries, with a
limited number conducted in low-incidence countries. Most of the completed studies either had low
power7–9 or used routinely collected data.10 More recent systematic reviews still conclude that the predictive
value of IGRAs is comparable to that of TST.11,12 We have updated these reviews in Diagnostic performance
of interferon gamma release assays for development of active tuberculosis: evidence summary.
National and international guidelines and policy context
National policy
The national policy for the control of TB is currently based on the Collaborative Tuberculosis Strategy for
England,3 published in January 2015, which outlines 10 action areas including treatment of LTBI in new entrants
to the UK from high-burden countries. Based on this strategy, Public Health England (PHE; formerly the
Health Protection Agency) recommends screening using IGRA alone.13 In contrast, the most recently
published (January 2016) National Institute for Health and Care Excellence (NICE) guidance14 recommended
that a TST and, where this is not available, an IGRA for migrants (as this was the most cost-effective
strategy based on analysis using predictive value data) and a two-step approach using the TST followed by
an IGRA if the TST was positive for contacts.
International policy
The World Health Organization (WHO) has published guidelines for the management of LTBI,12 which is
targeted at countries with an incidence of TB of < 100 cases per 100,000 people. These guidelines recommend
the use of either IGRAs or TST as alternatives based on very low-quality evidence. Internationally, individual
country guidelines differ considerably with five broad approaches: (1) an IGRA and TST as alternatives, (2) a
two-step process consisting of a TST followed by an IGRA, (3) an IGRA and TST together, (4) an IGRA alone,
replacing the TST, and (5) the TST alone.
Diagnostic performance of interferon gamma release assays for development of active
tuberculosis: evidence summary
Because of the known limitations of the TST, there is no gold standard against which to compare IGRAs to
estimate their sensitivity, specificity, positive predictive value (PPV) or negative predictive value (NPV) for the
presence of LTBI. However, for clinical and public health purposes, arguably a more important issue is what
a positive or negative IGRA result means for the risk of developing active TB. Several studies have estimated
PPV and NPV, sensitivity or specificity of IGRAs for the development of active TB, and two recent systematic
reviews15,16 have included meta-analyses of these parameters. A further, more up-to-date, review12
concluded that the two tests were not significantly different in terms of their PPV and NPV.
The two recently published reviews15,16 had slightly different objectives, inclusion criteria and analytical
approaches and, for this reason, reached different conclusions. One of them15 estimated a pooled PPV of
2.7% [95% confidence interval (CI) 2.3% to 3.2%] from 17 studies and 6.8% (95% CI 5.6% to 8.3%)
from 13 studies that were conducted in high-risk groups. The pooled NPV was considerably higher, at
99.7% (95% CI 99.5% to 99.8%). The included studies were heterogeneous for both PPV and NPV.
The other review16 compared rates and risks of TB disease in IGRA-positive and IGRA-negative individuals,
as well as estimating sensitivity and specificity of IGRAs for the development of active TB. The pooled rate
ratio was 2.10 (95% CI 1.42 to 3.08) and the pooled risk ratio was 3.54 (95% CI 2.23 to 5.60). Sensitivity
was estimated as 72% (95% CI 58% to 82%) and specificity as 50% (95% CI 41% to 58%) for the
ELISPOT assay; for whole-blood ELISA, only two eligible studies estimated sensitivity and specificity, with
values of 79% (95% CI 61% to 91%) and 43% (95% CI 18% to 72%) for sensitivity and 34% (95% CI
32% to 36%) and 59% (95% CI 55% to 62%) for specificity. In the subset of studies that assessed both
IGRA and TST, Rangaka et al.16 reported incidence rate ratios (IRRs) of 2.11 (95% CI 1.29 to 3.46) for
IGRA, 1.60 (95% CI 0.94 to 2.72) for TST with a 10-mm cut-off point and 1.43 (95% CI 0.75 to 2.72) for
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TST with a 5-mm cut-off point. In the review by Diel et al.,15 PPV appeared higher for IGRA (2.1%, 95% CI
1.7% to 2.5%) than for TST (1.4%, 95% CI 1.2% to 1.8%) in studies that assessed both tests.
The review by Rangaka et al.16 was updated by Pai et al.,11 who identified an additional five longitudinal
studies that compared the incidence of TB between individuals with positive and negative IGRA results.
Three of these studies were conducted in immunocompromised populations: human immunodeficiency
virus (HIV)-positive patients,17 patients with various immunosuppressive conditions18 and renal transplant
recipients19. The remaining two studies assessed the development of active TB among contacts of TB
cases in the UK7 and France,20 comparing those with a positive IGRA result at baseline with those with a
negative result. In the UK, this generated a rate ratio of 4.9 (95% CI 2.7 to 8.7) over 2 years,7 whereas
the French study reported a PPV of 1.96% among contacts who were not given chemoprophylaxis (CPX),
over a mean follow-up period of 34 months.20
PubMed was searched on 19 July 2016 to update the evidence base, using the search strategy of Rangaka
et al.16 (which was itself based on strategies used in previous reviews21) and restricting to publication dates
in 2013 or later. We sought to identify primary studies in which individuals underwent IGRA testing at
baseline and were followed up for the development of active TB, and which either presented estimates
of PPV and NPV or provided sufficient information for these to be estimated. Studies in which no cases
of active TB occurred were considered not to be informative for this purpose and were excluded.
The search of PubMed generated 2399 results (Figure 1), of which 597,9,10,22–77 included the required
information on PPV and/or NPV (see Appendix 2, Figure 14). In addition, we are aware of a further relevant
study78 that was published after we conducted our review. Many of these 59 studies did not have the primary
aim of assessing diagnostic accuracy. Many recorded few cases of active TB (often < 10)22,25–27,29–33,35–38,40,42–45,47,
48,50,51,56–59,62–65,67–75,77,78 and/or were restricted to groups such as patients infected with HIV,9,28,29,36,49,51,56,60,65,68,75
recipients of haemodialysis or kidney transplants,35,43,44,62–64 patients taking or initiating treatment with
biological agents such as tumour necrosis factor alpha (TNF-α) inhibitors,37–40,42,45,47,48,58,71,74 recipients of
haematopoietic stem cell transplants,50,57 lung cancer patients30 or patients with combinations of these
conditions.61 Four further studies were conducted among health-care workers.59,69,73,77 The duration of
follow-up ranged from 8 to 10 weeks to 10 years. Consistent with the previous systematic review,15 estimates
of PPV were consistently low, ranging from 0% to 24%; NPV was considerably higher (always ≥ 90%).
Search results
(n = 2399)
Full text sought
(n = 322)
Relevant papers
(n = 59)
Duplicates, n = 4
Exclusions based on title and / or abstract, n = 2073
Exclusions
• Outcome not active TB, n = 55
• No active TB cases, n = 51
• Editorial /comment (no primary data), n = 48
• No patient follow-up, n = 43
• TB results not stratified by IGRA status, n = 14
• Not an IGRA or not a commercially available IGRA, n = 12
• Review, n = 2
• Case report /case series, n = 1
• Other reason for exclusion, n = 23
• Could not be located and /or translated, n = 14
FIGURE 1 Flow diagram summarising study selection.
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Eighteen studies (including the additional study78) did specifically assess the diagnostic accuracy of IGRAs
for future development of active TB (Table 1) or otherwise quantify the association between a positive
IGRA and subsequent TB. Of these, five assessed both IGRAs and TST.23,52,56,62,72 Except when noted, these
studies did not include treatment for LTBI. In this subset of studies, estimates of the PPVs ranged from
< 1% to 17%, whereas the NPV was ≥ 97%. Sensitivity was reported as 37.5–100.0% and specificity as
27.0–86.0%. Even among these studies, case numbers were sometimes low (see Table 1). In addition,
several of the studies29,31,32,35,36,52,56,62,72 did not explicitly state that prevalent cases were excluded, although
the extent to which this may have affected their estimates was not always clear.
Within the subset of 18 studies, several compared the frequency of TB disease between IGRA-positive and
IGRA-negative participants, consistently finding that rates, hazards or odds of TB were higher among the
former (although CIs sometimes crossed the null value). Unadjusted estimates included a hazard ratio of
4.0 (95% CI 0.8 to 19.3),36 odds ratio of 2.10 (95% CI 0.13 to 34.4)35 and rate ratios of 8.5 (no CI given),34
2.9 (95% CI 2.8 to 21.2)78 and 7.7 (95% CI 2.8 to 21.2).52 Doyle et al.29 estimated the hazard ratio as 42.4
(95% CI 2.2 to 827) after adjustment for age, gender, cluster of differentiation 4 (CD4) count, viral load and
country of birth. Of the studies that did not specifically aim to assess diagnostic performance, such estimates
included unadjusted rate ratios of 2.12,24 3.4650 and 73.9 (95% CI 3.9 to 1397.7);75 odds ratios of 9.26
(95 CI 1.02 to 84.0)30 and 7.9 (95% CI 3.46 to 18.06);66 and hazard ratios were 16.82 (95% CI 5.84 to
48.46), excluding treated individuals, and 2.38 (95% CI 1.15 to 4.91), including treated individuals.41
Adjusted values included a hazard ratio of 2.0 (95% CI 1.2 to 3.3), after adjustment for BCG vaccination
scar, maternal education and current/prior household TB contact,54 and an odds ratio of 14.9 (95% CI
2.77 to 80.3), adjusted for the number of IGRA-positive contacts of the same index case, receipt of treatment
and place of contact (household vs. other).76 These effect estimates varied considerably and were often
imprecise. In addition, analyses of data from contacts often did not account for clustering by index case,
and logistic regression did not account for differences in time at risk of developing active TB.
Table 2 summarises the studies that compared IGRAs with TST in the same participants and assessed
predictive values, combining the results of our literature search with earlier studies identified in previous
reviews.12 Only four of these studies23,79–81 were conducted in low-incidence countries with a PPV range of 3%
to 17% for IGRA compared with 2–5% for TST. The estimates of NPV for both IGRA (range 98–100%) and
TST (99–100%) were very high. Studies from intermediate- and high-burden settings56,62,72,75,82–84 had a wider
range of PPV for both IGRA and TST and, similarly, a high but wider range of NPVs.
Our evidence review, and the previously published systematic reviews and meta-analyses, highlight several
important research gaps. There has been relatively little study of the diagnostic performance of IGRAs,
compared with TST, for the development of active TB in low-incidence countries and particularly in the UK.
The one study in Table 1 that was UK based7 did not include a head-to-head comparison with TST and
was focused on contacts of TB cases. Although contacts are an important risk group, current guidance in
many low-incidence countries includes testing of new entrants from high-burden countries, in whom there
is limited evidence of diagnostic performance. Predictive values, both positive and negative, depend on the
prevalence of the condition within the population of interest; consequently, results from high-incidence
settings may not be generalisable to the UK. Owing to the low risk of progression from LTBI to active TB
disease, the PPV of IGRAs for this outcome will, in general, be low.11 It is therefore important to identify
which individuals, among those with a positive IGRA (or TST) result, are most likely to develop disease
and, therefore, benefit from treatment of LTBI. The PREDICT (Prognostic Evaluation of Diagnostic IGRAs
ConsorTium) study aimed to address these gaps in the evidence base in order to inform UK and
international policy for testing and treating LTBI in contacts of TB cases and in migrants.
Review of cost-effectiveness studies
The NICE guideline on TB, which was published in 2006,85 recommended a two-step testing strategy to
diagnose LTBI: TST followed by IGRA for patients with a positive TST result. This recommendation was
informed by a cost-effectiveness analysis (CEA) based on a simple decision tree model, a systematic review of
diagnostic accuracy of TST compared with IGRA, and a series of assumptions about the predictive performance
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TABLE 1 Summary of studies estimating PPV, NPV, sensitivity and/or specificity of IGRAs for development of active TB
Study Population
Participants, n/N (%)
Number of active TB
cases
Follow-up
duration
PPV (%)
(95% CI)
NPV (%)
(95% CI)
Sensitivity
(%) (95% CI)
Specificity
(%) (95% CI)
IGRA
positive at
baseline
IGRA
negative at
baseline
IGRA
indeterminate
at baseline
IGRA
positive at
baseline
IGRA
negative
at baseline
aAltet et al.23 Contacts (Spain) 81/453 (18) 372/453 (82) 0 14 0 4 years 17
(9 to 26)
100
(100 to 100)
100
(100 to 100)
85
(81 to 88)
bBlount et al.78 New entrants
(USA)
513/1152 (45) 639/1152 (55) 0 (excluded) 5 2 10 years 0.97
(0.32 to 2.3)
99.7
(98.9 to 100)
71
(29 to 96)
56
(53 to 59)
cDoyle et al.29 HIV-positive
patients being
screened for LTBI
at a sexual health
centre (Australia)
29/917 (3) 884/917 (96) 4/917 (0.4) 1 1 Median
26.4 months
3.4
(0.1 to 17.8)
99.9
(99.4 to 99.9)
N/A N/A
aGeis et al.31 IGRA-positive
contacts without
history of TB
disease (Germany)
207/207 (100) 0 0 5 N/A ≈1 year 2.9 N/A N/A N/A
Goebel et al.32 Contacts
(Australia)
212/643 (33) 431/643 (67) 0 4 2 Mean
3.7 years
2 99 N/A N/A
Haldar et al.7 Contacts not
receiving LTBI
treatment (UK)
112/1669 (7) 1557/1669
(93)
0 Unclear Unclear 2 years 13
(7 to 20)
99
(98 to 100)
70
(46 to 88)
86
(83 to 88)
Hermansen
et al.34
General population
(Denmark)
1520/15,749
(10)
13,425/15,749
(85)
804/15,749 (5) 20 20 Median
3.36 years
1.3 99.9 N/A N/A
Jeong et al.35 Kidney transplant
recipients (Republic
of Korea)
42/129 (33) 87/129 (67) 0 1 1 Median
8.4 months
2.4 98.9 50 67.7
Jonnalagadda
et al.36
HIV-positive
pregnant women
tested during
pregnancy and
followed up for
post-partum TB
(Kenya)
125/327 (38) 157/327 (48) 45/327 (14) 7 2 1 year in primary
analysis (2 years
in supplementary
analysis)
5.9
(2.4 to 12.2)
N/A 77.7
(45.7 to 100.0)
54.6
(49.3 to 60.1)
continued
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TABLE 1 Summary of studies estimating PPV, NPV, sensitivity and/or specificity of IGRAs for development of active TB (continued )
Study Population
Participants, n/N (%)
Number of active TB
cases
Follow-up
duration
PPV (%)
(95% CI)
NPV (%)
(95% CI)
Sensitivity
(%) (95% CI)
Specificity
(%) (95% CI)
IGRA
positive at
baseline
IGRA
negative at
baseline
IGRA
indeterminate
at baseline
IGRA
positive at
baseline
IGRA
negative
at baseline
Lee et al.49 HIV-infected
patients (Taiwan)
90/772 (12) 651/772 (84) 31/772 (4) 6 10 Median 5.2 years N/A 98.5 37.5
aLeung et al.52 Contacts (Hong
Kong)
244/865 (28) 621/865 (72) 0 15 5 Mean 4.68 years 6.1
(3.5 to 9.9)
99.2
(98.1 to 99.9)
75.0
(50.9 to 91.3)
72.9
(69.8 to 75.9)
Mathad
et al.56
Pregnant women
infected with HIV
(India)
71/252 (28) 173/252 (69) 8/252 (3) 5 0 ≈1 year 7 N/A 100 27
Seyhan et al.62 Haemodialysis
patients (Turkey)
39/95 (41) 56/95 (59) 0 4 0 Mean 4.9 years 10.3 100 100 62
Shu et al.64 Haemodialysis
patients (Taiwan)
193/940 (21) 713/940 (76) 34/940 (4) 3 1 Average 3 years 1.6 99.9 75.0 79.7
Soborg et al.65 HIV-infected
patients (Denmark)
28/522 (5) 478/522 (91) 16/522 (4) 2 0 6 years 7
(1 to 22)
100
(99 to 100)
Sun et al.68 HIV-infected
patients (Taiwan)
64/608 (11) 534/608 (88) 10/608 (2) 1 0 Mean 2.6 years 1.6 100
Verhagen
et al.72
Indigenous child
contacts
(Venezuela)
56/142 (39) 76/142 (54) 10/142 (7) 2 2 12 months 4
(1 to 12)
97
(91 to 100)
dZellweger
et al.10
(QFT-GIT)
Contacts (multiple
European countries)
1068/3895
(27)
2803/3895
(72)
24/3895 (< 1) 17 3 Median 2.5 years 1.9
(1.1 to 3.0)
99.9
(99.7 to 100.0)
85.0
(62.1 to 96.6)
74.0
(72.5 to 75.5)
dZellweger
et al.10
(T-SPOT.TB)
Contacts (multiple
European countries)
299/1125 (27) 823/1125 (73) 3/1125 (< 1) 2 2 Median 2.5 years 0.7
(0.1 to 2.6)
99.7
(99.1 to 99.9)
50.0
(8.3 to 91.7)
73.6
(70.8 to 76.2)
N/A, not applicable.
a Data used excluded participants who received CPX.
b Identified subsequent to literature review. Included treated patients.
c Estimates of PPV and NPV excluded people previously diagnosed with TB or treated for TB and/or LTBI.
d Separate results for different IGRAs presented in the same study.
Note
Missing values indicate that information has not been provided.
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TABLE 2 Predictive value studies that compared IGRA and TST
Study Location Study population Follow-up
Mean follow-up
duration (months) Tests done
PPV of (%) NPV of (%)
TST IGRA TST IGRA
Altet et al.23 Spain Adult and child contacts Active 48 TST (5 mm) and QFT-GIT 2 17 100 100
Diel et al.79 Germany Adult and child contacts Passive 43 TST and QFT-GIT 5 13 99 100
Harstad et al.80 Norway Asylum seekers (adults) Passive 23–32 TST and QFT-GIT 2 3 100 100
Kik et al.81 The
Netherlands
Adult contacts in migrants Active 24 TST, QFT-GIT and T-SPOT.TB 3 3 100 98
Lee et al.82 Taiwan Adults with end-stage
renal disease
Active 24 TST and T-SPOT.TB 5 0 92 88
Leung et al.83 China Adult silicosis patients Passive 29.9 TST and T-SPOT.TB 7 8 96 99
Mahomed et al.84 South Africa Adolescents Active 27.6 TST and QFT-GIT 1 1 99 99
Mathad et al.56 India Pregnant women infected
with HIV
Active 12 TST and QFT-GIT 7 7 99 100
Seyhan et al.62 Turkey Dialysis patients Unclear 60 TST (10 mm/15 mm with BCG)
and QFT-IG
3 10 95 100
Verhagen et al.72 Venezuela Child contacts Active 12 TST and QFT-GIT 3 4 98 97
Yang et al.75 Taiwan Adults infected with HIV Active 35.6 TST and T-SPOT.TB 3 5 100 100
Notes
The top four studies in this table were conducted in low-incidence countries.
Studies published prior to 2013 were identified from Rangaka et al.16 and related references in PubMed. The full text of all articles, including those prior to 2013, were obtained and data
were extracted.
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of IGRA in populations at different levels of risk. The impact of transmission was estimated by assuming a fixed
number of incident cases in contacts of the modelled cohort. The Guideline Development Group noted the
high degree of uncertainty over the estimates of cost-effectiveness of different testing strategies for LTBI.
In 2011, NICE published an updated review86 of diagnostic accuracy of tests for LTBI and economic analysis,
reaching rather different conclusions. The revised model suggested that the IGRA-alone strategy (without TST)
was optimal, although the estimated differences in costs and quality-adjusted life-years (QALYs) were small.
Given the high level of uncertainty, the 2011 NICE guideline recommended IGRA-alone or TST-IGRA strategies
as options. Owing to limitations in the evidence base, the 200685 and 201186 NICE guidelines did not distinguish
between the two types of commercially available IGRAs [QuantiFERON TB Gold (QFT-G) and T-SPOT.TB], and
compared only three screening strategies (TST alone, IGRA alone and TST followed by IGRA if TST result was
positive). Both the 2006 and 2011 guidelines followed policy at the time, recommending two cut-off points
for defining a positive TST result: induration of ≥ 15 mm for patients with a prior BCG vaccination or ≥ 6 mm
for patients without a BCG vaccination. More recent NICE guidelines,14 published in 2016, based on a new
decision model, led to revised recommendations, described further in the following paragraphs.
A series of cost-effectiveness analyses have also been published in the literature. In 2011, Nienhaus et al.87
published a review of economic studies evaluating TST and/or IGRA as components of screening strategies
for groups at high risk of TB, such as migrants, close contacts and health-care workers, mostly in
low-incidence countries.87 Of the 13 papers that met their inclusion criteria, eight88–95 involved CEA,
whereas five96–100 were cost analyses.
The published cost-effectiveness studies reviewed by Nienhaus et al.87 all used Markov modelling to estimate
transition of a cohort through different health states, assuming a fixed rate of infection in the cohort. None
modelled the dynamics of transmission within a wider population. One CEA study95 presented results in terms
of cost per avoided TB case, whereas the remaining studies88–94 used QALYs or life-years gained as treatment
outcomes. The time horizon for analysis after initial testing for LTBI ranged from 2 years to lifetime in the
different CEA models. Some populations were stratified, for example health-care workers with/without BCG
vaccination. Although the CEA studies generally supported the IGRA-alone or IGRA-based strategies, Nienhaus
et al.87 noted that comparison of the different models was hindered by a wide range of assumptions. The
models were most sensitive to assumptions about specificity of TST, which varied among non-BCG-vaccinated
individuals from as low as 34% in one study to 98% in another. There was also significant uncertainty
surrounding the rates of progression to active TB following a positive test, as well as overassumptions for IGRA
and TST sensitivities.
In 2011, after the Nienhaus et al.87 review, Pareek et al.101 published a UK-based prospective assessment
and an economic analysis. They sought to address the limitations of the existing models and to examine
how LTBI prevalence varied by TB-incidence thresholds in migrants’ regions of origin. They found that
single-step QFT-GIT without port-of-arrival chest radiography could be cost-effective at certain incidence
thresholds. The results are, however, limited by the small number of participants and the fact that not all
of the participants received all three tests.
The NICE TB clinical guideline was updated again in 2016,14 making the following recommendations for
LTBI testing in contacts and new entrants to the UK.
l Offer TST to diagnose LTBI in adults aged 18–65 years who are close contacts of a person with
pulmonary or laryngeal TB:
¢ If the TST is inconclusive, refer the person to a TB specialist.
¢ If the TST is positive (an induration of ≥ 5 mm, regardless of BCG vaccination history), assess for
active TB.
¢ If the TST is positive but a diagnosis of active TB is excluded, consider an IGRA if more evidence of
infection is needed to decide treatment.
¢ If the TST is positive, and if an IGRA was carried out and that is also positive, offer treatment for LTBI.
BACKGROUND, AIMS AND OBJECTIVES
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l Offer TST as the initial diagnostic test for LTBI in people who have recently arrived from high-incidence
countries and who present to health-care services. If the TST is positive (an induration of ≥ 5 mm,
regardless of BCG vaccination history):
¢ assess for active TB
¢ and if this assessment is negative, offer treatment for LTBI
¢ if TST is unavailable, offer IGRA.
These recommendations differ from the previous NICE guidelines85,86 in two key respects. First, they
downplay the role of IGRA, recommending it as an option following TST when more evidence is needed
before treating contacts, or when TST is not available for new entrants to the UK. Second, they recommend
a single cut-off point for a positive TST (an induration of ≥ 5 mm) regardless of BCG vaccination status,
rather than two cut-off points, as recommended in previous guidelines (an induration of ≥ 6 mm without
prior BCG vaccination or an induration of ≥ 15 mm with prior BCG vaccination).
The 2016 NICE recommendations14 were informed by an evidence review and new economic analysis by
Auguste et al.102 (henceforth referred to as the Warwick Evidence report). Auguste et al.'s model consisted
of two stages. In the first stage (illustrated in Figures 2 and 3), a decision tree was used to represent LTBI
screening, active TB diagnosis and treatment adherence. They examined four diagnostic strategies:
A IGRA alone
B TST alone
C combined strategies – TST followed by IGRA if TST is positive
D simultaneous testing – both TST and IGRA are carried out.
New entrants
from high-
incidence
countries
IGRA alone
No LTBI
LTBI that progresses to
active TB
No LTBI
LTBI that progresses to
active TB
No LTBI
LTBI that progresses to
active TB
No LTBI
Go to D
Go to D
Go to C
Go to C
Go to B
Go to B
Go to A
Go to A
LTBI that progresses to
active TB
TST alone
TST followed by IGRA
Simultaneous testing
FIGURE 2 Starting decision tree of the Warwick Evidence analysis for new entrants from high-incidence countries.
Reproduced from Auguste et al.102 Contains information licensed under the Non-Commercial Government Licence v2.0.
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ADeterminate result
+ve IGRA
–ve IGRA
–ve chest radiograph
Refused CPX
1
Accept CPX
No active TB (LTBI)
Active TB and treated
Treatment adherence
No treatment adherence
CPX adherence
Clone 1: +ve IGRA, no active TB
No CPX adherence
+ve chest radiograph
Indeterminate result
FIGURE 3 Example decision tree extension from Figure 2, showing only strategy A (i.e. IGRA alone). +ve, positive; –ve, negative. Reproduced from Auguste et al.102 Contains
information licensed under the Non-Commercial Government Licence v2.0.
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Only the pathway for the IGRA-alone strategy (A) is presented here (see Figure 3). A do-nothing (no test)
strategy was not explored. The IGRA strategies A, C and D were evaluated for three types of commercially
available IGRAs: QTF-G, QFT-GIT and T-SPOT.TB.
The decision tree was used to estimate the proportion of patients emerging from the initial assessment,
diagnosis and treatment stages with different risks of disease progression in the second stage of the model.
Three populations were considered: (1) children, (2) immunocompromised individuals and (3) recently arrived
individuals from high-incidence countries.
The second stage of the Warwick Evidence model102 (Figure 4) was a transmission model, operationalised
using discrete event simulation (DES), programmed using R (The R Foundation for Statistical Computing,
Vienna, Austria). Individuals arriving from the decision tree were grouped as (1) having active TB, (2) already
successfully treated for LTBI and, hence, free of LTBI/TB or (3) untreated for LTBI. The model then tracked
disease progression, deaths and cases of new secondary infection. Secondary infection in other individuals
was modelled as a proportion of the initial cohort (sampled from a Poisson distribution) who progressed or
relapsed to active TB. The analysis assumed that individuals who entered the transmission model with LTBI
would ultimately develop active TB if they did not receive treatment, although they might die of other
causes before developing TB. In the initial population, as well as in secondary cases, people with LTBI who
do not progress to active TB were not simulated in the second part of the model. The risk of an event in the
transmission model, such as death or onset of active TB, was dependent on an individual’s age, TB status
and current treatment, and was updated when any of these factors changed. Time to activation of TB for
individuals entering stage two of the model with LTBI (untreated or unsuccessfully treated LTBI cases) was
simulated assuming a constant activation rate over time.
The Warwick Evidence analysis102 presented per-patient costs as well as a breakdown of total costs (including
costs of diagnosis, LTBI treatment, active TB and treatment-related hepatitis) for all of the strategies, based
on the mean values of all parameters after 250,000 individual patient simulations. The incidence rates (IRs) of
active TB in the initial cohort, the number of secondary infections and the mean life-years and QALYs per
strategy were also presented. In addition, based on 2000 Monte Carlo simulations, probabilistic estimates
of the total cost, incremental costs, diagnostic errors (false-positive results plus false-negative results),
No LTBI/TB
LTBI
Treatment
Death: all causes
Active TB Death: all causes
New secondary
infections
Death: TB
Resolved TB
FIGURE 4 Warwick Evidence analysis (Tuberculosis Clinical Guidance) transition model. Reproduced from Auguste
et al.102 Contains information licensed under the Non-Commercial Government Licence v2.0.
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incremental diagnostic error, mean QALYs, incremental QALYs and incremental cost-effectiveness ratios
(ICERs) were also presented.
The analysis suggested that, for new entrants from high-incidence countries, simultaneous testing
strategies were dominated by the equivalent sequential strategies. The QFT-GIT-alone strategy was least
costly, but the TST-positive (an induration of ≥ 5 mm) followed by QFT-GIT strategy had the fewest errors.
At a willingness-to-pay threshold of £20,000 per QALY gained, the TST-alone (≥ 5 mm) strategy was
optimal, with an ICER of £1524 per QALY gained compared with the QFT-GIT strategy. The TST-negative
(an induration of < 5 mm) followed by QFT-GIT strategy was ranked as the next most cost-effective
strategy, with an ICER of £58,720 per QALY gained compared with TST (an induration of ≥ 5 mm).
The other strategies were dominated. Univariate sensitivity analysis suggested that the TST-alone strategy
remained cost-effective in most scenarios. However, results were sensitive to LTBI prevalence, sensitivity of
QFT-GIT and sensitivity of TST.
A major common limitation of all current CEA of screening strategies for LTBI relates to assumptions
surrounding the predictive value of IGRAs and TST, because there is no gold standard against which to
establish the sensitivity or specificity of the different tests. Previous CEA studies have based their estimates
of LTBI predictive values on various, and often conflicting, sources and assumptions. This leaves considerable
uncertainty over the cost-effectiveness of LTBI screening strategies.
We adopted a different approach, basing our economic analysis on the ability of the three tests (TST,
QFT-GIT and T-SPOT.TB), individually and in combination, to predict progression to active TB in the
PREDICT cohort. This represents a much stronger evidence base for modelling the predictive performance
of LTBI test strategies than was available for previous economic evaluations, with three main advantages.
First, the cohort provides a coherent source of baseline data, including risk factors and TST, QFT-GIT
and T-SPOT.TB test results for large samples of new entrants and contacts being tested for LTBI in the UK.
Second, the long-term follow-up and predictive modelling of TB incidence bypasses the problems of
conventional diagnostic accuracy in the absence of a reliable reference standard test. Third, this evidence
source enables the comparison of two commercially available IGRAs (T-SPOT.TB and QFT-GIT) with
TST strategies with a single cut-off point (an induration of ≥ 5 mm) or with different cut-off points for
BCG-naive and BCG-experienced patients (indurations of ≥ 5 mm and ≥ 15 mm, respectively).
Objectives
Primary objectives
1. To assess the prognostic value of the two current IGRAs compared with the standard Mantoux test for
predicting the development of active TB among untreated individuals at increased risk of LTBI, specifically:
i. contacts of active TB cases
ii. new entrants to the UK from high-TB-burden countries.
2. To assess the cost-effectiveness of various screening strategies (including the NICE-recommended
two-step approach86) using IGRAs and/or TST in defined patient groups (contacts and new entrants to
the UK stratified by age and risk).
Secondary objectives
1. To quantify and compare the predictive value of a whole-blood ELISA and an ELISPOT-based assay
independently.
2. To develop a collection of specimens (serum and white blood cells), with linked clinical and epidemiological
information, to investigate the prognostic value of new biomarkers for TB infection and disease progression.
BACKGROUND, AIMS AND OBJECTIVES
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Structure of the report
In this chapter of the report, we have included a description of the background of the project as well as
the primary and secondary objectives. Chapter 2 describes the methods used in the research. In Chapter 3,
we present the results of the epidemiological study by describing the cohort and the development of active
TB in the cohort. We present the results of the economic analysis examining multiple screening scenarios in
Chapter 4 and, in Chapter 5, we discuss the findings, implications for TB testing and treatment guidelines
and recommended future research areas.
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Chapter 2 Methods
Design
Setting, population and disease burden
This prospective cohort study recruited individuals aged ≥ 16 years who were (1) close contacts of patients
with active TB or (2) new entrants to the UK arriving in the last 5 years from high-incidence countries,
defined as exceeding 40 cases per 100,000 people, and operationalised by focusing on those from
sub-Saharan Africa or Asia.
Participants were recruited in TB clinics from a network of hospitals in London, Leicester and Birmingham,
general practices (GPs) in London and several community settings in London (see Appendix 1). All study
sites were co-ordinated from the tuberculosis section of PHE.
Recruitment and inclusion criteria
Participants were recruited between May 2010 and July 2015. Contacts of active TB (pulmonary and
extrapulmonary) patients and new entrants arriving in the UK in the last 5 years from high-incidence countries
(as defined in Setting, population and disease burden) and attending participating TB clinics or primary care
centres for screening were invited to take part. Those born in high-incidence countries who entered the UK
> 5 years ago, but who had spent > 1 year (cumulative) in the past 5 years in a high-incidence country, as per
the study’s defined list, were also invited to participate. Contacts included all individuals with a cumulative
duration of exposure of > 8 hours to the relevant index case in a confined space during the period of
infectiousness (prior to initiation of treatment).
Eligible persons were identified by study TB specialists or practice nurses, and written informed consent
was obtained following the provision of information sheets (translated as appropriate). Baseline assessment
questionnaires, including demographic and clinical information, were completed by the research nurse.
In addition, recruitment was undertaken en masse using two methods.
1. New entrants to the UK were recruited from non-NHS community settings, such as places of worship
and community centres.
2. Contacts of active cases were recruited through mass screening events organised as part of the public
health response to a case of active TB in some situations. For example, clinical teams may attend workplaces
or colleges where an exposure had taken place, to facilitate screening of large numbers of contacts.
For recruitment through primary care, study flyers and the contact details of the co-ordinating centre
were displayed in general practices so that interested people could contact the study team to book an
appiontment. At the appointment, as with all recruitment meetings, a study nurse went through the full
patient information leaflet before taking written informed consent to undertake study procedures. We also
utilised the primary care trust (PCT)-held Flag 4 data (records held by the local primary care group about
international migrants who register with a NHS GP) to invite newly registered patients, recently arrived
from the countries of interest, to take part in the study.
At the time of the study, treatment of LTBI was recommended only for individuals aged < 35 years. We
therefore prioritised the recruitment of patients aged > 35 years (who were not eligible for CPX) in order
to estimate and compare the ability of the TST and IGRAs to predict natural progression to active disease
in the absence of treatment. Individuals aged 16–35 years were also eligible, as they may not be offered,
or may not accept, CPX.
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The general practioners of all participants were informed of their patients’ participation by letter.
Health technologies being assessed
Participants were tested by the Mantoux test and two IGRAs: ELISA (QFT-GIT) and ELISPOT assay (T-SPOT.TB).
All tests were conducted using standardised protocols.17–19 Tests for LTBI were undertaken among contacts at
about 6 weeks after last known exposure (consistent with NICE guidelines14), and at ≥ 6 weeks for new
entrants after arrival in the UK.
The QFT-GIT and T-SPOT.TB assay samples were transported to a study testing centre (see Statistical analysis).
After IGRA testing, samples were used for repetition of indeterminate assays. Paxgene tubes, plasma and
peripheral blood mononuclear cells were stored for future research.
Test results and further action
All test results were obtained by clinicians who were blind to other results. Clinicians were informed of
all test results by the testing laboratory for tests conducted at the National Mycobacterial Reference
Laboratory (NMRL), whereas those results from the Imperial College London laboratory were not reported.
Subsequent action after testing followed the version of NICE guidance that was applicable at the time of
screening and took place after discussion with participants. Further action followed one of three options:86
1. If the participant had a negative result in the TST and IGRA, follow-up only was conducted.
2. If the participant had a positive result in either the TST or IGRA, and active TB was excluded, follow-up
was conducted irrespective of age.
3. If the participant had a positive result in the TST and either one or both IGRA(s), follow-up only was
conducted for those aged ≥ 35 years, and, for those aged 16–35 years, CPX was offered within the
routine care setting after excluding active TB, with balanced advice about potential benefits and risks.
Follow-up
Participants were followed prospectively after IGRA/TST testing. Follow-up utilised multiple data sources
to enable the comprehensive national identification of participants and to minimise loss attributable to
transfer of care to other centres by physicians. Data were sourced from (1) telephone calls to the participants
at 12 months and at 24 months or at the end of follow-up, (2) a search of national mandatory enhanced
TB surveillance (ETS) reports, (3) a search of the national database of culture-proven TB and (4) a search of
clinical records. Individuals found to have active TB were excluded from the analysis if they had evidence of
active disease at the time of recruitment (see Primary outcome). Follow-up continued until the development
of active TB, death or May 2016.
Data collection
Baseline data were collected by trained research nurses using paper questionnaires. Outcome data
were collected using the four approaches outlined in Follow-up. Questionnaire data were entered into
a purpose-built database [using Microsoft Access® (Microsoft Corporation, Redmond, WA, USA)] that
was maintained at the TB section at PHE and linked, as necessary, to data from the other sources. IGRA
results were received from laboratories in Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA)
spreadsheets and imported into the database.
Data collected from participants included age; gender; country of birth and date of entry to the UK for
non-UK-born persons; ethnicity; current employment; the nature and duration (in hours) of contact with
the index case (for contacts); the time interval between the most recent suspected exposure date and
the date of diagnosis in the index case; details of any previous contact tracing; history of previous TB,
including treatment, results of previous TST and chest radiographic findings; BCG vaccination status
METHODS
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(assessed based on criteria in the Green Book:103 a scar or reliable recall or vaccination record); associated
medical diagnoses; and use of immunosuppressive agents. Self-reported HIV infection status was collected,
and further work through record linkage with the national HIV surveillance system will be used to improve
the completeness of HIV data. Quality-of-life data were collected using the EuroQol-5 Dimensions (EQ-5D)
questionnaire. During follow-up, information on the drugs used for the treatment of LTBI and adverse
effects of CPX was collected and validated through a review of clinical records.
Index cases (identified through clinical records) of contacts were identified through a web-based ETS system
using data provided by the contact and/or clinicians. The characteristics of index cases were summarised
descriptively. For contacts who progressed to active TB disease during follow-up, deoxyribonucleic acid (DNA)
fingerprinting data [24-locus mycobacterial interspersed repetitive unit – variable number tandem repeats
(MIRU-VNTR)] from the UK national TB strain typing database, hosted by PHE, were utilised to compare
strain types between index cases and subsequent diagnoses among contacts. This enabled the assessment
of whether any TB disease in secondary cases was likely to have arisen from the initial infection (i.e. that the
test result related to the outcome) and not as a result of subsequent exposure to another case.
Sample size
The study size (and associated power) was determined by simulating the study and its analysis 1000 times
and observing the proportion of simulations yielding significant results across various scenarios. Conventional
methods for sample size calculation would not account for the Poisson nature of the data and the within-patient
comparisons of the tests; therefore, simulation was necessary. The simulated data on the disease progression of
study participants were created, presuming a LTBI prevalence of 30% and presuming that 5% of participants
with LTBI would progress to active TB in 2 years if untreated, as observed in previous studies.81,104 Test results
were simulated for each participant using sensitivities and specificities of IGRA in the range of 65–95%.
The simulations indicated that a cohort of 5000 participants, among whom 90 incident events were observed,
would have around 85% power to detect significant (p < 0.05) differences in predictive performance that
would arise from differences in sensitivity and specificity of 10% between tests. These differences correspond
to increases in predictive performance (expressed as a ratio of relative rates between patients with a positive
test result) of 30%, which would be clinically useful.
It was assumed that 50% of TB contacts and new entrants would be aged ≥ 35 years, so a cohort of
10,000 would initially yield at least 5000 participants for the primary analysis of progression without
treatment, among whom 90 evaluable events would occur. Given the probable loss to follow-up (which,
based on clinic data, was likely to be around 20%) and the possibility that progression to disease may
be < 5%, the power of the study would be maintained by including in the cohort all participants aged
16–35 years who did not take CPX (estimated to be an additional 2500 participants). A total of 90 incident
events would still be observed should 7500 participants be recruited, 20% be lost to follow-up and the
rate of progression to disease be only 4.2%.
Primary outcome
The primary outcome of interest was the development of active TB, with the prognostic values of tests
quantified as IRRs, comparing those with positive results and those with negative results, among contacts
and new entrants to the UK. Individuals were considered to have progressed to active TB if they had
culture-confirmed TB or were clinically diagnosed with radiological or histological evidence of TB and a
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clinician had decided to treat the individual with a full course of anti-TB disease treatment, the definition
used for the TB register. In addition, participants were considered to have progressed to active TB only if:
l The participant had no evidence of active TB at the time of enrolment, determined through the review
of clinical records.
l The clinical diagnosis of active TB was at least 3 weeks after recruitment/enrolment to the PREDICT
study, based on the date of diagnosis (or treatment start date if date of diagnosis was not available).
In the absence of laboratory confirmation of TB, awareness by the clinician of a prior positive IGRA/TST
result should not influence the clinical diagnosis of active TB.
Any case that was subsequently denotified was excluded from analyses (i.e. when the clinician reported
that the patient did not have TB).
For any cases in which participants were reported to have TB in a follow-up telephone call at 12 or 24 months,
the record was searched in the national data set of clinical reports and through the review of case notes at
the hospital where the participant was treated. Only cases in which the participant was confirmed to have
active TB, meeting the criteria outlined above, were included as a case of TB. The central team ascertaining
the diagnosis were blinded to the IGRA and TST status of participants.
Statistical analysis
Primary analysis
The analysis estimated the ability of the tests (TST, T-SPOT.TB and QFT-GIT), individually and in
combination, to predict progression to active TB in latently infected individuals, and made comparisons
between tests. Estimated rates of progression to active TB were calculated, accounting for the follow-up
period for each individual.
The predictive performance of each test (TST, T-SPOT.TB and QFT-GIT) and of each two-step test strategy
[using combinations of TST + T-SPOT.TB, TST + QFT-GIT and IGRA (T-SPOT.TB or QFT-GIT) + TST] was
summarised by the calculation of IRs of developing active TB in the ‘test-positive’ and ‘test-negative’
groups, expressed with 95% CIs computed using Poisson exact methods. In each combination strategy,
the second test result was used if the first was positive, meaning that both tests must be positive for a
participant to be positive for the strategy. IRs were calculated using all available follow-up data and also at
1 year and 2 years after study entry. The discriminatory predictive value of the test was based on the
relative comparison of these rates (the relative IRs comparing those with positive test results and negative
test results), together with the prevalence of positive test results (indicating the number of patients who
would be treated should the test be used for recommending CPX).
The primary analyses of the performance of tests used only participants with test result data for all three
tests. Participants who were treated for LTBI were excluded.
We made pairwise comparisons of the ability of tests and strategies to identify (1) those participants who
progress and (2) those participants who do not progress using generalised estimating equation (GEE)
marginal regression models.105 These models estimate (1) ratios of positive test results and (2) ratios of
negative test results in those participants who progress compared with those participants who do not,
which are comparable to positive and negative likelihood ratios for diagnostic studies. We compute ratios
of these ratios to make pairwise comparisons between tests, accounting for the paired data. A marginal
regression GEE model was fitted, with the two test results as outcomes (with a positive test result coded as
the event) and with test type and progression status as predictors, and an interaction term between test
type and progression. The interaction term assessed whether or not the relationship between progression
and test positivity was stronger for one test than the other. A similar second model was fitted with test
METHODS
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negative as the outcome, such that the interaction term assessed whether or not the relationship between
non-progression and test negativity was stronger for one test than the other. The model accounted for the
intra-individual correlation between tests using an unstructured correlation matrix and was configured
to give population average estimates. The primary analysis fitted models with a binomial error structure
and a log link (as described by Pepe105). In a sensitivity analysis, we adapted the Poisson model to include
follow-up using an offset and obtained identical point estimates to two decimal places and confidence
limits to one decimal place. We report the binomial model results.
Regression models were fitted in Stata® version 15.0 (StataCorp LP, College Station, TX, USA).
Positive predictive values and NPVs were also calculated as the percentage of people with a positive result
developing TB across all follow-up (PPV) and as the percentage of people with a negative result who did
not develop TB (NPV).
Owing to testing processes, a small number of participants had two T-SPOT.TB and/or QFT-GIT tests
performed (T-SPOT.TB, n = 21; QFT-GIT, n = 33). For participants with multiple results for a single test,
results from the primary research laboratories were used (Imperial College London and NMRL), with results
from Imperial College London being used if the test was carried out at both Imperial College London and
NMRL. For some participants, neither T-SPOT.TB result was obtained from Imperial College London or
NMRL and, therefore, the result from Oxford Immunotec or SYNLAB (London, UK) was used.
The QuantiFERON TB Gold In-Tube test
The QuantiFERON test results were classified as positive, negative or indeterminate according to the
manufacturer’s algorithm.106 For analysis purposes, indeterminate results were treated as missing.
The T-SPOT.TB test
The T-SPOT.TB test can have positive, borderline positive, negative, borderline negative or indeterminate results.
All categories of test results were reported. For the majority of participants, the required test information (spot
count) was available and T-SPOT.TB test result classifications were calculated by the study team in accordance
with the manufacturer’s algorithm (Figure 5)107 For 660 tests (7.9% of the 8387 participants, or of the
8366 participants with a duplicate test for 21 participants) in which the necessary information (T-SPOT.TB
counts and positive and negative control values) was not provided, the classification of results reported from
the laboratory was used in all subsequent analyses.
Indeterminate results were treated as missing, borderline positive results were treated as positive and
borderline negative results were treated as negative, in line with the interpretation of results in
clinical practice.1
The Mantoux test
The TST was administered in accordance with national guidelines. Different thresholds for TST positivity
were considered. In the primary analysis, participants were considered to have a positive result if they had
a skin induration of ≥ 5 mm (this will be referred to as TSTa), consistent with the 2016 NICE guidelines.14
Alternatively considered was the strategy varying with BCG status, in which a skin induration measuring
≥ 6 mm following the standard TST test was considered a positive result if the participant was not known
to have had a BCG vaccination, and in which a skin induration of ≥ 15 mm following the standard TST
test indicated a positive result for those known to have had a BCG vaccination, the strategy previously
recommended by NICE.86 When BCG vaccination status was unknown, BCG vaccination was assumed
for those participants who were born outside the UK and, for UK-born participants with unknown BCG
vaccination status, a positive or negative TST result could not be obtained. The secondary definition will be
referred to as TSTb.
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Sensitivity analyses
Sensitivity analyses were carried out using all available test data rather than using data only from participants
with results for all three tests. Analyses were also performed excluding those participants with BCG vaccination
status assumed to generate a TSTb result and those participants with an uncertain progression status because of
a short period between testing and diagnosis. Additional sensitivity analyses were performed using data from
new entrants only and restricted to 2 years of follow-up, and from contacts of pulmonary TB cases only.
Economic analysis
The decision problem
We developed an individual-level DES model to estimate the effect of different test strategies on risk
prediction, use of preventative CPX and BCG vaccination, subsequent incidence of TB, and, hence, costs to
the health-care system and health outcomes for patients. We considered a DES model to be most suitable
as individual simulation and a bootstrapping approach preserved individual patient data and the correlation
between baseline risk factors and the test results. The analysis followed the NICE reference case for public
health interventions. Health outcomes were quantified using QALYs, including the impact of TB and
treatment-related adverse effects on mortality and health-related quality of life (the utility). EuroQol-5
Dimensions, three-level version scores from the PREDICT study were valued using the UK general population
tariff. Costs were estimated from a UK public sector perspective, including costs for case finding, prevention
(BCG vaccination and CPX) and treatment of active TB and adverse effects. In the base case, we discounted
costs and QALYs at 3.5% per annum and simulated outcomes over a lifetime horizon for a cohort of
patients undergoing tests for LTBI.
Negative
Borderline
negative
Borderline
positive
Positive
Positive
control
≥ 20 spots
Nil control
≤ 10 spots
Nil control
> 10 spots
Patient sample
Positive
control
< 20 spots
Indeterminate
Difference
< 5 spots
Difference
= 5 spots
Difference
= 6 or 7 spots
Difference
> 7 spots
Difference
< 6 spots
FIGURE 5 T-SPOT.TB result classification algorithm.
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Population
We evaluated the cost-effectiveness of LTBI testing strategies in the PREDICT cohort. The model used an
individual patient data set comprising 4162 contacts and 3795 new entrants without active TB at baseline
(total of 7957 participants) with sufficient data: age, sex, BCG vaccination status, baseline EQ-5D score
(utility) and contact/new entrant status. We excluded participants with active TB at the baseline assessment,
but included those with missing values for one or more baseline LTBI tests (TST, QFT-GIT or T-SPOT.TB) in
order to model the impact of missing or indeterminate test results.
For our base-case analyses, we evaluated results for the whole cohort, and also for the two subgroups: new
entrants to the UK and contacts. We had initially intended to present stratified analysis for other risk factors:
age, BCG vaccination status, previous treatment status and baseline risk (defined by level of exposure or
duration and nature of contact; or by country or region of birth for new entrants to the UK). However,
an analysis of the PREDICT results did not show any important or statistically significant differences in
incidence according to these risk factors (see Chapter 4). Instead, we investigated the sensitivity of results for
populations at different a priori levels of risk in the absence of preventative treatment (BCG vaccination or
CPX). This illustrated the possible effects of changing referral thresholds for LTBI tests, such as the threshold
for defining a ‘close’ contact or ‘high-incidence’ country of recent residence.
In our modelling protocol, we stated that we would consider additional exploratory analyses in other
subgroups, such as people infected with HIV or who have diabetes mellitus, but the numbers of
participants in these groups were too low to support such analysis.
Interventions and comparators
We compare 11 approaches to LTBI testing:
0. no test
1. T-SPOT.TB
2. QFT-GIT
3. TSTa: positive if induration is ≥ 5 mm
4. TSTb: positive if induration is ≥ 6 mm without prior BCG vaccination or ≥ 15 mm with prior
BCG vaccination
5. TSTa + T-SPOT.TB: positive if both TSTa and T-SPOT.TB are positive
6. TSTa + QFT-GIT: positive if both TSTa and QFT-GIT are positive
7. TSTa + IGRA: positive if TSTa is positive and either T-SPOT.TB or QFT-GIT are positive
8. TSTb + T-SPOT.TB: positive if both TSTb and T-SPOT.TB are positive
9. TSTb + QFT-GIT: positive if both TSTb and QFT-GIT are positive
10. TSTb + IGRA: positive if TSTb is positive and either T-SPOT.TB or QFT-GIT are positive.
In the single-test strategies (1–4), participants who tested positive for LTBI were assumed to undergo
diagnostic tests to rule out active TB, then to be offered appropriate treatment (CPX if aged ≤ 35 years),
whereas those who tested negative for LTBI would be offered BCG vaccination if eligible (no previous BCG
vaccination and age ≤ 35 years). Participants with missing test results for a strategy were assumed not to
receive any preventative treatment (CPX or BCG vaccination).
In the dual-test strategies (5, 6, 8 and 9), the second test would only be carried out if the first test result
was positive. Participants who tested positive in the second test (T-SPOT.TB or QFT-GIT) would be further
evaluated to rule out active TB, and offered CPX or BCG vaccination if appropriate. Participants without a
TST result, or with a positive TST result but missing T-SPOT.TB or QFT-GIT data, were assumed to not
receive any preventative treatment.
In the three-test strategies (7 and 10), we assumed that participants with a positive TST result would have
both IGRAs (T-SPOT.TB and QFT-GIT). Then, if either of the IGRAs were positive, they would be tested for
active disease and offered treatment or CPX if appropriate. If both IGRAs were negative they would be
DOI: 10.3310/hta22560 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 56
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Abubakar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
offered a BCG vaccination if appropriate. Participants with an indeterminate result attributable to one or
more missing test results would not receive preventative treatment; this included all participants with a
missing TST result, and those with a positive TST result and either both IGRAs missing or one negative
IGRA and one missing IGRA.
The ‘no test’ strategy was included as a comparator, which allowed us to investigate changes to the
referral thresholds for LTBI testing.
Outcomes
Strategies were evaluated in terms of the health-care costs and health outcomes measured using QALYs.
For validation purposes, we also present disaggregated outcomes (numbers of incident TB cases; numbers
given a BCG vaccination, CPX and active TB treatment; treatment-related adverse events; deaths from TB;
and life-years) and costs [costs of diagnosis, preventative treatment (BCG vaccination and CPX) and active
TB treatment (including treatment of adverse effects)].
Modelling methods
Model structure
Figure 6 is a process map of our model. The software used to develop the DES model was SIMUL8
Professional 2017 (SIMUL8 Corporation, Boston, MA, USA).
Cohort selection
The model was programmed so that a cohort of patients with chosen initial characteristics could be
selected to run through the pathway, to allow flexible subgroup analysis. However, for this report we
present results only for the whole cohort, and for the ‘new entrant’ and ‘contact’ subgroups.
Individual participants from the PREDICT cohort were randomly sampled (with replacement) from an
individual-level data set from the PREDICT cohort. This data set included individuals’ demographic
information and baseline characteristics: age, gender, prior BCG vaccination status, utility (EQ-5D scores)
and LTBI test results (TST, T-SPOT.TB and QFT-GIT). For the purposes of this analysis, we excluded patients
who were diagnosed with active TB at the beginning of the PREDICT study (n = 175). This left a data set of
7957 individuals for inclusion in the economic analysis.
The size of the sampled population in the model can be changed, but for the analysis presented below
we used a bootstrapping approach; for each probabilistic iteration of the model, we sampled a simulation
cohort (with replacement) of the same size as the individual patient data set (n = 7957). This scales
uncertainty over the distribution of baseline characteristics in our probabilistic sensitivity analysis (PSA) to
reflect sampling error in the PREDICT cohort.
Screening, diagnosis and treatment initiation
The model can be set to one of the 11 test strategies, and members of the cohort enter to be offered the
chosen strategy. Treatment decisions, such as whether a patient is offered BCG vaccination, CPX or treatment
for active TB, depend on the patient’s test results and history or demographic data. For example, under
strategy 5 (TSTa + T-SPOT.TB), an individual aged ≤ 35 years with no prior BCG vaccination, no active TB, a
TST induration of 7 mm and a negative T-SPOT.TB test result would be offered a BCG vaccination. Or, under
the same strategy, a patient aged ≤ 35 years, who has had a BCG vaccination, with no TB, a TST induration
of 18 mm and a positive T-SPOT.TB result would be offered CPX.
This first section of the model is treated as timeless; patients cannot experience adverse events and their
utility is fixed at their baseline EQ-5D value (as observed in PREDICT), but they accrue costs based on
choices that are made within the model as per LTBI testing, active TB diagnosis, BCG vaccination and
initiation of CPX and treatment of active disease.
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FIGURE 6 Model process map. –ve, negative; +ve, positive; AE, adverse event; LTFU, lost to follow-up; Tx, treatment for active TB.
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Health status
Having received tests and treatments, or having been lost to follow-up, participants flow into the second
part of the model, in which time starts to elapse. At any time, each member of the cohort who is alive is in
one, and only one, of the following health states:
l Active TB and on treatment – participants in this state have been diagnosed with active TB and are
being treated. From this state, participants might successfully finish treatment, experience an adverse
reaction to treatment and/or drop out of treatment, or they may die from TB or other causes.
l Active TB and not on treatment – this state includes participants with active TB who have not yet been
diagnosed, as well as participants who have been diagnosed but have stopped treatment for some
reason. From this state, participants might present clinically with symptoms and be diagnosed, or they
might die from TB or other causes. Contacts of people with untreated active TB who are at heightened
risk enter the model in the ‘no TB and not on CPX’ state.
l No TB and on CPX – these participants do not have TB but have tested positive for LTBI (according to
the defined test strategy) and are taking prophylactic treatment. Future possibilities for this group are
to complete CPX, have an adverse event and/or stop CPX, progress to TB or to die from other causes.
l No TB and not on CPX – this state includes all participants who do not have TB and are not taking
CPX. This is a diverse group including participants who have tested positive for LTBI but did not start
CPX or defaulted from CPX, those who have tested negative for LTBI and who may or may not have
been vaccinated, as well as those who did not complete the LTBI test(s) or who had indeterminate
results. All of these people are at risk of progressing to TB or they might die from other causes.
Note that LTBI is not modelled as a ‘disease state’ as such, but rather it means that each person who does
not currently have active TB is at risk of developing active TB. Each person’s risk of an event is estimated
using observed IRs in the PREDICT cohort, based on their current status, other characteristics and
treatment effects. Then, for each possible event, a time to event is sampled.
Events and outcomes
The possible events are:
l Adverse events from treatment for active TB or CPX – this may result in death, in which case costs
and QALYs are calculated. If the individual survives, the adverse event (drug-induced hepatotoxicity)
may resolve with the participant continuing treatment, or symptoms may persist, in which case the
participant is withdrawn from treatment.
l Dropout from CPX or treatment for active TB – for simplicity, we assume that dropout from CPX and
treatment for active TB will take place halfway through the treatment period (after 1.5 months for CPX or
3 months for treatment for active TB). Possible events following dropout from CPX are death and progression
to active TB. The next event after dropout from active TB treatment is either reinitiation of treatment (as
patients with active disease are likely to re-present at some time), death from TB or death from other causes.
l Complete CPX or treatment for active TB – participants who complete CPX (after 3 months) may still
progress to active TB, or die from other causes. Individuals who complete treatment for active TB (after
6 months) may be reinfected but we assume that this would be captured as secondary infection in a
new incident cohort and is therefore outside the scope of this model. They may also suffer reactivation.
The next event after completing treatment for active TB may therefore be death from other causes or
active TB diagnosis if reactivation takes place.
l Progression to active TB – all individuals without current active TB have a risk of progressing to active
TB. Those with positive LTBI test results are at higher risk. Once participants progress, they become
undiagnosed cases of TB and the next event may be death or active TB diagnosis.
l Active TB diagnosis – individuals with active TB who are not on treatment will develop symptoms and are
likely to present clinically, leading to diagnosis and an offer of treatment. We assume a fixed time to
diagnosis for these individuals based on the average time between onset of symptoms and diagnosis
(3 months).
l Death from active TB or other causes – costs and QALYs are calculated at this point.
METHODS
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Model assumptions
The key modelling assumptions are:
l Only BCG-naive individuals who are aged ≤ 35 years are offered a BCG vaccination, a proportion of
whom accept (94% in the base-case model). Any adverse effects of BCG vaccination are assumed to
be negligible.
l Only those individuals aged ≤ 35 years are offered CPX; this reflects UK practice and guidelines86
during the study period. A proportion of patients who are eligible accept and start CPX (94% in the
base case), although they may drop out or suffer an adverse event.
l Death from a CPX-related adverse event (hepatotoxicity) is possible, and is assumed to take place at
the start of treatment. Fatal adverse reactions to CPX are very rare; thus, the timing of adverse events
during treatment is unlikely to influence the results.
l If the patient survives and the adverse event resolves, the patient resumes CPX but may drop out later.
We assume that if the patient resumes CPX they will not experience a second adverse event. If the adverse
event is not resolved, the patient stops CPX and will either develop active TB or die from other causes.
l Patients who drop out from CPX are assumed to do so in 1.5 months and incur half of the cost of a
complete course (3 months) of CPX. Incomplete CPX provides some protection against progression to
active TB, but is less effective than complete CPX.
l After completing CPX patients may still progress to active TB (despite preventative treatment) or die
from other causes.
l All individuals have a risk of developing active TB with a hazard conditional on their baseline test results
(based on IRs estimated and sampled probabilistically from the PREDICT study). Hazards are estimated
based on patients’ available test results, using the test or combination of tests with the greatest
predictive value.
l Once an individual progresses to active TB they may be diagnosed, die from active TB or die from other
causes. For patients who are diagnosed with active TB, the time from TB onset to diagnosis is assumed
to be 3 months.
l All those diagnosed with active TB are assumed to start treatment, although they may drop out or
suffer an adverse event.
l A treatment-related adverse event can only take place once. Death from an adverse event is possible
and is assumed to take place at the start of treatment.
l If the patient survives, and the adverse event resolves, the patient resumes treatment but may drop out
later. A second adverse event is not possible.
l If the patient survives but the adverse event is not resolved, the patient stops treatment and will either die
from active TB or die from other causes. For simplicity, we have not modelled second and subsequent lines
of treatment for patients who experience adverse reactions or resistance to the standard regimen.
l Patients who drop out from treatment for active TB are assumed to do so in 3 months and incur half of
the cost of a complete course of 6 months. They do not get any treatment benefits from incomplete
treatment for active TB and are still at risk of active TB death, as well as death from other causes.
However, patients who have dropped out may be identified through opportunistic testing or clinical
presentation, and will be offered a repeat course of treatment.
l Patients who complete treatment for active TB are assumed to be free of TB and will die only from
other causes.
l Individuals come into the model with a utility estimated from their PREDICT EQ-5D data. For simplicity,
we have assumed that an individual’s utility score remains constant as they age. As utility tends to fall
with increasing age, QALY differences between strategies will be overestimated.
l Individuals’ utility scores are adjusted when they have active TB. A pre-treatment utility multiplier is
applied as soon as the patient develops active TB to reflect the impact of emerging TB symptoms prior
to treatment. A lower utility multiplier is applied during the first 3 months of treatment to reflect
continuing symptoms, inconvenience and distress caused by isolation and adverse effects of treatment
that are tolerated. The utility multiplier applied during the last 3 months of treatment is then higher as
most patients will have less-severe symptoms by this time, and the prevalence of adverse effects is likely
to be lower. After completion of treatment, patients are assumed to return to their initial utility value.108
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l It is assumed that CPX has a negligible impact on utility.108
l For simplicity, our base-case model does not include transmission from members of the cohort who
develop TB to their contacts. This will tend to underestimate the benefits (QALY gain and health-care
cost savings) associated with TB prevention. We conducted a scenario analysis with a ‘cascade’
approach to model the impact of secondary transmission.
Model parameters
Tuberculosis incidence
The incidence of TB was modelled using a Weibull distribution to reflect the falling number of cases over
time in the PREDICT cohort. This is expected as contacts of people with active TB are most likely to develop
TB close to the time of exposure, and, similarly, migrants from high-incidence countries are at most risk shortly
after entry to the country they are migrating to. In the PREDICT cohort, 77 participants were diagnosed with
active TB over a total of 20,571.4 person-years at risk. This equates to an overall IR of 0.00374 per person-
year. We used a calibration approach to fit a Weibull distribution to these data (Table 3). Our best estimate
used a scale parameter of 2.5 and a shape parameter of 6. This achieved an IR of 0.00932 in year 1 (matching
that in PREDICT), 0.00115 in year 2 (compared with 0.00167 in PREDICT) and 0.00373 averaged over the first
3 years (compared with 0.00375 in PREDICT).
Test performance
Estimates of the predictive performance of the various test strategies were taken from the analysis of
PREDICT data presented in Chapter 3. For the PSA, we used a chained approach to generate correlated
estimates of the TB IRs for patients testing positive or negative for each of the modelled strategies.
We started by estimating IRs for patients with a negative TSTa result [IR(TSTa–)] from the overall incidence
of TB in the population (R), the proportion of person-years in patients with a positive TSTa result (p) and
the IRR for TSTa positive compared with TST negative [IRR(TSTa+ vs. TSTb–)]:
IR(TSTa−) = R / ½1−p + p* IRR(TSTa+ vs: TSTa−) (1)
The IR for patients with a positive TSTa result is then:
IR(TSTa+ ) = IR(TSTa−)* IRR(TST
a+ vs: TSTa−) (2)
For each strategy, the positive predictive performance statistic compared with TSTa was used to estimate
the IR for patients with a positive result. Similarly, the negative predictive performance compared with TSTa
was used to generate estimates of IRs for patients with negative results for each strategy.
The overall incidence rate (R) and the proportion of observed person-years in people with a positive
baseline TSTa result (p) were sampled from beta distributions. IRRs were sampled using gamma
distributions, fitted to the mean and standard error of the multilevel Poisson regression results for each
comparison (Table 4). The resulting estimates of IRs (per person-year) and hazards are shown in Table 5.
TABLE 3 Model parameters: TB IR
Parameter Base-case value 95% CI PSA distribution Source
IR (TB incidence per person-year) 0.00374 0.00296 to 0.00462 Beta (77, 20,494.4) PREDICT
Hazard multiplier for year 1 2.5 – – Fitted Weibull
distribution
Shape parameter 6.0 – –
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TABLE 4 Model parameters: test performance
Parameter Base-case value 95% CI PSA distribution Source
Person-years TSTa+ (%) 0.458 0.451 to 0.465 Beta (9416.8, 11,154.6) PREDICT
IRR TSTa+ vs. TSTa– 5.83 2.89 to 9.79 Gamma (10.805, 0.540) PREDICT
Positive predictive performance: IRR for positive results
TSTb vs. TSTa 1.64 1.28 to 2.04 Gamma (72.087, 0.023) PREDICT
T-SPOT.TB vs. TSTa 1.99 1.43 to 2.63 Gamma (41.709, 0.048) PREDICT
QFT-GIT vs. TSTa 1.52 1.08 to 2.04 Gamma (38.285, 0.040) PREDICT
TSTa+ T-SPOT.TB vs. TSTa 2.39 1.77 to 3.11 Gamma (48.637, 0.049) PREDICT
TSTa+QFT-GIT vs. TSTa 1.97 1.45 to 2.57 Gamma (47.230, 0.042) PREDICT
TSTa+ IGRA vs. TSTa 2.01 1.52 to 2.56 Gamma (57.755, 0.035) PREDICT
TSTb+ T-SPOT.TB vs. TSTa 2.92 2.09 to 3.89 Gamma (40.152, 0.073) PREDICT
TSTb+QFT-GIT vs. TSTa 2.43 1.72 to 3.27 Gamma (37.737, 0.064) PREDICT
TSTb+ IGRA vs. TSTa 2.58 1.88 to 3.40 Gamma (44.298, 0.058) PREDICT
Negative predictive performance: IRR for negative results
TSTb vs. TSTa 1.35 0.84 to 1.98 Gamma (21.155, 0.064) PREDICT
T-SPOT.TB vs. TSTa 1.28 0.70 to 2.04 Gamma (13.761, 0.093) PREDICT
QFT-GIT vs. TSTa 1.60 0.88 to 2.55 Gamma (13.997, 0.115) PREDICT
TSTa+ T-SPOT.TB vs. TSTa 1.41 0.82 to 2.16 Gamma (16.740, 0.084) PREDICT
TSTa+QFT-GIT vs. TSTa 1.68 0.98 to 2.55 Gamma (17.343, 0.097) PREDICT
TSTa+ IGRA vs. TSTa 1.32 0.79 to 1.99 Gamma (18.313, 0.072) PREDICT
TSTb+ T-SPOT.TB vs. TSTa 1.58 0.90 to 2.46 Gamma (15.503, 0.102) PREDICT
TSTb+QFT-GIT vs. TSTa 1.83 1.04 to 2.83 Gamma (15.837, 0.115) PREDICT
TSTb+ IGRA vs. TSTa 1.52 0.87 to 2.35 Gamma (16.105, 0.095) PREDICT
TABLE 5 Model parameters: expected TB incidence by test strategy results
Test strategy
Results
Positive Negative
Per person-year Hazard Per person-year Hazard
1: no test (all results) 0.00374 0.00375
4: TSTa 0.00680 0.00682 0.00117 0.00117
5: TSTb 0.01115 0.01121 0.00157 0.00157
2: T-SPOT.TB 0.01350 0.01360 0.00149 0.00149
3: QFT-GIT 0.01034 0.01039 0.00187 0.00187
6: TSTa+ T-SPOT.TB 0.01628 0.01641 0.00164 0.00164
7: TSTa+QFT-GIT 0.01341 0.01350 0.00195 0.00196
8: TSTa+ IGRA 0.01365 0.01374 0.00154 0.00154
9: TSTb + T-SPOT.TB 0.01984 0.02003 0.00184 0.00185
10: TSTb +QFT-GIT 0.01654 0.01667 0.00213 0.00213
11: TSTb + IGRA 0.01754 0.01770 0.00177 0.00178
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Each individual in the PREDICT cohort was allocated a best estimate of their TB hazard, conditional on their
baseline test results. Overall, there were 36 different combinations of positive, negative and missing/
indeterminate results for the four tests measured at baseline (TSTa, TSTb, QFT-GIT and T-SPOT.TB). For each
combination, participants were assigned the hazard for the test strategy for which they had a non-missing/
indeterminate result with the greatest predictive power (highest IRR for positive vs. negative results). For
example, participants with no missing or discordant results were assigned hazards for the TSTb + T-SPOT.TB
strategy (0.00682 if positive or 0.00117 if negative). Participants with discordant QFT-GIT and T-SPOT.TB
results (one positive and one negative) were assigned to the TSTb + IGRA hazards. The mean hazard rate
estimates for each combination are shown in Table 6.
Chemoprophylaxis
It was assumed that participants aged ≤ 35 years who tested positive for LTBI would be offered CPX.
Parameters related to the uptake of CPX in this eligible group, and the incidence and consequences of adverse
reactions to CPX, were based on those used in the Warwick Evidence economic analysis by Auguste et al.102
(Table 7). We assumed that, of those participants who experienced a non-fatal adverse event, 50% would
resume CPX. We also assumed that, of those participants who started CPX and did not stop because of an
adverse event, 85% would complete a full course of 3 months’ duration. The remaining 15% of participants
who dropped out of CPX were assumed to stop after 1.5 months. The effectiveness of CPX was based on
results from the International Union Against Tuberculosis trial,110 as used in the Pooran et al.95 economic model.
Bacillus Calmette–Guérin vaccination
Patients with a negative test result for LTBI, who were aged ≤ 35 years and who had not previously been
vaccinated were assumed to be offered a BCG vaccination. Uptake in this eligible group was assumed to
be 94%, following the assumption in the Warwick Evidence analysis102 for the proportion of patients
returning to have a TST result read (see Table 7). The efficacy of BCG vaccination was based on a
published meta-analysis.111
Tuberculosis treatment
Parameters related to the diagnosis and treatment of active disease are shown in Table 7. We assumed
that diagnosis would take place 3 months after the onset of active TB, at which time all patients would
start treatment. A proportion was assumed to experience adverse effects, with a small mortality risk, as
in the Warwick Evidence analysis.102 We assumed that, of those patients with a non-fatal adverse event,
50% would continue treatment. As with CPX, we assumed that 85% of patients (who started treatment
for active disease and did not stop because of an adverse event) would complete a full course of 6 months.
Those with an incomplete course were assumed to drop out after 3 months of treatment, but to re-present
and start a new course of treatment after 3 months. For patients who completed a complete course,
treatment was assumed to be 100% effective with no residual mortality risk or loss of utility.
Health impact of tuberculosis
The model applied a case fatality rate for patients who progressed to active TB, based on estimates reported
by Crofts et al.112 At younger ages, the proportion of participants dying of TB within 12 months of the start
of treatment or notification rate was relatively low (1.2% for those aged 15–44 years and 4.8% for those
aged 45–54 years), but the risk was much higher for older participants (17.6% for those aged ≥ 65 years)
(Table 8). For simplicity, we modelled any TB-related deaths as taking place at the time of diagnosis.
Members of the cohort entered the model with an initial utility based on their EQ-5D score at baseline.
This value was adjusted on progression to TB to reflect the impact of symptoms on quality of life. For the
time between the onset of TB and diagnosis (assumed to be 3 months) in the model, a multiplier of
0.9 was applied to individuals’ utility scores. This multiplier was an assumption as utility scores are not
available for this pre-diagnostic phase, when symptoms are developing. Utility multipliers for the first
3 months after diagnosis (the ‘acute’ period), and for the remaining time up to the completion of
treatment (the ‘post-acute’ period), were estimated using a EQ-5D survey of 61 participants with active TB113
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TABLE 6 Assigned hazard rates for each combination of test results in the PREDICT cohort
Combination
Test
Most predictive
strategy Hazard CommentsTSTa TSTb T-SPOT.TB QFT-GIT
1 + + + + TSTb + T-SPOT.TB+ 0.02003 All tests available
2 + + + – TSTb + IGRA+ 0.01770 Discordant IGRA results
3 + + + ? TSTb + T-SPOT.TB 0.02003 No QFT-GIT
4 + + – + TSTb + IGRA+ 0.01770 Discordant IGRA results
5 + + – – TSTb + T-SPOT.TB– 0.00185 All tests available
6 + + – ? TSTb + T-SPOT.TB– 0.00185 No QFT-GIT
7 + + ? + TSTb +QFT-GIT+ 0.01667 No T-SPOT.TB
8 + + ? – TSTb +QFT-GIT– 0.00213 No T-SPOT.TB
9 + + ? ? TSTb+ 0.01121 No T-SPOT.TB or QFT-GIT
10 + – + + TSTb + T-SPOT.TB– 0.00185 All tests available
11 + – + – TSTb + IGRA– 0.00178 Discordant IGRA results
12 + – + ? TSTb + T-SPOT.TB– 0.00185 No QFT-GIT
13 + – – + TSTb + IGRA– 0.00178 Discordant IGRA results
14 + – – – TSTb + T-SPOT.TB– 0.00185 All tests available
15 + – – ? TSTb + T-SPOT.TB– 0.00185 No QFT-GIT
16 + – ? + TSTb +QFT-GIT– 0.00213 No T-SPOT.TB
17 + – ? – TSTb +QFT-GIT– 0.00213 No T-SPOT.TB
18 + – ? ? TSTb– 0.00157 No T-SPOT.TB or QFT-GIT
19 – – + + TSTb + T-SPOT.TB– 0.00185 All tests available
20 – – + – TSTb + IGRA– 0.00178 Discordant IGRA results
21 – – + ? TSTb + T-SPOT.TB– 0.00185 No QFT-GIT
22 – – – + TSTb + IGRA– 0.00178 Discordant IGRA results
23 – – – – TSTb + T-SPOT.TB– 0.00185 All tests available
24 – – – ? TSTb + T-SPOT.TB– 0.00185 No QFT-GIT
25 – – ? + TSTb +QFT-GIT– 0.00213 No T-SPOT.TB
26 – – ? – TSTb +QFT-GIT– 0.00213 No T-SPOT.TB
27 – – ? ? TSTb– 0.00157 No T-SPOT.TB or QFT-GIT
28 ? ? + + T-SPOT.TB+ 0.01360 No TST
29 ? ? + – T-SPOT.TB+ 0.01360 No TST
30 ? ? + ? T-SPOT.TB+ 0.01360 Only T-SPOT.TB
31 ? ? – + T-SPOT.TB– 0.00149 No TST
32 ? ? – – T-SPOT.TB– 0.00149 No TST
33 ? ? – ? T-SPOT.TB– 0.00149 Only T-SPOT.TB
34 ? ? ? + QFT-GIT+ 0.01039 Only QFT-GIT
35 ? ? ? – QFT-GIT– 0.00187 Only QFT-GIT
36 ? ? ? ? No test 0.00375 No tests available
–, negative; +, positive; ?, missing/indeterminate.
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TABLE 7 Model parameters: CPX, BCG vaccination and treatment of active TB
Parameter
Base-case
value 95% CI PSA distribution Source
Uptake of CPX (%) 0.94 0.90 to 0.97 Beta (141, 9) Warwick Evidence102
CPX adverse event (%) 0.0040 0.0007 to
0.0101
Beta (2.7, 664) Warwick Evidence102
Death from CPX event (%) 0.00002 0.00000 to
0.00010
Beta (0.5, 25,125) Warwick Evidence102
CPX event resolved (%) 0.50 0.30 to 0.70 Beta (11.51, 11.51) Assumption
Completion for CPX (%) 0.85 N/A N/A Mears et al.109
Duration of complete CPX (months) 3 N/A N/A NG3314
Duration of incomplete CPX (months) 1.5 N/A N/A Assumption
TB cases with complete CPX (%) 0.33 0.24 to 0.43 Beta (32, 65) IUAT, 1982110
TB cases with incomplete CPX (%) 0.78 0.70 to 0.86 Beta (76, 21) IUAT, 1982110
Uptake of BCG vaccination (%) 0.94 0.90 to 0.97 Beta (164, 10.5) Warwick Evidence102
TB cases averted with BCG vaccination (%) 0.49 0.34 to 0.7 Beta (14.03, 14.60) Colditz et al.111
Treatment for active TB adverse event (%) 0.0040 0.0007 to
0.0101
Beta (2.7, 664) Warwick Evidence102
Death from treatment for active TB event (%) 0.00002 0.00000 to
0.00010
Beta (0.5, 25,125) Warwick Evidence102
Treatment for active TB event resolved (%) 0.50 0.30 to 0.70 Beta (11.51, 11.51) Assumption
Completion for treatment for active TB (%) 0.85 N/A N/A Mears et al.109
Duration of complete treatment for active TB
(months)
6 N/A N/A NG3314
Duration of incomplete treatment for active
TB (months)
3 N/A N/A Assumption
Time to diagnosis for active TB (months) 3 N/A N/A Assumption
Time to presentation for treatment for active
TB after initial dropout (months)
3 N/A N/A Assumption
IUAT, International Union Against Tuberculosis; N/A, not applicable.
TABLE 8 Model parameters: outcomes (TB case fatality and utility)
Parameter
Base-case
value 95% CI
PSA
distribution Source
Case fatality for participants, by age group
15–44 years 0.012 0.010 to 0.015 Beta (88, 7249) Crofts et al.112
45–64 years 0.048 0.040 to 0.056 Beta (125, 2500) Crofts et al.112
≥ 65 years 0.176 0.160 to 0.191 Beta (413, 1940) Crofts et al.112
Initial utility N/A N/A N/A PREDICT EQ-5D scores
(from this trial)
Utility multiplier
When active TB progression takes place 0.900 N/A N/A Assumption
An acute treatment period during
treatment (the first 3 months)
0.675 N/A N/A Kruijshaar et al.113
For a post-acute treatment period during
treatment for active TB
0.813 N/A N/A Kruijshaar et al.113
N/A, not applicable.
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(see Table 8). Participants who dropped out of treatment retained the lower, acute-period utility until they
re-presented and completed the first 3 months of treatment.
General mortality was modelled by simulating a time to death from other causes (not TB) at the time of
model entry for all participants. Individual values were sampled using a Gompertz distribution with life
expectancy by age from UK life tables114 and assuming a 5-year standard deviation. As TB is a rare cause of
death in the UK, we did not adjust all-cause mortality.
Resource use and costs
The costs of treatments and tests are shown in Table 9. We assumed that test strategies involving TST
would require two clinic visits, whereas those involving only IGRAs (T-SPOT.TB or QFT-GIT or both) would
only require one clinic visit.
Ethics and research governance
This study was approved by the Brent Research Ethics Committee (10/H0717/14). Written informed
consent was obtained from all participants. For community recruitment, formal NHS Research and
Development permission was sought from the managers or leaders of the institutions to conduct the study
on their premises, and to ensure that appropriate areas to protect individuals’ privacy were available and
were clinically appropriate.
Latent TB infection treatment was recommended only to those aged < 35 years, by their general
practioner, following NICE guidelines at the time of the study. Any treatment for active TB was offered to
participants through the TB clinic after communication of the results, separately from the study procedures.
TABLE 9 Model parameters: resource use and costs
Parameter
Base-case
value 95% CI PSA distribution Source
BCG vaccination £4 £1 to £10 Gamma (2.46, 1.63) NICE CG3385
Adverse event (assumed to be the same
for treatment for active TB and CPX)
£397 £161 to £737 Gamma (7.13, 55.64) Warwick Evidence102
Active TB diagnosis £434 £353 to £523 Gamma (100, 4.34) Mears et al.109
Treatment for active TB (6 months) £1114 £906 to £1343 Gamma (100, 11.14) Mears et al.109
CPX (3 months) £743 £605 to £896 Gamma (100, 7.43) Mears et al.109
TST £1.22 N/A N/A NICE CG11786
T-SPOT.TB £71 N/A N/A Pareek et al.101
QFT-GIT £41 N/A N/A Pareek et al.101
IGRA £112 N/A N/A Assumed to be sum
of T-SPOT.TB and
QFT-GIT
Clinic visit: TB specialist nursing, adult,
face to face
£62 N/A N/A Department of Health
and Social Care’s NHS
Reference Costs115
Number of clinic visits for T-SPOT.TB or
QFT-GIT
1 N/A N/A Assumption
Number of clinic visits for TST or
two-step tests
2 N/A N/A Assumption
CG, clinical guideline; N/A, not applicable.
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All study data were held in accordance with NHS data protection principles, including the use of secure
password-protected systems.
Although this was not a randomised controlled trial, a formal independent data monitoring committee and
a trial steering committee were set up (see Acknowledgements for a full list of members).
The study was registered with ClinicalTrials.gov (NCT01162265). The full protocol is available at
https://njl-admin.nihr.ac.uk/document/download/2006769 (accessed 12 June 2017).
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Chapter 3 Results: progression to active
tuberculosis
Baseline participant information
The PREDICT study recruited 10,045 participants between May 2010 and July 2015. Of these participants,
175 were identified as having TB at baseline (i.e. diagnosed or treated < 21 days after being recruited) and
an additional 260 participants received treatment for latent TB during the study. Removing those with TB at
baseline and those receiving latent TB treatment left 9610 evaluable participants (Figure 7).
Participants were recruited from 54 different NHS centres and community settings located in London,
Leicester and Birmingham. Participants were recruited from health-care, work and community settings
including places of worship, schools, colleges and workplaces.
Owing to the small numbers of participants who were receiving treatment for LTBI and those who were
diagnosed with a HIV infection, further analyses of these groups were not performed.
Participants recruited
(n = 10,045)
Participants without TB
at baseline
(n = 9870)
Analysed participants
(n = 9610)
TSTa
(developed TB n/N)
+ 64/2957
– 13/3423
TSTb
(developed TB n/N)
+ 52/1485
– 25/4895
T-SPOT.TB
(developed TB n/N)
+ 52/1235
– 25/5145
QFT-GIT
(developed TB n/N)
+ 47/1444
– 30/4936
TSTa
(developed TB n/N)
+ 77/3513
– 15/4320
No result 5/1777
TSTb
(developed TB n/N)
+ 60/1729
– 31/5940
No result 6/1941
T-SPOT.TB
(developed TB n/N)
+ 56/1571
– 29/6414
No result 12/1625
QFT-GIT
(developed TB n/N)
+ 53/1892
– 33/6640
No result 11/1078
Participants with all test results and follow-up* (developed TB n/N) = 77/6380
Participants with baseline
TB excluded
(n = 175)
Participants known to have
been treated for latent TB
(n = 260)
FIGURE 7 Study flow chart. *Six participants did not have data allowing follow-up to be calculated, leaving a total
of 6380 participants for analysis. Table 16 provides further details of ‘no results’ for each test, Figure 8 provides
all details of available data for all test combinations and Tables 25, 27 and 28 provide full results for all test
combinations. Note that in accordance with national guidelines, only contacts aged < 35 years were
offered treatment.
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Of the 9610 participants, 4861 individuals (50.6%) had contact with someone with TB and 4749
participants (49.4%) were new entrants to the UK from a high-incidence country. The proportion of
participants who reported not being born in the UK was 83.3% (n = 8008), and 57.5% (n = 5526) were
aged ≤ 35 years. Full participant demographics are given in Table 10.
A BCG vaccination was reported by 6618 participants (68.9%) and previous contact with TB was reported
by 1207 participants (12.6%). Only 55 participants (0.6%) reported being HIV positive. Many of the
participants had travelled or lived outside the UK (not including Western Europe, the USA, Canada and
Australia) in the last 2 years (n = 3563, 37.1%) and before the last 2 years (n = 3033, 31.6%). Full
participant risk factors are provided in Table 11.
Information that was collected for the 4861 participants in the study who had a contact with TB indicated
that the most common type of contact with someone with TB was ‘household non-sexual’, reported by
2402 participants (49.4%). ‘Household sexual’ contact was reported by 673 contact participants (13.8%).
Table 12 provides full details of contact types.
TABLE 10 Participant demographics
Characteristic
Participants
Contacts (N= 4861) New entrants (N= 4749) All (N= 9610)
Sex, n (%)
Female 2400 (49.4) 2329 (49.0) 4729 (49.2)
Male 2433 (50.1) 2376 (50.0) 4809 (50.0)
Missing 28 (0.6) 44 (0.9) 72 (0.8)
Ethnicity, n (%)
Bangladeshi 201 (4.1) 515 (10.8) 716 (7.5)
Black African 770 (15.8) 368 (7.8) 1138 (11.8)
Black Caribbean 235 (4.8) 7 (0.2) 242 (2.5)
Indian 1352 (27.8) 2629 (55.4) 3981 (41.4)
Mixed 654 (13.5) 238 (5.0) 892 (9.3)
Other 194 (4.0) 126 (2.7) 320 (3.3)
Pakistani 398 (8.2) 508 (10.7) 906 (9.4)
White 942 (19.4) 231 (4.9) 1173 (12.2)
Missing 115 (2.4) 127 (2.7) 242 (2.5)
Age (years), median (IQR) 32 (25–44) 33 (26–51) 33 (26–47)
Missing, n (%) 7 (0.1) 15 (0.3) 22 (0.2)
Age (years), n (%)
≤ 35 2849 (58.6) 2677 (56.4) 5526 (57.5)
> 35 2005 (41.3) 2057 (43.3) 4062 (42.3)
Missing 7 (0.1) 15 (0.3) 22 (0.2)
UK born, n (%)
No 3414 (70.2) 4594 (96.7) 8008 (83.3)
Yes 1423 (29.3) 129 (2.7) 1552 (16.2)
Missing 24 (0.5) 26 (0.6) 50 (0.5)
IQR, interquartile range.
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TABLE 11 Participant risk factors
Risk factor
Participants
Contacts
(N= 4861)
New entrants
(N= 4749)
All
(N= 9610)
Previous TB contact prior to the recent exposure, n (%) 670 (13.8) 537 (11.3) 1207 (12.6)
Missing 156 (3.2) 224 (4.7) 380 (4.0)
Previous TB diagnosis, n (%) 140 (2.9) 213 (4.5) 353 (3.7)
Missing 79 (1.6) 108 (2.3) 187 (2.0)
BCG vaccination, n (%) 3685 (75.8) 2933 (61.8) 6618 (68.9)
Missing 640 (13.2) 882 (18.6) 1522 (15.8)
BCG vaccination,a n (%) 4155 (85.5) 3791 (79.8) 7946 (82.7)
Missing 170 (3.5) 24 (0.5) 194 (2.0)
Diabetes mellitus, n (%) 325 (6.7) 481 (10.1) 806 (8.4)
Missing 17 (0.4) 23 (0.5) 40 (0.4)
Haematological malignancy, n (%) 10 (0.2) 6 (0.1) 16 (0.2)
Missing 36 (0.7) 54 (1.1) 90 (0.9)
HIV positive, n (%) 43 (0.9) 12 (0.3) 55 (0.6)
Missing 182 (3.7) 498 (10.5) 680 (7.1)
Smoker, n (%) 1172 (24.1) 635 (13.4) 1807 (18.8)
Missing 31 (0.6) 36 (0.8) 67 (0.7)
Previous transplant, n (%) 15 (0.3) 10 (0.2) 25 (0.3)
Missing 33 (0.7) 42 (0.9) 75 (0.8)
Anti-TNF-α, n (%) 17 (0.4) 15 (0.3) 32 (0.3)
Missing 180 (3.7) 620 (13.1) 800 (8.3)
Immunosuppressive drugs, n (%) 43 (0.9) 32 (0.7) 75 (0.8)
Missing 179 (3.7) 631 (13.3) 810 (8.4)
Problem drug use, n (%) 166 (3.4) 32 (0.7) 198 (2.1)
Missing 23 (0.5) 40 (0.8) 63 (0.7)
Homeless, n (%) 111 (2.3) 73 (1.5) 184 (1.9)
Missing 22 (0.5) 34 (0.7) 56 (0.6)
BMI (kg/m2), mean (SD) 25.3 (4.9) 25.0 (4.6) 25.1 (4.8)
Missing, n (%) 368 (7.6) 307 (6.5) 675 (7.0)
Occupation, n (%)
Health care 257 (5.3) 95 (2.0) 352 (3.7)
Social/prison sector 33 (0.7) 9 (0.2) 42 (0.4)
Laboratory/pathology 11 (0.2) 4 (0.1) 15 (0.2)
Agriculture/animal care 0 (0.0) 0 (0.0) 0 (0.0)
Education 974 (20.0) 708 (14.9) 1682 (17.5)
None 1119 (23.0) 1881 (39.6) 3000 (31.2)
Other 2257 (46.4) 1691 (35.6) 3948 (41.1)
Unknown 210 (4.3) 361 (7.6) 571 (5.9)
continued
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A total of 2211 index cases were identified for the 4861 contacts (i.e. 45.5% of contacts had an identified
index case). The number of contacts participating in PREDICT per index case ranged from 1 to 20 (median 2).
Most of the index case patients (693/1263, 54.9%) had pulmonary TB, with (n = 138) or without (n = 555)
TB disease at extrapulmonary sites. The infecting species was reported in 875 index cases, being identified
as M. tuberculosis or M. tuberculosis complex in 858 cases and one case, respectively, as M. bovis in four
cases andM. africanum in five cases. Seven index case participants were reported to have mixed infections
with members of the M. tuberculosis complex (M. tuberculosis andM. africanum, n = 5; M. tuberculosis and
M. bovis, n = 2). A total of 549 out of 1263 index case participants (43.5%) were female and the median
age was 35 years [interquartile range (IQR) 26–49 years]. Of 1250 index cases in which the participant’s
country of birth was known, 992 participants (79.4%) were born outside the UK.
Test results
The QFT-GIT tests were carried out in four centres (NMRL, Imperial College London, Royal Free London NHS
Foundation Trust and SYNLAB) and the T-SPOT.TB test was carried out in three centres (NMRL, Imperial College
London and Oxford Immunotec Ltd). The results are summarised in Table 13. Positive test results (positive and
borderline positive) were seen for participants when using the T-SPOT.TB test (n= 1571, 16.3%), QFT-GIT
(n= 1892, 19.7%), TSTa (n= 3513, 36.6%) and TSTb (n= 1729, 18.0%). There were 6520 participants (67.8%)
with a non-missing or indeterminate result (positive or negative) for the three tests (T-SPOT.TB, QFT-GIT and TSTa)
and 6386 participants (66.5%) had a non-missing or indeterminate result (positive or negative) for all tests
TABLE 11 Participant risk factors (continued )
Risk factor
Participants
Contacts
(N= 4861)
New entrants
(N= 4749)
All
(N= 9610)
Travelb in the last 2 years, n (%) 1822 (37.5) 1741 (36.7) 3563 (37.1)
Missing 159 (3.3) 937 (19.7) 1096 (11.4)
Travelb before the last 2 years, n (%) 1630 (33.5) 1403 (29.5) 3033 (31.6)
Missing 414 (8.5) 1099 (23.1) 1513 (15.7)
BMI, body mass index; SD, standard deviation.
a Includes those assumed to have had a BCG vaccination (BCG vaccination data are missing and participant was not born
in the UK).
b Travelled or lived outside the UK (not including Western Europe, the USA, Canada and Australia).
TABLE 12 Tuberculosis contact types
Contact type Contact participants (N= 4861), n (%)
Household sexual 673 (13.8)
Household non-sexual 2402 (49.4)
Health care 141 (2.9)
Education 238 (4.9)
Detention 5 (0.1)
Homeless 23 (0.5)
Other congregate living 1 (0.0)
Travel 6 (0.1)
Workplace/social 747 (15.4)
Other 304 (6.3)
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including TSTb. An ‘error’ was reported when a result could not be obtained as a result of the testing procedures,
for example because there was not enough sample material.
Some participants had multiple tests carried out (21 participants had two T-SPOT.TB tests and 33 participants
had two QFT-GIT tests).
In the following discussion, ‘borderline positive’ results are categorised as positive; ‘borderline negative’
results are categorised as negative; and ‘error’ and ‘indeterminate’ results are categorised as missing,
as only positive and negative results can be used in decision-making.
Evaluation of the combination of results for the different tests showed that, when considering the results from
the three tests, T-SPOT.TB, QFT-GIT and TSTa (6520 participants had available data), the results were positive
for all three for 797 participants (12.2%) and were negative for all three for 2995 participants (45.9%), and
the three results differed for 2728 participants (41.8%). When comparing the results for T-SPOT.TB and TSTa
(6843 participants had available data), the results were both positive for 1020 participants (14.9%), were both
negative for 3414 participants (49.9%) and disagreed for 2409 participants (35.2%). Comparing the results
for QFT-GIT and TSTa (7041 participants had available data), 1113 participants (15.8%) had positive results
for both, 3373 participants (47.9%) had a negative result for both and 2555 participants (36.3%) had
discordant results.
A total of 6386 participants had a test result for each of T-SPOT.TB, QFT-GIT and TSTb. Of the 6706
participants with T-SPOT.TB and TSTb results, 743 (11.1%) had positive results for both, 4598 (68.6%) had
negative results for both and the results disagreed for 1365 participants (20.4). For the 6897 participants
with TSTb and QFT-GIT results, 785 (11.4%) had positive results for both, 4563 (66.2%) had negative
results for both and the results for 1549 participants (22.5%) disagreed. Of the 6386 participants with
all results, 620 (9.7%) had all positive results, 4026 (63.0%) had all negative results and the results for
1740 participants (27.2%) disagreed.
A comparison of the results for the two IGRAs only (data were available for 7594 participants) showed that
1176 participants (15.5%) had a positive result for both, 5588 participants (73.6%) had a negative result for
both, and 830 participants (10.9%) had discordant results. Tables 14 and 15 show the cross-tabulations of test
results, and Figure 8 shows the completeness of data for each testing combination. Further cross-tabulations of
results showing the full categorisation of results (including missing, indeterminate and error) are presented in
Appendix 2, Tables 44 and 45. Cross-tabulations for participants who did and did not progress to active TB are
shown in Appendix 2, Tables 46–48.
TABLE 13 The T-SPOT.TB, QFT-GIT and TST results
Result
Test, n (%)
T-SPOT.TB QFT-GIT TSTa TSTb
Positive 1381 (14.4) 1892 (19.7) 3513 (36.6) 1729 (18.0)
Borderline positive 190 (2.0) N/A N/A N/A
Borderline negative 126 (1.3) N/A N/A N/A
Negative 6288 (65.4) 6640 (69.1) 4320 (45.0) 5940 (61.8)
Indeterminate 121 (1.3) 163 (1.7) N/A N/A
Error 260 (2.7) 65 (0.7) N/A N/A
Missing 1244 (12.9) 850 (8.8) 1777 (18.5) 1941 (20.2)
N/A, not applicable.
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TABLE 14 Cross-tabulations of test results
QFT-GIT
Test result, n (%)
TSTa positive TSTa negative TSTa missing
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
Positive 797 (22.7) 249 (7.1) 67 (1.9) 1113 (31.7) 195 (4.5) 230 (5.3) 25 (0.6) 450 (10.4) 184 (10.4) 52 (2.9) 93 (5.2) 329 (18.5)
Negative 173 (4.9) 1791 (51.0) 141 (4.0) 2105 (59.9) 90 (2.1) 2995 (69.3) 288 (6.7) 3373 (78.1) 36 (2.0) 802 (45.1) 324 (18.2) 1162 (65.4)
Missing 50 (1.4) 57 (1.6) 188 (5.4) 295 (8.4) 27 (0.6) 189 (4.4) 281 (6.5) 497 (11.5) 19 (1.1) 49 (2.8) 218 (12.3) 286 (16.1)
Total 1020 (29.0) 2097 (59.7) 396 (11.3) 3513 (100.0) 312 (7.2) 3414 (79.0) 594 (13.8) 4320 (100.0) 239 (13.4) 903 (50.8) 635 (35.7) 1777 (100.0)
Notes
TSTa was considered positive if participants had a skin induration measuring ≥ 5mm.
Percentages are of the total for each test combination.
TABLE 15 Cross-tabulations of test results
QFT-GIT
Test result, n (%)
TSTb positive TSTb negative TSTb missing
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
Positive 620 (35.9) 124 (7.2) 41 (2.4) 785 (45.4) 356 (6.0) 345 (5.8) 48 (0.8) 749 (12.6) 200 (10.3) 62 (3.2) 96 (4.9) 358 (18.4)
Negative 89 (5.1) 655 (37.9) 56 (3.2) 800 (46.3) 171 (2.9) 4026 (67.8) 366 (6.2) 4563 (76.8) 39 (2.0) 907 (46.7) 331 (17.1) 1277 (65.8)
Missing 34 (2.0) 16 (0.9) 94 (5.4) 144 (8.3) 43 (0.7) 227 (3.8) 358 (6.0) 628 (10.6) 19 (1.0) 52 (2.7) 235 (12.1) 306 (15.8)
Total 743 (43.0) 795 (46.0) 191 (11.0) 1729 (100.0) 570 (9.6) 4598 (77.4) 772 (13.0) 5940 (100.0) 258 (13.3) 1021 (52.6) 662 (34.1) 1941 (100.0)
Notes
TSTb was considered positive if participants without a previous BCG vaccination had a skin induration measuring ≥ 6 mm following the standard TST; for participants with a previous BCG
vaccination, a skin induration of ≥ 15mm following the standard TST indicated a positive result.
Percentages are of the total for each test combination.
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Progression to active tuberculosis
Of the total number of participants, 97 (1.0%) developed active TB. Of the participants progressing to active
TB, 66 (68.0%) were aged ≤ 35 years and 63 (64.9%) were recruited to the study because of contact with
an individual with TB. The follow-up duration for participants in the study ranged from 21 days to 5.9 years
(for non-progressing participants: range 0.3–5.9 years, mean 2.9 years, median 3.0 years; for progressing
participants: range 21 days–4.1 years, mean 0.8 years, median 0.5 years) (Figure 9).
Fifty-two out of the 97 participants (53.6%) who progressed to active TB developed TB within 6 months of
follow-up (33 contact participants and 19 new entrant participants), and within 12 months 70 participants
(72.2%) had progressed to active TB (46 contact participants and 24 new entrant participants). Twenty-seven
participants (27.8%) developed active TB after 1 year of follow-up.
The characteristics of the 97 participants who progressed to active TB are summarised in Table 16. Forty-five
of these participants had pulmonary TB, with (n = 7) or without (n = 38) TB disease at an extrapulmonary
site; the remaining 52 participants had extrapulmonary TB only. Approximately two-thirds of participants
were contacts and 48.5% were female. A total of 81 out of 97 participants (83.5%) were born outside the
UK. The majority of participants (74.2%) had received a BCG vaccination. Sixteen participants (16.5%)
reported contact with a patient with TB prior to the contact that led to their enrolment in the study. At the
time of enrolment, four of the participants (4.1%) who went on to develop active TB reported problem drug
use and three (3.1%) were homeless.
All data
Participants, n = 9610 (100.0%)
Developing TB, n = 97 (100.0%)
Any IGRA result
Participants, n = 8923 (92.9%)
Developing TB, n = 90 (92.8%)
T-SPOT.TB result
Participants, n = 8985 (83.1%)
Developing TB, n = 85 (87.6%)
QFT-GIT result
Participants, n = 8532 (88.8%)
Developing TB, n = 86 (88.7%)
TSTa result
Participants, n = 7833 (81.5%)
Developing TB, n = 92 (94.8%)
TSTb result
Participants, n = 7669 (79.8%)
Developing TB, n = 91 (93.8%)
T-SPOT.TB and QFT-GIT
Participants, n = 7594 (79.0%)
Developing TB, n = 81 (83.5%)
IGRA and TSTa
Participants, n = 7833 (81.5%)
Developing TB, n = 92 (94.8%)
IGRA and TSTb
Participants, n = 7669 (79.8%)
Developing TB, n = 91 (93.8%)
T-SPOT.TB and TSTa
Participants, n = 6843 (71.2%)
Developing TB, n = 82 (84.5%)
T-SPOT.TB and TSTb
Participants, n = 6706 (69.8%)
Developing TB, n = 81 (83.5%)
All*
Participants, n = 6520 (67.8%)
Developing TB, n = 78 (80.4%)
QFT-GIT and TSTa
Participants, n = 7041 (73.3%)
Developing TB, n = 82 (84.5%)
QFT-GIT and TSTb
Participants, n = 6897 (71.8%)
Developing TB, n = 81 (83.5%)
All†
Participants, n = 6386 (66.5%)
Developing TB, n = 77 (79.4%)
FIGURE 8 Test result combinations. *T-SPOT.TB, QuantiFERON + TSTa; †T-SPOT.TB, QuantiFERON + TSTb. TSTa was
considered positive if participants had a skin induration measuring ≥ 5mm. TSTb was considered positive if
participants without a previous BCG vaccination had a skin induration measuring ≥ 6mm following the standard
TST; for participants with a previous BCG vaccination, a skin induration of ≥ 15mm following the standard TST
indicated a positive result.
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FIGURE 9 Histogram of follow-up duration for participants who progressed to active TB and participants who did
not progress to active TB.
TABLE 16 Baseline characteristics of participants who progressed to active TB
Characteristic
Participants
Progressing to active TB (N= 97)
With all test results and progressing
to active TB (N= 77)
Contact or migrant, n (%)
Contact 63 (65.0) 51 (66.2)
Migrant 34 (35.1) 26 (33.8)
Sex, n (%)
Female 47 (48.5) 37 (48.1)
Male 50 (51.6) 40 (52.0)
Age (years), median (IQR) 30 (26–38) 30 (26–38)
Age (years), n (%)
≤ 35 66 (68.0) 52 (67.5)
> 35 31 (32.0) 25 (32.5)
UK born, n (%)
No 81 (83.5) 64 (83.1)
Yes 16 (16.5) 13 (16.9)
BCG vaccination, n (%) 72 (74.2)a 57 (74.0)a
Smoker, n (%) 18 (18.6) 15 (19.5)
BMI (kg/m2), mean (SD) 23.6 (4.5)b 23.4 (4.5)c
BMI, body mass index; SD, standard deviation.
a Information is missing for 14 cases.
b Information is missing for eight cases.
c Information is missing for six cases.
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There were 14 index case/contact pairs with 24-locus MIRU-VNTR data available for both individuals’
infections: 11 of 12 pairs with data on ≥ 22 loci were identical at all available loci and one pair was
identical at the 12 loci available.
T-SPOT.TB, QFT-GIT, TSTa and TSTb identified 56 (57.7%), 53 (54.6%), 77 (79.4%) and 60 (61.9%) of
the participants developing active TB as positive, respectively. Participants who progressed to active TB
accounted for 3.6%, 2.8%, 2.2% and 3.5% of the positive results for T-SPOT.TB, QFT-GIT, TSTa and TSTb
(PPVs), respectively, and 0.5%, 0.5%, 0.3% and 0.5% of the negative results for each test, respectively
(NPVs of 99.5%, 99.5%, 99.7% and 99.5%) (Table 17).
For the participants aged ≤ 35 years, individuals developing active TB accounted for 4.7%, 3.9%, 2.7%
and 4.6% of the positive results for T-SPOT.TB, QFT-GIT, TSTa and TSTb, respectively; for participants aged
> 35 years, this was 2.4%, 1.8%, 1.6% and 2.2%, respectively. For contact participants, individuals who
progressed to active TB accounted for 4.3%, 3.5%, 2.5% and 3.7% of the positive results for T-SPOT.TB,
QFT-GIT, TSTa and TSTb, respectively; for the new entrant participants, this was 2.9%, 2.1%, 1.7% and
3.2%, respectively. Tables 17–19 provide further information.
Primary analyses
For the primary analyses, the data for the 6386 participants who had all test data were used, which
included 77 participants who developed active TB. As six of these participants did not have data enabling
time in the study to be calculated, the final sample used for the primary analyses was 6380 participants,
and 77 of these participants developed TB.
Incidence rates and incidence rate ratios for individual tests
When utilising all follow-up data, the IR of TB per 1000 participants per annum for those with a positive result
for T-SPOT.TB was 13.2 (95% CI 9.9 to 17.4), and it was 1.5 (95% CI 1.0 to 2.2) for those with a negative
result. For QFT-GIT, the IRs for participants with positive and negative results were 10.1 (95% CI 7.4 to 13.4)
and 1.9 (95% CI 1.3 to 2.7). For TSTa, the IRs for participants with positive and negative results were 6.8
(95% CI 5.2 to 8.7) and 1.2 (95% 0.6 to 2.0), respectively. For TSTb, the IR for participants with positive results
was 11.1 (95% CI 8.3 to 14.6), and it was 1.6 (95% CI 1.0 to 2.3) for those with negative results (Table 20).
When restricting the follow-up of participants to just 1 year, 59 of the 77 participants (76.6%) who
progressed to active TB in the total study duration had progressed at this stage. With the 1-year restricted
follow-up, the IR of TB per 1000 participants per annum for participants with a positive T-SPOT.TB result
was 34.0 (95% CI 24.4 to 46.2), and it was 3.5 (95% CI 2.1 to 35.1) for participants with a negative
T-SPOT.TB result. For participants with a positive QFT-GIT test result, the IR was 25.4 (95% CI 17.8 to
35.1), and it was 4.7 (95% CI 3.0 to 7.0) for those with a negative result. For participants with a positive
TSTa result, the IR was 17.1 (95% CI 12.7 to 22.6), and it was 2.6 (95% CI 1.2 to 5.0) for those with a
positive result; for TSTb, the IR for participants with a positive result was 28.9 (95% CI 2.08 to 39.1), and
it was 3.5 (95% CI 2.0 to 5.6) for those with a negative result (Table 21).
When extending the follow-up period to 2 years, the IR decreased. For participants with a positive T-SPOT.TB
result, the IR was 20.5 (95% CI 15.1 to 27.2), and it was 2.1 (95% CI 1.3 to 3.2) for participants with a
TABLE 17 Incident TB cases with T-SPOT.TB, QFT-GIT and TST results at baseline
Test result
Test, number of progressors/total number (%)
T-SPOT.TB QFT-GIT TSTa TSTb
Positive 56/1571 (3.6) 53/1892 (2.8) 77/3513 (2.2) 60/1729 (3.5)
Negative 29/6414 (0.5) 33/6640 (0.5) 15/4320 (0.3) 31/5940 (0.5)
Missing 12/1625 (0.7) 11/1078 (1.0) 5/1777 (0.3) 6/1941 (0.3)
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TABLE 19 Incident TB cases with T-SPOT.TB, QFT-GIT, TSTa and TSTb test results at baseline, by participant type
Test result
Test, number of progressors/total number (%)
T-SPOT.TB QFT-GIT TSTa TSTb
Participant type
Contacts New entrants Contacts New entrants Contacts New entrants Contacts New entrants
Positive 34/800 (4.3) 22/771 (2.9) 33/952 (3.5) 20/940 (2.1) 51/2019 (2.5) 26/1494 (1.7) 38/1036 (3.7) 22/693 (3.2)
Negative 23/3475 (0.7) 6/2939 (0.2) 22/3324 (0.7) 11/3316 (0.3) 9/2249 (0.4) 6/2071 (0.3) 21/3081 (0.7) 10/2859 (0.3)
Missing 6/586 (1.0) 6/1039 (0.6) 8/585 (1.4) 3/493 (0.6) 3/593 (0.5) 2/1184 (0.2) 4/744 (0.5) 2/1197 (0.2)
TABLE 18 Incident TB cases with TSTa, TSTb, T-SPOT.TB and QFT-GIT results at baseline, by age group
Test result
Test, number of progessors/total number (%)
TSTa TSTb T-SPOT.TB QFT-GIT
Age group, n/N (%)
≤ 35 years > 35 years Missing ≤ 35 years > 35 years Missing ≤ 35 years > 35 years Missing ≤ 35 years > 35 years Missing
Positive 53/1995 (2.7) 24/1516 (1.6) 0/2 (0.0) 42/923 (4.6) 18/804 (2.2) 0/2 (0.0) 38/805 (4.7) 18/763 (2.4) 0/3 (0.0) 36/935 (3.9) 17/953 (1.8) 0/4 (0.0)
Negative 8/2804 (0.3) 7/1514 (0.5) 0/2 (0.0) 19/3767 (0.5) 12/2173 (0.6) 0/0 (0.0) 20/4122 (0.5) 9/2284 (0.4) 0/8 (0.0) 22/3991 (0.6) 11/2641 (0.4) 0/8 (0.0)
Missing 5/727 (0.7) 0/1032 (0.0) 0/18 (0.0) 5/836 (0.6) 1/1085 (0.1) 0/20 (0.0) 8/599 (1.3) 4/1015 (0.4) 0/11 (0.0) 8/600 (1.3) 3/468 (0.6) 0/10 (0.0)
Notes
TSTa was considered positive if participants had a skin induration measuring ≥ 5mm. TSTb was considered positive if participants without a previous BCG vaccination had a skin induration
measuring ≥ 6mm following the standard TST; for participants with a previous BCG vaccination, a skin induration of ≥ 15mm following the standard TST indicated a positive result.
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negative result. For participants who had a positive QFT-GIT result, the IR was 15.6 (95% CI 11.3 to 21.0),
and it was 2.7 (95% CI 1.8 to 4.0) for those with a negative result. For TSTa, the IR for participants with a
positive result was 10.0 (95% CI 7.6 to 13.0), and for those with a negative result it was 1.8 (95% CI 0.9 to
3.2); for TSTb, the IR for participants with a positive result was 16.6 (95% CI 1.2 to 22.1), and for those with
a negative result it was 2.3 (95% CI 1.5 to 3.5).
TABLE 21 The IR and IRR for each single test at different follow-up lengths
Progression measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
1 year of follow-up
Progression (n/N) 41/1235 18/5145 36/1444 23/4936 50/2957 9/3423 42/1485 17/4895
Years at risk 1204.4 5125.3 1418.7 4911.1 2918.9 3410.8 1453.7 4876.0
IR (per 1000
participants per annum)
34.0 3.5 25.4 4.7 17.1 2.6 28.9 3.5
95% CI 24.4 to
46.2
2.1 to 5.6 17.8 to
35.1
3.0 to 7.0 12.7 to
22.6
1.2 to 5.0 20.8 to
39.1
2.0 to 5.6
IRR (per 1000
participants per annum)
9.7 5.4 6.5 8.3
95% CI 5.6 to 16.9 3.2 to 9.1 3.2 to 13.2 4.7 to 14.6
2 years of follow-up
Progression (n/N) 48/1235 21/5145 43/1444 26/4936 57/2957 12/3423 47/1485 22/4895
Years at risk 2340.6 9987.7 2761.4 9566.9 5683.5 6644.8 2824.0 9504.3
IR (per 1000
participants per annum)
20.5 2.1 15.6 2.7 10.0 1.8 16.6 2.3
95% CI 15.1 to
27.2
1.3 to 3.2 11.3 to
21.0
1.8 to 4.0 7.6 to 13.0 0.9 to 3.2 12.2 to
22.1
1.5 to 3.5
IRR (per 1000
participants per annum)
9.8 5.7 5.6 7.2
95% CI 5.8 to 16.3 3.5 to 9.3 3.0 to 10.3 4.3 to 11.9
TABLE 20 The IR and IRR for each single test
Progression measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
Progression (n/N) 52/1235 25/5145 47/1444 30/4936 64/2957 13/3423 52/1485 25/4895
Total years at risk 3926.2 16,645.3 4649.9 15,921.6 9416.8 11,154.6 4674.8 15,896.6
IR (per 1000
participants per annum)
13.2 1.5 10.1 1.9 6.8 1.2 11.1 1.6
95% CI 9.9 to 17.4 1.0 to 2.2 7.4 to 13.4 1.3 to 2.7 5.2 to 8.7 0.6 to 2.0 8.3 to 14.6 1.0 to 2.3
IRR (per 1000
participants per annum)
8.8 5.4 5.8 7.1
95% CI 5.5 to 14.2 3.4 to 8.5 3.2 to 10.6 4.4 to 11.4
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The IRR (the incidence of TB for those with a positive test result compared with those with a negative test
result, with adjustment for person-years) for T-SPOT.TB was 8.8 (95% CI 5.5 to 14.2), for QFT-GIT it was
5.4 (95% CI 3.4 to 8.5), for TSTa it was 5.8 (95% CI 3.2 to 10.6) and for TSTb it was 7.1 (95% CI 4.4
to 11.4). Similar IRRs were produced for each test when restricting the follow-up duration to 1 year and
2 years (see Tables 20 and 21).
Incidence rates and incidence rate ratios for test strategies
For the two-step strategies, the IRs for positive and negative results were 15.9 (95% CI 11.7 to 21.1) and
1.7 (95% CI 1.1 to 2.4) for TSTa + T-SPOT.TB, respectively; 13.2 (95% CI 9.6 to 17.8) and 2.0 (95% CI
1.4 to 2.7) for TSTa +QFT-GIT, respectively; and 13.4 (95% CI 10.0 to 17.6) and 1.6 (95% CI 1.0 to 2.3)
for IGRA + TSTa, respectively. For the two-step strategies including TSTb, the IRs for positive and negative
results were 19.6 (95% CI 14.2 to 26.4) and 1.9 (95% CI 1.3 to 2.6) for TSTb + T-SPOT.TB, respectively;
16.4 (95% CI 11.6 to 22.6) and 2.1 (95% CI 1.5 to 2.9) for TSTb +QFT-GIT, respectively; and 17.4
(95% CI 12.7 to 23.2) and 1.8 (95% CI 1.2 to 2.5) for TSTb + IGRA, respectively (Tables 22 and 23).
For the two-step strategies using results from each IGRA with the TSTa result, the calculated IRRs were 9.6
(95% CI 6.1 to 15.3) for TSTa + T-SPOT.TB, 6.7 (95% CI 4.3 to 10.5) for TSTa + QFT-GIT and 8.6 (95% CI
5.4 to 13.8) for IGRA + TSTa. For the two-step strategies using results from each IGRA with the TSTb result,
the calculated IRRs were 10.6 (95% CI 6.7 to 16.6) for TSTb + T-SPOT.TB, 7.7 (95% CI 4.9 to 12.0) for
TSTb + QFT-GIT and 9.8 (95% CI 6.2 to 15.4) for IGRA + TSTa (see Tables 22 and 23). See Appendix 2,
Figures 12 and 13, for tables showing the results for each step of the investigated two-step strategies.
TABLE 22 The IR and IRR for test strategies with TSTa
Progression measure
Test and result
TSTa+ T-SPOT.TB TSTa+QFT-GIT TSTa+ IGRA
Positive Negative Positive Negative Positive Negative
Progression (n/N) 48/954 29/5426 43/1028 34/5352 51/1199 26/5181
Years at risk 3017.6 17,553.8 3256.1 17,315.3 3813.5 16,757.9
IR (per 1000 participants
per annum)
15.9 1.7 13.2 2.0 13.4 1.6
95% CI 11.7 to 21.1 1.1 to 2.4 9.6 to 17.8 1.4 to 2.7 10.0 to 17.6 1.0 to 2.3
IRR (per 1000 participants
per annum)
9.6 6.7 8.6
95% CI 6.1 to 15.3 4.3 to 10.5 5.4 to 13.8
TABLE 23 The IR and IRR for test strategies with TSTb
Progression measure
Test and result
TSTb+ T-SPOT.TB TSTb+QFT-GIT TSTb+ IGRA
Positive Negative Positive Negative Positive Negative
Progression (n/N) 43/709 34/5671 38/744 39/5636 45/833 32/5547
Years at risk 2198.1 18,373.3 2311.8 18,259.6 2590.7 17,980.7
IR (per 1000 participants
per annum)
19.6 1.9 16.4 2.1 17.4 1.8
95% CI 14.2 to 26.4 1.3 to 2.6 11.6 to 22.6 1.5 to 2.9 12.7 to 23.2 1.2 to 2.5
IRR (per 1000 participants
per annum)
10.6 7.7 9.8
95% CI 6.7 to 16.6 4.9 to 12.0 6.2 to 15.4
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Comparative performance of tests and test strategies
Positive predictive performance
Formal statistical comparisons of the predictive value of positive and negative results of tests and strategies
showed that a positive result for TSTa was a significantly poorer predictor of progression to active TB than
positive results for all other tests (TSTb, T-SPOT.TB, QFT-GIT, TSTa + T-SPOT.TB, TSTa +QFT-GIT, TSTa + IGRA,
TSTb + T-SPOT.TB, TSTb +QFT-GIT and TSTb + IGRA), with TSTb + T-SPOT.TB yielding the largest difference
[ratio of likelihood ratio (RLR) 2.92, 95% CI 2.40 to 3.56; p < 0.001]. Comparing positive results for tests and
strategies with positive results for TSTb alone, T-SPOT.TB (RLR 1.21, 95% CI 1.01 to 1.45; p = 0.037), the
strategies TSTa + T-SPOT.TB (RLR 1.46, 95% CI 1.23 to 1.74; p < 0.001), TSTa + IGRA (RLR 1.22, 95% CI
1.04 to 1.43; p = 0.014) and the three combination strategies including TSTb [TSTb + T-SPOT.TB (RLR 1.78,
95% CI 1.51 to 2.10; p< 0.001), TSTb +QFT-GIT (RLR 1.48, 95% CI 1.24 to 1.77; p< 0.001) and TSTb + IGRA
(RLR 1.57, 95% CI 1.36 to 1.82; p < 0.001)] were significantly superior predictors of progression.
When comparing positive results for tests and test strategies with positive results for T-SPOT.TB alone,
TSTa + T-SPOT.TB (RLR 1.21, 95% CI 1.04 to 1.40; p = 0.016), TSTb + T-SPOT.TB (RLR 1.47, 95% CI 1.27 to
1.70; p < 0.001), TSTb + QFT-GIT (RLR 1.22, 95% CI 1.01 to 1.49; p = 0.041) and TSTb + IGRA (RLR 1.30,
95% CI 1.11 to 1.52; p = 0.001) were significantly superior predictors of progression. Compared with
positive results for QFT-GIT alone, positive results for T-SPOT.TB (RLR 1.31, 95% CI 1.13 to 1.51; p < 0.001),
TSTa + T-SPOT.TB (RLR 1.57, 95% CI 1.33 to 1.86; p < 0.001), TSTa +QFT-GIT (RLR 1.30, 95% CI 1.15 to
1.47; p < 0.001), TSTa + IGRA (RLR 1.32, 95% CI 1.16 to 1.51; p < 0.001), and for the three combination
strategies including TSTb [TSTb + T-SPOT.TB (RLR 1.92, 95% CI 1.59 to 2.32; p < 0.001), TSTb +QFT-GIT
(RLR 1.60, 95% CI 1.34 to 1.91; p < 0.001) and TSTb + IGRA (RLR 1.70, 95% CI 1.43 to 2.01; p < 0.001)]
were significantly superior predictors of progression.
When comparing positive results for tests and test strategies with positive results for test strategies including
TSTa, compared with TSTa + T-SPOT.TB, TSTb + T-SPOT.TB (RLR 1.22, 95% CI 1.09 to 1.37; p = 0.001) was a
significantly superior predictor of progression; compared with TSTa + QFT-GIT, TSTa + T-SPOT.TB (RLR 1.21,
95% CI 1.05 to 1.40; p = 0.007), and the three combination strategies including TSTb [TSTb + T-SPOT.TB
(RLR 1.48, 95% CI 1.25 to 1.75; p < 0.001), TSTb +QFT-GIT (RLR 1.23, 95% CI 1.03 to 1.48; p = 0.022)
and TSTb + IGRA (RLR 1.31, 95% CI 1.14 to 1.50; p < 0.001)] were significantly superior predictors of
progression; and, compared with TSTa + IGRA, the strategies TSTa + T-SPOT.TB (RLR 1.19, 95% CI 1.09 to
1.31; p < 0.001), TSTb + T-SPOT.TB (RLR 1.45, 95% CI 1.26 to 1.68; p = 0.001), TSTb +QFT-GIT (RLR 1.21,
95% CI 1.04 to 1.42; p = 0.016) and TSTb + IGRA (RLR 1.29, 95% CI 1.14 to 1.45; p < 0.001) were
significantly superior predictors of progression.
Comparing positive results from tests and test strategies with positive results from test strategies including TSTb
showed that when comparing with positive results from TSTb+QFT-GIT, positive results from TSTb + T-SPOT.TB
were significantly superior predictors of progression (RLR 1.20, 95% CI 1.05 to 1.37; p= 0.007); and, also,
when comparing positive results from TSTb+ IGRA, positive results from TSTb + T-SPOT.TB were significantly
superior predictors of progression (RLR 1.13, 95% CI 1.04 to 123; p= 0.006). Table 24 provides all results.
Negative predictive performance
When evaluating the negative predictive performance of tests and strategies, negative results for
TSTa + QFT-GIT were significantly poorer predictors of non-progression than negative results for TSTa
(RLR 1.68, 95% CI 1.08 to 2.60; p = 0.021), T-SPOT.TB (RLR 1.31, 95% CI 1.01 to 1.69; p = 0.040) and
TSTa + IGRA (RLR 1.27, 95% CI 1.11 to 1.45; p = 0.001).
Negative results for TSTb + QFT-GIT were significantly poorer predictors of non-progression than negative
results for TSTa (RLR 1.83, 95% CI 1.16 to 2.89; p = 0.010), TSTb (RLR 1.36, 95% CI 1.06 to 1.73;
p = 0.014), T-SPOT.TB (RLR 1.43, 95% CI 1.10 to 1.86; p = 0.008), TSTa + T-SPOT.TB (RLR 1.30, 95% CI
1.05 to 1.60; p = 0.015), TSTa + IGRA (RLR 1.38, 95% CI 1.12 to 1.70; p = 0.002), TSTb + T-SPOT.TB
(RLR 1.16, 95% CI 1.00 to 1.33; p = 0.043) and TSTb + IGRA (RLR 1.20, 95% CI 1.09 to 1.32; p < 0.001).
Table 25 provides all results.
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TABLE 24 Pairwise comparisons between tests, showing ratios of likelihood ratios, 95% CIs and p-values based on the Wald test
Reference strategy B
Strategy A, ratio of likelihood ratios (95% CI); p-value
TSTa TSTb T-SPOT.TB QFT-GIT
TSTa+
T-SPOT.TB
TSTa+
QFT-GIT TSTa+ IGRA
TSTb+
T-SPOT.TB
TSTb+
QFT-GIT TSTb+ IGRA
TSTa 1.64
(1.44 to 1.87);
< 0.001
1.99
(1.68 to 2.34);
< 0.001
1.52
(1.26 to 1.83);
< 0.001
2.39
(2.03 to 2.83);
< 0.001
1.97
(1.64 to 2.37);
< 0.001
2.00
(1.74 to 2.32);
< 0.001
2.92
(2.40 to 3.56);
< 0.001
2.43
(1.96 to 3.03);
< 0.001
2.58
(2.15 to 3.10);
< 0.001
TSTb 1.21
(1.01 to 1.45);
0.037
0.93
(0.76 to 1.13);
0.453
1.46
(1.23 to 1.74);
< 0.001
1.20
(1.00 to 1.45);
0.054
1.22
(1.04 to 1.43);
0.014
1.78
(1.51 to 2.10);
< 0.001
1.48
(1.24 to 1.77);
< 0.001
1.57
(1.36 to 1.82);
< 0.001
T-SPOT.TB 0.77
(0.66 to 0.89);
< 0.001
1.21
(1.04 to 1.40);
0.016
0.99
(0.84 to 1.17);
0.935
1.01
(0.89 to 1.14);
0.865
1.47
(1.27 to 1.70);
< 0.001
1.22
(1.01 to 1.49);
0.041
1.30
(1.11 to 1.52);
0.001
QFT-GIT 1.57
(1.33 to 1.86);
< 0.001
1.30
(1.15 to 1.47);
< 0.001
1.32
(1.16 to 1.51);
< 0.001
1.92
(1.59 to 2.32);
< 0.001
1.60
(1.34 to 1.91);
< 0.001
1.70
(1.43 to 2.01);
< 0.001
TSTa+ T-SPOT.TB 0.82
(0.72 to 0.95);
0.007
0.84
(0.77 to 0.92);
< 0.001
1.22
(1.09 to 1.37);
0.001
1.02
(0.86 to 1.21);
0.857
1.08
(0.94 to 1.23);
0.274
TSTa+QFT-GIT 1.02
(0.93 to 1.11);
0.697
1.48
(1.25 to 1.75);
< 0.001
1.23
(1.03 to 1.48);
0.022
1.31
(1.14 to 1.50);
< 0.001
TSTa+ IGRA 1.45
(1.26 to 1.68);
< 0.001
1.21
(1.04 to 1.42);
0.016
1.29
(1.14 to 1.45);
< 0.001
TSTb + T-SPOT.TB 0.83
(0.73 to 0.95);
0.007
0.88
(0.81 to 0.97);
0.006
TSTb +QFT-GIT 1.06
(0.97 to 1.16);
0.174
TSTb + IGRA
Notes
Values indicate the ratio of positive likelihood ratios comparing strategy A with strategy B.
A value of > 1 indicates that a positive result on Test A is a stronger indicator of probable progression to active TB than a positive result on Test B.
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TABLE 25 Pairwise comparisons between tests, showing ratios of likelihood ratios, 95% CIs and p-values based on the Wald test
Reference strategy B
Strategy A, ratio of likelihood ratios (95% CI); p-value
TSTa TSTb T-SPOT.TB QFT-GIT
TSTa+
T-SPOT.TB
TSTa+
QFT-GIT TSTa+ IGRA
TSTb+
T-SPOT.TB
TSTb+
QFT-GIT TSTb+ IGRA
TSTa 1.35
(0.90 to 2.01);
0.147
1.28
(0.77 to 2.12);
0.337
1.60
(0.97 to 2.65);
0.065
1.41
(0.90 to 2.21);
0.134
1.68
(1.08 to 2.60);
0.021
1.32
(0.86 to 2.03);
0.202
1.58
(0.99 to 2.52);
0.053
1.83
(1.16 to 2.89);
0.010
1.52
(0.96 to 2.40);
0.071
TSTb 0.95
(0.67 to 1.36);
0.784
1.19
(0.84 to 1.68);
0.319
1.05
(0.77 to 1.42);
0.771
1.25
(0.93 to 1.67);
0.142
0.98
(0.72 to 1.34);
0.912
1.17
(0.91 to 1.51);
0.212
1.36
(1.06 to 1.73);
0.014
1.13
(0.89 to 1.43);
0.305
T-SPOT.TB 1.25
(0.97 to 1.61);
0.081
1.10
(0.93 to 1.30);
0.265
1.31
(1.01 to 1.69);
0.040
1.03
(0.82 to 1.3);
0.787
1.24
(0.99 to 1.55);
0.067
1.43
(1.10 to 1.86);
0.008
1.19
(0.92 to 1.53);
0.186
QFT-GIT 0.88
(0.68 to 1.14);
0.324
1.05
(0.88 to 1.24);
0.601
0.82
(0.66 to 1.03);
0.091
0.99
(0.76 to 1.27);
0.916
1.14
(0.92 to 1.41);
0.226
0.95
(0.75 to 1.21);
0.668
TSTa+ T-SPOT.TB 1.19
(0.98 to 1.44);
0.079
0.94
(0.80 to 1.10);
0.426
1.12
(0.96 to 1.31);
0.148
1.30
(1.05 to 1.60);
0.015
1.08
(0.89 to 1.31);
0.438
TSTa+QFT-GIT 0.79
(0.69 to 0.90);
0.001
0.94
(0.77 to 1.15);
0.569
1.09
(0.94 to 1.27);
0.258
0.91
(0.76 to 1.08);
0.280
TSTa+ IGRA 1.20
(0.96 to 1.48);
0.104
1.38
(1.12 to 1.70);
0.002
1.15
(0.95 to 1.39);
0.143
TSTb + T-SPOT.TB 1.16
(1.00 to 1.33);
0.043
0.96
(0.86 to 1.07);
0.492
TSTb +QFT-GIT 0.83
(0.76 to 0.92);
< 0.001
TSTb + IGRA
Notes
Values indicate the ratio of negative likelihood ratios comparing strategy A with strategy B.
A value of < 1 indicates that a negative result on Test A is a stronger indicator of probable non-progression to active TB than a negative result on Test B.
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Association of participant risk factors and progression to active tuberculosis
For the 6380 participants included in the main analysis, further analyses to identify associations of
participants’ demographic characteristics and risk factors with progression to active TB identified that an
increased body mass index (BMI) was associated with a lower IR of progression to active TB (IRR 0.92, 95% CI
0.86 to 0.97; p = 0.003). A borderline significant association was seen with haematological malignancy;
however, only one participant with haematological malignancy progressed to active TB (Tables 26 and 27).
TABLE 26 Results of Poisson regression models separately fitted for each participant demographic characteristic
Demographic characteristic
Progression to active TB?
IRR 95% CI p-valueNo Yes
Sex (n)
Male 3173 40 – – –
Female 3103 37 0.98 0.63 to 1.54 0.940
Missing 27 0 – – –
Participant type (n)
TB contact 3513 51 – – –
New entrant 2790 26 0.70 0.44 to 1.13 0.143
Ethnicity (n)
Indian 2257 31 – – –
White 817 9 0.82 0.39 to 1.72 0.596
Black African 846 7 0.57 0.25 to 1.30 0.184
Mixed 642 7 0.78 0.34 to 1.76 0.545
Pakistani 644 10 1.11 0.55 to 2.27 0.769
Bangladeshi 555 4 0.54 0.19 to 1.53 0.244
Black Caribbean 156 4 1.66 0.58 to 4.69 0.342
Other 222 5 1.77 0.69 to 4.54 0.238
Missing 164 0 – – –
Age (years), median (IQR) 31 (25–42) 30 (26–38) 0.99 0.97 to 1.01 0.202
Age (years) (n)
≤ 35 4008 52 – – –
> 35 2294 25 0.85 0.53 to 1.37 0.499
Missing 1 0 – – –
UK born (n)
No 5277 64 – – –
Yes 1011 13 1.03 0.57 to 1.87 0.921
Missing 15 0 – – –
–, baseline.
Notes
Summaries are frequencies unless otherwise stated.
For categorical risk factors, the top reported category is the reference category.
Missing/unknown categories were not used in modelling.
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Test performance in new entrants and contacts
The test performance for new entrants and contacts (separately) is shown in Table 28; CIs for the IRRs
among contacts and new entrants overlapped for all tests. Point estimates of IRRs were higher among new
entrants than contacts for T-SPOT.TB, QFT-GIT and TSTb, but not for TSTa. The difference was more marked
for T-SPOT.TB for new entrants (IRR 15.7, 95% CI 5.9 to 41.6) than for contacts (IRR 7.2, 95% CI 4.1 to 12.7).
TABLE 27 Results of Poisson regression models separately fitted for each participant risk factor
Risk factor
Progression to active TB?
IRR 95% CI p-valueNo Yes
Previous TB contact (n) 746 12 1.37 0.74 to 2.54 0.318
Previous TB diagnosis (n) 152 2 1.03 0.25 to 4.19 0.968
BCG vaccination (n) 4553 57 1.17 0.60 to 2.29 0.650
Diabetes mellitus (n) 411 4 – – –
Haematological malignancy (n) 10 1 6.76 0.94 to 48.61 0.058
HIV positive (n) 40 0 – – –
Smoker (n) 1277 15 0.92 0.53 to 1.62 0.781
Previous transplant (n) 12 0 – – –
Anti-TNF-α (n) 18 0 – – –
Immunosuppressive drugs (n) 40 0 – – –
Problem drug use (n) 141 4 2.23 0.82 to 6.10 0.118
Homeless (n) 120 3 1.80 0.57 to 5.70 0.320
BMI (kg/m2), mean (SD) 24.5 (4.7) 22.8 (4.5) 0.92 0.86 to 0.97 0.003
Occupation (n)
Education 1239 16 – – –
Health care 254 3 0.90 0.26 to 3.08 0.865
Social/prison sector 32 1 2.40 0.32 to 18.07 0.395
Laboratory/pathology 12 0 – – –
Agriculture/animal care 0 0 – – –
None 1943 22 0.93 0.49 to 1.77 0.820
Other 2510 32 1.07 0.59 to 1.95 0.818
Unknown 313 3 – – –
Travela in the last 3 years (n) 2014 18 0.66 0.38 to 1.13 0.128
Travela before the last 3 years (n) 1738 21 1.13 0.66 to 1.91 0.660
–, baseline; SD, standard deviation.
a Travelled or lived outside the UK (not including Western Europe, the USA, Canada and Australia).
Notes
Summaries are frequencies unless otherwise stated.
Some models did not converge because of a lack of data.
For binary risk factors, presence is compared with absence.
For categorical risk factors, the top reported category is the reference category.
Missing/unknown categories were not used in modelling.
DOI: 10.3310/hta22560 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 56
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Abubakar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
Test performance by demographic group
Table 26 provides further subgroup analysis by age, gender and ethnic group, showing the number of
participants progressing to active TB and the IRR for each demographic group. Although there is variation
by subgroup, the observed differences were not significant.
Use of Mantoux testing
The difference between the two outcomes of Mantoux testing (TSTa and TSTb) is shown further in
Appendix 2, with the combination of results highlighting the additional number of positive results for TSTa
compared with TSTb.
Sensitivity analyses
Sensitivity analyses were performed excluding those participants with assumed BCG vaccination status,
excluding participants with an unclear progression status, using all available test results rather than only
using participants with all test results available, using data from new entrants with 2 years of follow-up
only and using data for contacts of pulmonary TB patients only. The results of these analyses are provided
in Appendix 2, Tables 50–55.
TABLE 28 The IRs and IRRs for new entrants and contacts (separately)
Progression
measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
New entrants only
Progression (n/N) 21/587 5/2229 17/651 9/2165 21/1253 5/1563 18/586 8/2230
Years at risk 1826.0 6823.5 2036.0 6613.4 3874.5 4775.0 1812.4 6837.0
IR (per 1000
participants per
annum)
11.5 0.7 8.3 1.4 5.4 1.0 9.9 1.2
95% CI 7.1 to 17.6 0.2 to 1.7 4.9 to 13.4 0.6 to 2.6 3.4 to 8.3 0.3 to 2.4 5.9 to 15.7 0.5 to 2.3
IRR (per 1000
participants per
annum)
15.7 6.1 5.2 8.5
95% CI 5.9 to 41.6 2.7 to 13.8 2.0 to 13.7 3.7 to 19.5
Contacts only
Progression (n/N) 31/648 20/2916 30/793 21/2771 43/1704 8/1860 34/899 17/2665
Years at risk 2100.1 9821.8 2613.8 9308.2 5542.3 6379.6 2862.4 9059.6
IR (per 1000
participants per
annum)
14.8 2.0 11.5 2.3 7.8 1.3 11.9 1.9
95% CI 10.0 to 21.0 1.2 to 3.1 7.7 to 16.4 1.4 to 3.4 5.6 to 10.5 0.5 to 2.5 8.2 to 16.6 1.1 to 3.0
IRR (per 1000
participants per
annum)
7.2 5.1 6.2 6.3
95% CI 4.1 to 12.7 2.9 to 8.9 2.9 to 13.2 3.5 to 11.3
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Chapter 4 Results: economic analysis
Base-case analysis
Stability of results by number of iterations
For the base-case analyses, we performed 5000 PSA iterations for each strategy, using bootstrap samples
of 4162 patients for contacts and 3795 for new entrants for each iteration (reflecting the sample sizes
available for economic analysis).
Figure 10 shows the incremental effects (mean discounted QALYs per patient for each strategy compared
with the ‘no test’ strategy) for contacts and new entrants at increasing numbers of PSA iterations. The
estimates and ranking of test strategies by incremental effect stabilise after around 3500 iterations in the
contacts subgroup. Results are less stable in the new entrant subgroup, and there is still some swapping
of position among strategies at the cut-off point of 5000 runs. Owing to the very small QALY differences
between strategies, longer runs are required to rank strategies confidently according to effectiveness
alone, but, at a runtime of about 2 hours per strategy for 5000 iterations, additional runs are
computationally prohibitive.
Figure 11 shows incremental net benefit (INB) estimates for the contacts and new entrant subgroups; these
are the mean monetary values per patient for each strategy compared with the ‘no test’ strategy, with
QALYs valued at £20,000 (the lower end of the cost-effectiveness threshold range used by NICE). It can be
seen that INB is much more stable than QALYs, resolving after about 250 iterations. This suggests that INB
differences between strategies are largely driven by cost differences rather than by QALYs.
Clinical outcomes
Key health outcomes from the base-case analysis are shown in Tables 29 and 30 for the contacts and
new entrant subgroups, respectively. Strategies are ranked by undiscounted QALYs. It can be seen that
without testing or preventative treatment (no test), the estimated mean life expectancy was approximately
47 years for contacts and 44 years for new entrants; these estimates reflect the lower mean age of
contacts at baseline in the PREDICT cohort. The mean numbers of QALYs per participant in the contacts
and new entrant subgroups were 46.01 and 42.96, respectively. The small differences between QALY
and life-year estimates can be explained the high baseline EQ-5D scores for PREDICT participants. The
simulated number of TB cases (over the lifetime horizon) per 10,000 people without testing was 189 for
contacts and 179 for new entrants. This equates to an annual rate of approximately 42 cases per 100,000
people. For comparison, the rate of TB in the non-UK-born population of England in 2015 was 51 cases
per 100,000 people.116 However, the use of a fitted Weibull distribution in our model to estimate the
long-term incidence from PREDICT data means that the simulated incidence was much higher in the first
year and levelled off over time.
The QALY estimates were higher in all of the LTBI testing strategies than for the ‘no test’ strategy. This
was generally because of the lower number of TB cases predicted, attributable to the use of preventative
treatments (CPX). It should be noted, however, that QALYs are not always directly related to the number
of TB cases because of QALY losses as a result of adverse reactions to CPX; for example, in the new
entrant subgroup, although there are three fewer TB cases with TSTa than with T-SPOT.TB, there are also
four more CPX-related adverse events, and, hence, mean QALYs are slightly lower with TSTa than with
T-SPOT.TB.
A further ranking of strategies by the number of TB cases that were prevented (compared with ‘no test’),
cases in which CPX was started and cases in which BCG vaccination was offered is presented in Table 31.
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FIGURE 10 Incremental effectiveness (compared with ‘no test’) by number of iterations. (a) Contacts; and
(b) migrants.
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FIGURE 11 Incremental net benefit (compared with ‘no test’) by number of iterations. (a) Contacts; and
(b) migrants.
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TABLE 29 Modelled health outcomes for contacts: base case (mean of 5000 PSA iterations)
Strategy
Number of cases (per 10,000 patients offered LTBI test)
Mean per patient
(undiscounted)
TB BCG Started CPX CPX AE
Started
treatment
for active TB
Treatment
for active
TB AE Life-years QALYs
10: no test 189 0 0 0.0 189 0.8 46.91772 46.00851
5: TSTb +QFT-GIT 162 665 365 1.6 162 0.6 46.91782 46.00903
1: TSTa+QFT-GIT 160 665 533 2.3 160 0.6 46.91781 46.00903
6: TSTb + T-SPOT.TB 161 665 361 1.6 161 0.6 46.91783 46.00903
2: TSTa+ T-SPOT.TB 161 665 474 2.1 161 0.6 46.91782 46.00904
8: QFT-GIT 157 606 858 3.7 157 0.6 46.91778 46.00906
9: T-SPOT.TB 158 615 668 2.9 158 0.6 46.91780 46.00907
7: TSTb + IGRA 158 645 438 1.9 158 0.6 46.91784 46.00910
3: TSTa+ IGRA 156 645 648 2.8 156 0.6 46.91782 46.00910
4: TSTb 152 531 1078 4.6 152 0.5 46.91783 46.00917
0: TSTa 145 522 2192 9.6 145 0.5 46.91775 46.00921
AE, adverse event.
TABLE 30 Modelled health outcomes for new entrants: base case (mean of 5000 PSA iterations)
Strategy
Number of cases (per 10,000 patients offered LTBI test)
Mean per patient
(undiscounted)
TB BCG Started CPX CPX AE
Started
treatment
for active TB
Treatment
for active
TB AE Life-years QALYs
10: no test 179 0 0 0.0 179 0.7 44.44023 42.96137
1: TSTa+QFT-GIT 145 1132 580 2.5 145 0.5 44.44031 42.96193
5: TSTb +QFT-GIT 146 1147 401 1.8 146 0.5 44.44034 42.96195
2: TSTa+ T-SPOT.TB 145 1129 578 2.5 145 0.5 44.44031 42.96195
6: TSTb + T-SPOT.TB 146 1144 407 1.8 146 0.5 44.44033 42.96195
3: TSTa+ IGRA 142 1097 709 3.1 142 0.5 44.44032 42.96200
8: QFT-GIT 139 1040 974 4.2 139 0.5 44.44028 42.96200
7: TSTb + IGRA 143 1122 473 2.1 143 0.5 44.44035 42.96201
4: TSTb 141 936 832 3.7 141 0.5 44.44032 42.96202
0: TSTa 135 884 1815 8.0 135 0.4 44.44023 42.96202
9: T-SPOT.TB 138 1074 905 4.0 138 0.5 44.44032 42.96205
AE, adverse event.
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Cost-effectiveness
Tables 32 and 33 show the estimated mean discounted costs and QALYs per participant by strategy under
the base-case analysis, for the two subgroups. The ‘no test’ strategy had the lowest costs and QALYs.
The incremental costs for the LTBI testing strategies compared with ‘no test’ were between £156 (TSTb +
QFT-GIT) and £273 (TSTa) for contacts and between £155 (TSTb + QFT-GIT) and £247 (TSTa) for new
entrants. The additional cost yielded few extra QALYs; there was a mean gain of around 0.0002 per
patient. Although none of the strategies under this base-case scenario appeared to be cost-effective
compared with ‘no test’, the primary objective of this study was to assess the most cost-effective test or
combination of tests and not to assess the cost-effectiveness of contact tracing or migrant tracing. Other
QALY benefits will accrue from contact tracing and migrant screening through the detection of active TB
and from the prevention of subsequent transmission, which we have not accounted for in the base case.
Nevertheless, the comparison of strategies remains valid as the probable subsequent benefit was directly
proportional to the extent to which each testing strategy prevented incident cases.
TABLE 31 Strategies ranked by the number of TB cases prevented, cases in which CPX was started and cases in
which BCG vaccination was offered
TB cases prevented* Cases in which
Strategy n
CPX was started BCG vaccination was offered
Strategy n Strategy n
Contacts
10: no test 0.0 11: no test 0.0 11: no test 0.0
5: TSTb +QFT-GIT 27.3 7: TSTb+ T-SPOT.TB 361.0 1: TSTa 522.4
6: TSTb + T-SPOT.TB 27.4 6: TSTb+QFT-GIT 365.4 5: TSTb 531.4
2: TSTa+ T-SPOT.TB 28.2 8: TSTb+ IGRA 437.8 9: QFT-GIT 605.8
1: TSTa+QFT-GIT 28.5 3: TSTa+ T-SPOT.TB 473.9 10: T-SPOT.TB 615.0
7: TSTb + IGRA 31.0 2: TSTa+QFT-GIT 532.7 8: TSTb+ IGRA 644.7
9: T-SPOT.TB 31.2 4: TSTa+ IGRA 647.9 4: TSTa+ IGRA 644.7
8: QFT-GIT 32.3 10: T-SPOT.TB 668.1 6: TSTb+QFT-GIT 665.0
3: TSTa+ IGRA 32.5 9: QFT-GIT 858.0 2: TSTa+QFT-GIT 665.0
4: TSTb 36.9 5: TSTb 1077.7 7: TSTb+ T-SPOT.TB 665.0
0: TSTa 44.3 1: TSTa 2191.7 3: TSTa+ T-SPOT.TB 665.0
New entrants
10: no test 0.0 11: no test 0.0 11: no test 0.0
5: TSTb +QFT-GIT 32.3 6: TSTb+QFT-GIT 401.3 1: TSTa 883.9
6: TSTb + T-SPOT.TB 32.7 7: TSTb+ T-SPOT.TB 406.6 5: TSTb 935.7
1: TSTa+QFT-GIT 33.4 8: TSTb+ IGRA 473.2 9: QFT-GIT 1039.7
2: TSTa+ T-SPOT.TB 33.7 3: TSTa+ T-SPOT.TB 577.9 10: T-SPOT.TB 1074.5
7: TSTb + IGRA 35.7 2: TSTa+QFT-GIT 579.7 4: TSTa+ IGRA 1097.2
3: TSTa+ IGRA 37.1 4: TSTa+ IGRA 708.6 8: TSTb+ IGRA 1121.8
4: TSTb 37.7 5: TSTb 832.1 3: TSTa+ T-SPOT.TB 1129.2
8: QFT-GIT 40.0 10: T-SPOT.TB 905.3 2: TSTa+QFT-GIT 1132.0
9: T-SPOT.TB 40.2 9: QFT-GIT 973.8 7: TSTb+ T-SPOT.TB 1144.0
0: TSTa 44.0 1: TSTa 1814.8 6: TSTb+QFT-GIT 1146.7
*Compared with the ‘no test’ strategy.
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TABLE 32 The modelled costs and effects in contacts: base case (mean of 5000 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 301.53 22.131076 272.96 0.0002367 –268.22 0.0
3: TSTa+ IGRA 241.73 22.131048 213.15 0.0002081 –208.99 0.0
4: TSTb 224.24 22.131074 195.67 0.0002347 –190.97 0.0
2: TSTa+ T-SPOT.TB 212.93 22.131021 184.36 0.0001811 –180.74 0.0
7: TSTb + IGRA 205.05 22.131047 176.48 0.0002076 –172.33 0.0
1: TSTa+QFT 204.41 22.131019 175.84 0.0001788 –172.26 0.0
9: T-SPOT.TB 204.07 22.131031 175.49 0.0001917 –171.66 0.0
6: TSTb + T-SPOT.TB 191.09 22.131021 162.51 0.0001808 –158.90 0.7
8: QFT 187.25 22.131027 158.68 0.0001872 –154.94 35.6
5: TSTb +QFT 184.73 22.131019 156.16 0.0001795 –152.57 63.7
10: no test 28.57 22.13084 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
TABLE 33 The modelled costs and effects in new entrants: base case (mean of 5000 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 273.62 21.042235 246.59 0.0002179 –242.23 0.0
3: TSTa+ IGRA 233.06 21.042235 206.03 0.0002178 –201.67 0.0
9: T-SPOT.TB 218.03 21.042253 191.00 0.0002359 –186.28 0.0
2: TSTa+ T-SPOT.TB 211.15 21.042212 184.12 0.0001949 –180.22 0.0
4: TSTb 205.43 21.042244 178.40 0.0002272 –173.86 0.0
1: TSTa+QFT 201.63 21.042205 174.60 0.0001881 –170.84 0.0
7: TSTb + IGRA 197.80 21.042242 170.77 0.0002249 –166.27 0.0
8: QFT 192.88 21.042230 165.85 0.0002134 –161.58 3.8
6: TSTb + T-SPOT.TB 187.27 21.042215 160.24 0.0001983 –156.27 2.4
5: TSTb +QFT 182.32 21.042213 155.29 0.0001963 –151.36 93.7
10: no test 27.03 21.042017 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
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The most cost-effective of the LTBI strategies was TSTb + QFT-GIT because, although the QALY gain was
lower than for some of the other strategies (e.g. TSTb alone in both subgroups), it was cheaper. The
estimated INB differences between the LTBI test strategies were small. In particular, in both subgroups,
very similar INB estimates were obtained for the three most cost-effective test strategies: (1) TSTb +QFT-GIT,
(2) TSTb + T-SPOT.TB and (3) QFT-GIT alone. Despite this, the conclusion that TSTb +QFT-GIT was the most
cost-effective of the LTBI test strategies was relatively robust in the PSA. In the contacts subgroup, the
estimated probability that TSTb + QFT-GIT was the most cost-effective of the LTBI test strategies was 64%,
followed by QFT-GIT alone (with 36% probability). Using a higher cost-effectiveness threshold of £30,000
per QALY gained, the estimated probabilities were 59% for TSTb + QFT-GIT and 39% for QFT-GIT alone.
In the new entrant subgroup, the estimated probability that TSTb +QFT-GIT was the most cost-effective of
the LTBI test strategies was 94% at a cost-effectiveness threshold of £20,000 per QALY and 87% at a
cost-effectiveness threshold of £30,000 per QALY.
Sensitivity analyses
We conducted a number of one-way and two-way sensitivity analyses to test the robustness of the
base-case results to key uncertainties in model parameters. The results for most sensitivity analyses were
estimated from 500 PSA iterations. Although longer model runs are preferred, these analyses offer fairly
robust indications of how parameter changes are likely to influence cost-effectiveness.
Doubled baseline incidence of tuberculosis in both subgroups
When the baseline incidence of TB was doubled for contacts (Table 34), compared with the base-case
analysis (see Table 32) only the TSTa + QFT and TSTb + IGRA strategies swap positions. In the new entrants’
subgroup, doubling the baseline incidence of TB does not alter the position of strategies and the
difference in probability of cost-effectiveness is marginal (Table 35). Although the increasing costs observed
with doubling the TB incidence accrues from treating more TB cases, the lowered INBs suggest that the
LTBI test strategies become more cost-effective at higher TB incidences.
TABLE 34 The modelled costs and effects in contacts: double baseline TB incidence (mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 321.64 22.112022 266.04 0.0005891 –254.26 0
3: TSTa+ IGRA 264.09 22.111876 208.50 0.0004435 –199.63 0
4: TSTb 245.71 22.111962 190.12 0.0005292 –179.53 0
2: TSTa+ T-SPOT.TB 235.90 22.111813 180.30 0.0003803 –172.70 0
1: TSTa+QFT-GIT 227.36 22.111821 171.76 0.0003876 –164.01 0
7: TSTb + IGRA 227.56 22.111866 171.96 0.0004335 –163.29 0
9: T-SPOT.TB 226.54 22.111830 170.95 0.0003973 –163.00 0
6: TSTb + T-SPOT.TB 214.12 22.111801 158.53 0.0003676 –151.18 1
8: QFT-GIT 209.72 22.111825 154.13 0.0003918 –146.29 47
5: TSTb +QFT-GIT 207.74 22.111815 152.15 0.0003817 –144.52 52
10: no test 55.59 22.111433 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
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Decreased cost per patient of T-SPOT.TB to equal that of QuantiFERON TB Gold In Tube
Compared with the base-case cost-effectiveness results, Tables 36 and 37 show that when the costs of
T-SPOT.TB and QFT-GIT are equal, at £41, the T-SPOT.TB -based LTBI strategies become optimal. Among
contacts, T-SPOT.TB was the most cost-effective strategy, whereas TSTb + T-SPOT.TB was the most
cost-effective strategy among new entrants.
TABLE 35 The modelled costs and effects in new entrants: double baseline TB incidence (mean of 500 PSA
iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 292.83 21.025638 239.92 0.0005958 –228.00 0
3: TSTa+ IGRA 253.59 21.025557 200.68 0.0005144 –190.39 0
9: T-SPOT.TB 237.81 21.025593 184.90 0.0005507 –173.89 0
2: TSTa+ T-SPOT.TB 232.12 21.025512 179.21 0.0004695 –169.82 0
4: TSTb 225.86 21.025552 172.95 0.0005102 –162.75 0
1: TSTa+QFT-GIT 222.65 21.025478 169.74 0.0004361 –161.01 0
7: TSTb + IGRA 218.61 21.025536 165.70 0.0004941 –155.81 0
8: QFT-GIT 212.66 21.025574 159.75 0.0005312 –149.12 13
6: TSTb + T-SPOT.TB 208.52 21.025496 155.61 0.0004535 –146.54 5
5: TSTb +QFT-GIT 203.53 21.025463 150.62 0.0004203 –142.22 82
10: no test 52.91 21.025042 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
TABLE 36 The modelled costs and effects in contacts: cost of T-SPOT.TB equal to QFT (mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 301.33 22.134428 272.38 0.0002381 –267.62 0
3: TSTa+ IGRA 229.49 22.134375 200.54 0.0001853 –196.83 0
4: TSTb 224.36 22.134422 195.40 0.0002329 –190.74 0
1: TSTa+QFT-GIT 204.75 22.134354 175.79 0.0001647 –172.50 0
2: TSTa+ T-SPOT.TB 200.70 22.134348 171.74 0.0001586 –168.57 0
7: TSTb + IGRA 198.67 22.134373 169.71 0.0001838 –166.03 0
8: QFT-GIT 187.69 22.134321 158.73 0.0001318 –156.10 0
6: TSTb + T-SPOT.TB 184.72 22.134340 155.76 0.0001509 –152.74 1
5: TSTb +QFT-GIT 184.99 22.134356 156.03 0.0001665 –152.70 0
9: T-SPOT.TB 174.38 22.134336 145.42 0.0001467 –142.49 99
10: no test 28.96 22.134189 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
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Further increased baseline incidence by multiples of 2 for TSTb +QuantiFERON TB Gold
In-Tube compared with no test
In Tables 38 and 39, the baseline incidence of TB is increased by multiples of 2 and the comparison is only
between TSTb + QFT-GIT and no test. This analysis was carried out to explore a TB incidence threshold or
range for cost-effectiveness and for model validation, rather than to explore cost-effectiveness among LTBI
test strategies. TSTb +QFT-GIT appeared to become cost-effective at a lower incidence in new entrants
than in contacts. However, the high incidences that are required to achieve cost-effectiveness in both
subgroups (compared with no test) are probably overestimated, as the analysis did not account for the
benefits from LTBI testing, because the number of individuals who were offered CPX or a BCG vaccination
was fixed at for all scenarios.
TABLE 37 The modelled costs and effects in new entrants: cost of T-SPOT.TB equal to QFT (mean of 500 PSA
iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 273.49 21.045602 246.11 0.0002356 –241.40 0
3: TSTa+ IGRA 223.57 21.045583 196.19 0.0002165 –191.86 0
4: TSTb 205.62 21.045569 178.25 0.0002025 –174.20 0
1: TSTa+QFT-GIT 201.82 21.045546 174.44 0.0001788 –170.87 0
2: TSTa+ T-SPOT.TB 201.63 21.045569 174.25 0.0002023 –170.20 0
7: TSTb + IGRA 193.45 21.045575 166.07 0.0002079 –161.91 0
8: QFT-GIT 192.83 21.045586 165.46 0.0002190 –161.08 1
9: T-SPOT.TB 188.04 21.04560 160.66 0.0002336 –155.99 16
5: TSTb +QFT-GIT 182.55 21.045539 155.17 0.0001718 –151.74 46
6: TSTb + T-SPOT.TB 182.94 21.045563 155.57 0.0001959 –151.65 38
10: no test 27.38 21.045367 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
TABLE 38 The modelled costs and effects: baseline incidence of TB increased by multiples of 2 in contacts –
TSTb+QFT-GIT vs. no test (mean of 500 PSA iterations)
Incidence
Mean per patient (discounted) Incremental (vs. no test)
INB* (£)Cost (£) QALYs Cost (£) QALYs
Incidence X4 250.22 22.07031 145.25 0.000829 –128.66
Incidence X8 329.25 21.99264 134.06 0.00178 –98.47
Incidence X16 457.58 21.85984 119.08 0.003896 –41.16
Incidence X18 490.25 21.82729 116.49 0.004309 –30.32
Incidence X20 515.22 21.80021 114.38 0.004800 –18.39
Incidence X22 533.86 21.78072 112.94 0.005150 –9.94
Incidence X26 582.56 21.72964 109.58 0.006059 11.60
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
DOI: 10.3310/hta22560 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 56
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Abubakar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
Changed chemoprophylaxis uptake to 59.9% and chemoprophylaxis completion rate to
57%, as stated in the Tuberculosis in England 2016 report2
We tested lower proportions of CPX uptake (59.9%) and CPX completion (57%) as reported in the
Tuberculosis in England 2016 report.2 Tables 40 and 41 indicate that, with fewer individuals being offered
CPX and completing CPX, QFT-GIT was the most cost-effective LTBI strategy with a probability of cost-
effectiveness of 98% for contacts and 84% for new entrants.
Used a 20-year time horizon
Compared with a lifetime horizon in the base case, Tables 42 and 43 show an almost identical ordering of
strategies. However, there is a huge drop in QALYs, from about 22.0 to 14.0 in contacts and from about
21.0 to 13.6 in new entrants. Compared with QALYs, the drop in costs from the base case is negligible.
TABLE 39 The modelled costs and effects: baseline incidence of TB increased by multiples of 2 in new entrants –
TSTb+QFT-GIT vs. no test (mean of 500 PSA iterations)
Incidence
Mean per patient (discounted) Incremental (vs. no test)
INB* (£)Cost (£) QALYs Cost (£) QALYs
Incidence X4 242.89 20.98666 142.37 0.000897 –124.44
Incidence X8 316.03 20.91454 128.50 0.001999 –88.51
Incidence X16 436.56 20.79132 109.68 0.004382 –22.04
Incidence X18 467.96 20.76073 106.11 0.004839 –9.33
Incidence X20 492.26 20.73590 103.20 0.005407 4.94
Incidence X22 510.24 20.71721 100.97 0.005792 14.86
Incidence X26 557.77 20.66879 96.15 0.00679 39.65
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
TABLE 40 The modelled costs and effects at a 59.9% CPX uptake rate and a 57% CPX completion rate in contacts
(mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 249.02 22.13418 220.06 –0.000005 –220.15 0
3: TSTa+ IGRA 226.93 22.13420 197.98 0.000014 –197.69 0
2: TSTa+ T-SPOT.TB 202.27 22.13421 173.31 0.000016 –172.99 0
4: TSTb 198.88 22.13422 169.92 0.000035 –169.21 0
7: TSTb + IGRA 195.30 22.13421 166.34 0.000023 –165.89 0
1: TSTa+QFT 192.29 22.13421 163.33 0.000018 –162.96 0
9: T-SPOT.TB 188.68 22.13417 159.73 –0.000016 –160.04 0
6: TSTb + T-SPOT.TB 183.12 22.13420 154.16 0.000013 –153.90 0
5: TSTb +QFT 176.61 22.13422 147.65 0.000027 –147.11 2
8: QFT 167.34 22.13415 138.39 –0.000039 –139.17 98
10: no test 28.96 22.13419 0.00 0.0000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
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TABLE 41 The modelled costs and effects at a 59.9% CPX uptake rate and a 57% CPX completion rate in new
entrants (mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 230.28 21.04539 202.90 0.000021 –202.48 0
3: TSTa+ IGRA 216.77 21.04541 189.40 0.000047 –188.45 0
2: TSTa+ T-SPOT.TB 197.92 21.04542 170.55 0.000054 –169.47 0
9: T-SPOT.TB 196.84 21.04541 169.46 0.000041 –168.63 0
1: TSTa+QFT 188.40 21.04540 161.02 0.000036 –160.30 0
7: TSTb + IGRA 187.25 21.04541 159.88 0.000045 –158.97 0
4: TSTb 186.12 21.04539 158.75 0.000023 –158.28 0
6: TSTb + T-SPOT.TB 178.26 21.04542 150.88 0.000053 –149.83 0
5: TSTb +QFT 173.40 21.04540 146.03 0.000034 –145.34 16
8: QFT-GIT alone 170.04 21.04540 142.66 0.000034 –141.97 84
10: no test 27.38 21.04537 0.00 0.000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
TABLE 42 The modelled costs and effects at a 20-year time horizon: contacts (mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 298.94 13.99950 273.40 0.000506 –263.27 0
3: TSTa+ IGRA 239.42 13.99937 213.88 0.000376 –206.36 0
4: TSTb 221.80 13.99944 196.26 0.000441 –187.44 0
2: TSTa+ T-SPOT.TB 210.54 13.99932 184.99 0.000325 –178.49 0
1: TSTa+QFT-GIT 202.00 13.99932 176.45 0.000326 –169.92 0
7: TSTb + IGRA 202.66 13.99936 177.11 0.000363 –169.86 0
9: T-SPOT.TB 201.71 13.99934 176.16 0.000343 –169.30 0
6: TSTb + T-SPOT.TB 188.63 13.99931 163.09 0.000313 –156.82 0
8: QFT-GIT 185.02 13.99933 159.47 0.000338 –152.72 38
5: TSTb +QFT-GIT 182.21 13.99931 156.67 0.000318 –150.30 62
10: no test 25.55 13.99899 0.00 0.000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
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Allowing for transmission
The results for a modelled transmission scenario are reported in Appendix 2, Tables 58 and 59. Our
approach to modelling transmission was based on the assumption that, for every case of active TB in the
original cohorts (4162 in the contacts subgroup and 3795 in the new entrants subgroup), four new
secondary contacts were traced. The traced contacts, drawn randomly from the original contacts cohort,
were introduced into the model and subsequently followed the same pathway as individuals from the
original cohort. For instance, of 4162 participants in the original cohort, 79 developed active TB (i.e. there
were 79 index cases, each accounting for four secondary cases randomly drawn into the model) (see
Appendix 2, Table 58). The number of secondary cases is slightly higher than the sum of 4 and 79 because
some of the secondary contacts also develop active TB, resulting in additional participants being introduced
into the model.
TABLE 43 The modelled costs and effects at a 20-year time horizon: new entrants (mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test)
INB* (£) Probability† (%)Cost (£) QALYs Cost (£) QALYs
0: TSTa 271.35 13.62039 247.11 0.000487 –237.37 0
3: TSTa+ IGRA 230.96 13.62032 206.72 0.000413 –198.46 0
9: T-SPOT.TB 215.81 13.62036 191.57 0.000451 –182.54 0
2: TSTa+ T-SPOT.TB 208.95 13.62028 184.71 0.000376 –177.18 0
4: TSTb 203.33 13.62032 179.09 0.000412 –170.85 0
1: TSTa+QFT 199.44 13.62027 175.20 0.000360 –168.00 0
7: TSTb + IGRA 195.73 13.62030 171.49 0.000396 –163.56 0
8: QFT 190.61 13.62035 166.37 0.000440 –157.58 5
6: TSTb + T-SPOT.TB 185.16 13.62027 160.92 0.000363 –153.65 2
5: TSTb +QFT 180.14 13.62025 155.90 0.000346 –148.97 93
10: no test 24.24 13.61991 0.00 0.000000 0.00 –
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that the strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
RESULTS: ECONOMIC ANALYSIS
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Chapter 5 Discussion
Main findings
Diagnostic accuracy
We assessed the ability of 12 screening strategies to predict the development of active TB through latent
TB detection that used IRRs comparing those with positive and negative screening results. The point
estimate of the IR for active TB per annum was 10-fold or more higher in those with a positive IGRA result
or in whom the TSTb strategy was applied. TSTa was less predictive, at about a sevenfold higher IR when
comparing those with a positive test result and those with a negative test result. Although T-SPOT.TB and
combinations of T-SPOT.TB with various thresholds of TST appeared to perform better, the confidence
limits for all strategies overlapped.
The TSTa approach identified more progressors than any other strategy. The IRs in the TSTa-positive and
TSTa-negative groups were lower than in the corresponding positive and negative groups identified by
the other individual tests, although we did not find evidence that these differences were real rather than
chance occurrences. The poorer predictive value of the TSTa approach than of IGRAs was consistent with
the greater number of false-positive results because of a previous BCG vaccination; this was expected in
this TST strategy that did not take prior vaccination into account. In the secondary analysis, assessing
contacts and migrants separately, progression rates were higher among contacts than among migrants,
although, again, this may have been attributable to chance.
Although no test was clearly superior to other tests or test strategies in all test dimensions, for PPV, all
strategies appeared to be better than TSTa alone. The combination of T-SPOT.TB alone, QFT-GIT alone and
TSTb (in that order) appears to be the most favourable option for predicting the development of active TB.
Although the effect was more modest, combining TSTb with any of the IGRAs also appeared to be better
than TSTb alone. The approaches using T-SPOT.TB or QFT-GIT alone were also not as good in their PPVs as
strategies that combine TST with the respective IGRA.
For the NPVs of tests and strategies, all tests appeared to have high predictive values. Compared with
TSTa + QFT-GIT, TSTa, T-SPOT.TB and TSTa + IGRA appeared to be the best approaches. Compared with
TSTb +QFT-GIT, TSTa, TSTb, T-SPOT.TB, TSTa + T-SPOT.TB, TSTa + IGRA and TSTb + IGRA were better.
Cost-effectiveness
We developed a DES model to estimate the cost-effectiveness of alternative testing strategies for LTBI in two
high-risk subgroups: contacts of people with active TB and recent migrants from high-incidence countries.
The model used individual data from the PREDICT cohort to characterise baseline risk factors and test results
in these subgroups, simulated the LTBI screening process and, when appropriate, preventative treatment
with CPX or a BCG vaccination. The model accounted for missing and indeterminate test results, as
observed in PREDICT, and simulated imperfect uptake and completion of preventative treatment and related
adverse events. TB incidence was simulated over the individuals’ lifetimes, using available information on
their actual test results and estimates of the prognostic value of tests from the statistical analyses, with
adjustment for the effects of any preventative treatment. Public sector costs were estimated, including LTBI
testing, preventative treatment and treatment of adverse events and active TB. Health outcomes were
estimated in the form of QALYs, calculated from simulated survival and quality-of-life impact of incident TB
and adverse events. The costs and QALYs were both discounted at the current recommended rate of 3.5%
per year.
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In these populations (contacts of people with active TB and recent migrants from high-incidence countries),
although none of the test strategies was cost-effective, our base-case assumptions and parameters limited
the application of this analysis to a comparison of strategies with no testing for the following reasons:
l The model did not reflect transmission of infection, and so would underestimate health gain and cost
savings from TB prevention.
l The model did not account for cases of active TB detected at baseline, which, if asymptomatic, may be
detected through further investigation following a positive LTBI test.
Partly attributable to these assumptions, the estimated QALY gains of 0.0002 per person were small,
despite LTBI testing and treatment preventing TB cases, for an additional cost of between £150 and £270.
The model predicted that LTBI testing and preventative treatment would prevent between 27 and 44 cases
of TB in a population of 10,000 people over the lifetime horizon, depending on the test strategy. To
achieve this, between 361 and 2192 people would need to start CPX and between 522 and 1146 people
would need to have a BCG vaccination. In general, strategies with a higher number of individuals starting
CPX had fewer patients developing active TB. However, diminishing returns were observed, with fewer
additional cases prevented from successive increases in the number of individuals given CPX.
The most cost-effective LTBI test strategy was QFT-GIT following a positive TSTb result, which had an estimated
cost per QALY gained (compared with no testing) of > £790,000 in new entrants or > £870,000 in contacts.
The less discriminating strategies (i.e. the strategies that generate the greatest number of LTBI-positive results,
such as TSTa), and consequently those in which the greatest numbers of patients received CPX, were generally
the least cost-effective, suggesting that CPX costs are the main driver of cost-effectiveness. Although less
obvious, the cost of the IGRAs does also influence cost-effectiveness. In particular, we noted that TSTb+Q
FT-GIT and TSTb+ T-SPOT.TB prevented about the same number of TB cases and yielded similar QALY increases,
but TSTb+QFT-GIT appeared to be more cost-effective as it was cheaper.
Comparison with previous studies
Head-to-head interferon gamma release assay versus tuberculin skin test
comparison studies
This study provides a comprehensive comparison of latent TB testing strategies. Prior comparison studies
have largely been in high-incidence countries, where the risk of reinfection limits the applicability of results
to the UK. Four head-to-head comparison studies23,80,81,104 have been published in low-incidence countries.
Only one of these studies81 compared the TST with each of the commercially available IGRAs; the other
three23,80,104 utilised QFT-GIT alone. Sample sizes ranged from 339 to 1335 people, and all four studies
included ≤ 15 individuals who progressed to active TB. None directly compared rates of TB development
between individuals with positive and negative baseline test results.
Our study is the largest study of the predictive values of IGRAs published to date, in terms of both the
number of participants and the number of progressions to active TB in a low-incidence setting. This has
allowed us to quantify the prognostic value of IGRAs, in direct comparisons with the TST, with a high
degree of precision and taking into account follow-up duration. The results are directly relevant to clinical
practice in the UK because the study population comprised individuals who are being targeted for
screening in national policies.
Of the four previous studies, two reported point estimates of PPV for IGRA that were higher than those
for the TST (17% for IGRA vs. 2% for TST23 and 13% for IGRA vs. 5% for TST104). The other two studies
reported a similar PPV for IGRA and TST (3% for IGRA vs. 2% for TST80 and 3% for IGRA vs. 3% for TST81).
The TST threshold that was used in these studies differed. We found only limited differences between the
PPVs of T-SPOT.TB, QFT-GIT, TSTa and TSTb, which ranged from 2.2% for TSTa to 3.6% for T-SPOT.TB.
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Our estimates of NPV were high (≥ 99.5%) for all four tests; this was consistent with the four previous
studies, all of which reported NPVs of ≥ 98%.
Comparison with previous estimates of interferon gamma release assay predictive value
The pooled IRR (comparing individuals with a positive IGRA result with those with a negative result) from a
previous meta-analysis was 2.11 (95% CI 1.29 to 3.46) for IGRA, 1.60 (95% CI 0.94 to 2.72) for TST with
a 10-mm cut-off point and 1.43 (95% CI 0.75 to 2.72) for TST with a 5-mm cut-off point.16 Results for
IGRAs published since the systematic review117 included hazard ratios ranging from 2.054 to 42.4,29 odds
ratios of 2.10–14.935,76 and rate ratios of 2.12–73.9.24,75 Our estimates for T-SPOT.TB and QFT-GIT were
8.8 (95% CI 5.5 to 14.2) and 5.4 (95% CI 3.4 to 8.5), respectively; these were higher than the pooled
estimate and broadly consistent with the less extreme estimates from the later studies.
Our estimates of PPV were at the lower end of those previously reported (see Table 1), but were fairly
similar to the pooled estimate of 2.7% (95% CI 2.3% to 3.2%) from a meta-analysis of risk groups.15
The PPV for the development of active TB depends in part on the incidence of TB in the study population,
being higher when the incidence is higher; consistent with this, the pooled estimate among high-risk
groups was 6.8% (95% CI 5.6% to 8.3%).15 Although our study focused on high-risk groups within the
UK, the incidence here is still relatively low compared with the high-burden countries in which many of the
previous studies were conducted. Our estimates of NPV were similar to those previously published; for
example, the meta-analysis produced a pooled estimate of 99.7% (95% CI 99.5% to 99.8%).15
The PREDICT study therefore confirmed the relatively low PPV of IGRA for the development of active TB
disease. Several factors contributed to this relatively poor performance. First, the test detects an immune
response to M. tuberculosis antigens, rather than the presence of the organism itself. A positive result
therefore did not necessarily indicate that the bacterium was present in the body and able to reactivate to
cause disease. Second, although there were accepted cut-off values to define positive and negative IGRA
results, categorical results may vary within the same individual, particularly if they were close to the cut-off
value.118 Further analysis of the PREDICT data will help to determine the utility of quantitative (rather than
categorical) IGRA results in predicting active TB.
Strengths and limitations
To our knowledge, this is the largest study that has compared the two commercially available IGRAs with the
TST to study their predictive value. Both contacts and migrants were invited to participate in the study based
on standardised criteria, limiting selection bias for inclusion in the study. We used four different approaches
to identify participants who progressed to active TB, maximising ascertainment of the outcome. Every
participant in our primary analysis had all three assays, making the estimates for the tests comparable; in
addition, a sensitivity analysis using all available participants generated similar results. The assessment of
exposure, outcome and covariates was done using the same standards for all participants, minimising the
chance of information bias. We utilised standardised testing methods for both IGRAs in five laboratories, and
TST was administered using the Mantoux test by our trained research nurses to decrease measurement error.
We also sought to minimise so-called ‘incorporation bias’, which is likely to arise when IGRA results are
incorporated into the reference standard for diagnosis of active TB (i.e. if the IGRA result influences the
clinician’s investigation for, or diagnosis of, TB, then those classified as having active TB would be more
likely to have been from the IGRA-positive group, consequently favouring IGRAs). Although IGRAs are part
of the UK guidance, we limited the analysis to participants who were not treated for latent TB, minimising
incorporation bias. Participants were deliberately recruited from the groups that were not eligible for
treatment to ensure a higher probability of progression and to decrease incorporation bias.
The assessment for active TB by the central team was completed blind to IGRA results. As those
participants who were recruited in primary care were not referred for treatment of latent TB, we further
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minimised bias in subsequent active TB diagnoses. These measures minimised any bias arising from either
TST- or IGRA-positive results, leading to further TB investigations that might be more extensive than they
would be for those with a negative TST or IGRA results; this is the so-called ‘work-up bias’.
Despite the large sample size and numerous strengths of our design, our study has some limitations.
Although follow-up within the UK was extensive, it is likely that any participants who have left the UK
would not have been included in the progression data. We may therefore have underestimated the overall
progression rate; however, this effect is likely to be similar for the positive and negative groups as defined
by each assay.
High-quality studies of the predictive values of IGRAs require microbiological confirmation of cases.16 We
sought culture confirmation of all cases; however, consistent with variable confirmation rates for TB in the
UK, not all cases in this cohort were culture confirmed. Among the cases with culture confirmation and
results of MIRU-VNTR typing for both the index case and subsequent progressing case, nearly all had the
same fingerprint, with only two cases differing by one locus. This is consistent with the conclusion that,
at least for these cases, the observed incident cases are likely to have progressed from recent infection
(i.e. as a result of the contact with the index case just prior to recruitment). However, we cannot exclude the
possibility that index cases and contacts became infected with the same strain from a shared or different
source. Among migrants, we did not have information on the related source cases as transmission might
have occurred many years prior to recruitment to this study or overseas. We conducted a sensitivity analysis,
removing participants whose diagnosis of active TB was uncertain, and our results remained consistent with
the main analysis. Despite our large sample size, the trial may not have been adequately powered to detect
differences in subgroup analyses.
A further weakness of our study was the self-reported nature of comorbidities. We did not test participants
for a HIV infection or diabetes mellitus. Furthermore, our study protocol included secondary objectives to
investigate the prognostic value of IGRAs compared with TST for predicting active disease in HIV-infected
individuals, including those from high-burden countries and among those having treatment for LTBI. The
small number of participants having LTBI treatment and with self-reported HIV infection prevented us from
undertaking such analysis. Future analysis of this cohort should include record linkage to the national HIV
database to determine the predictive value of these assays in HIV-infected populations.
The health economic model had several strengths. The PREDICT study represents a much stronger evidence
base for modelling the predictive performance of LTBI test strategies than was available for previous economic
evaluations, with three main advantages. First, the cohort provides a coherent source of baseline data, including
risk factors and TST, QFT-GIT and T-SPOT.TB test results for large samples of new entrants and contacts being
tested for LTBI in the UK. These data integrate correlations between test results and between individual
characteristics, test results and eligibility for preventative treatment. Second, the long-term follow-up and
predictive modelling of TB incidence bypasses the problems of conventional diagnostic accuracy in the absence
of a reliable reference standard test. Third, this evidence source enables the comparison of two commercially
available IGRAs (T-SPOT.TB and QFT-GIT) and TST strategies with a single cut-off point (an induration of
≥ 5mm) or with different cut-off points for BCG-naive and BCG-experienced patients (indurations of ≥ 5mm
and ≥ 15mm, respectively). The model also allows for costs and delays in treatment associated with missing or
indeterminate results for each of these tests, as observed in the PREDICT cohort.
However, the model is subject to a number of limitations. Most significantly, in this project we were not
able to model the full population effect of better LTBI testing and treatment on the transmission of
M. tuberculosis. Thus, our model is likely to underestimate the health benefits and cost savings associated
with preventing progression within the cohort, making LTBI testing appear less cost-effective than it is
actually likely to be. If the rate of TB transmission in the community is very high, the net benefit per index
case prevented might be much higher than our estimate, possibly to the extent that a less discriminating
test than TSTb +QFT-GIT would become optimal. Adapting the economic model into a full-population
dynamic model is therefore a priority for future research. In a sensitivity analysis, we extended the model
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to estimate the impact of transmission using a simple cascading approach in which, for every case of
active TB (index case), four new secondary contacts entered the model through contact tracing. This
demonstrated that the addition of transmission made little difference to the cost-effectiveness results,
given the low incidence of TB in the PREDICT cohort. Although more cases of TB were simulated when
transmission was considered, the number of additional cases was small: 3–6 secondary cases were
generated in the model from contacts of 50–80 cases in the initial cohorts. Further analysis that varies
the number of contacts traced per case and TB incidence in the population being screened may be
worth exploring.
Quality-adjusted life-years were similar to life-years, which is partly attributable to the high quality of
life reported in the cohort: most participants reported a ‘perfect’ health state (an EQ-5D score of 11111).
This might reflect the nature of the population, which was mostly made up of young healthy individuals.
However, it is also possible that there might have been a degree of reporting bias; for example, new
entrants to the UK or people from vulnerable groups who were being tested for TB might not want to
report ill health. We also note that the QALY loss attributable to TB symptoms and treatment was relatively
modest; this is because of the rarity of progression and assumptions about the duration of symptoms and
impact on quality of life. We further note that, for simplicity, we did not introduce a reduction in quality of
life associated with ageing in the model. This means that the QALY estimates for all scenarios are likely to
be overestimated.
Other potentially important limitations of our analysis relate to the availability and use of data from
PREDICT, the paucity of good-quality evidence to inform some input parameter estimates, and our
modelling assumptions. First, we note that of the 9610 PREDICT participants included in the total analysis
(this excludes 175 participants who were treated for active TB and 260 who were treated for latent TB),
7957 had sufficient data for inclusion in our simulation data set (age, sex, BCG vaccination status, baseline
EQ-5D score and contact/migrant status). We did not attempt imputation for these missing data and,
therefore, our sample might be subject to selection bias, making the results less generalisable. We did
include patients in our data set who had missing or indeterminate results for one or more of the LTBI tests,
in order to model the costs and treatment delay associated with incomplete testing. This did, however,
necessitate assumptions to estimate TB hazard rates for the individuals within the simulation (see Table 6).
In addition, for participants with results for all three LTBI tests (TST, T-SPOT.TB and QFT-GIT), we estimated
hazards based only on the pair of tests with the best predictive value (the highest IRR for positive vs.
negative results). A more powerful approach might be to estimate hazards from a predictive equation
including all three tests and information on other baseline risk factors as covariates. We might also be
able to improve on our method for extrapolating incidence beyond the PREDICT follow-up period. We
used a simple calibration approach to fit a Weibull distribution to the observed IRs over 1, 2 and 3 years of
follow-up. A more thorough approach would be to estimate and compare alternative survival functions,
using statistical measures of fit (such as the Akaike information criterion) and also to consider other
external data for validation (e.g. considering the long-term incidence projection in relation to national
data). Finally, the model included a number of simplifying assumptions and some of the sources for input
parameter estimates were weak. In particular, estimates of rates of uptake, completion and duration of
treatment, delay from onset of symptoms to TB diagnosis and incidence and resolution of treatment-
related adverse events were based on informal estimates and might be improved. Assumptions were also
required to estimate the extent of utility loss associated with TB symptoms and treatment.
Clinical implications
Our results have implications for UK, and global, LTBI screening among contacts of TB cases and recent
migrants from high-TB-burden countries. In the UK, there are implications for NICE guideline recommendations
on contact investigation and for the NHS England/PHE screening programme.
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The current recommendation by NICE14 for contacts is to offer the Mantoux test using a 5-mm threshold as
the more cost-effective option, and to consider IGRAs if TST is not available. Our results suggest that a
two-step process using the more nuanced TSTb strategy, which stratifies the TST by prior BCG vaccination,
followed by an IGRA is the most cost-effective approach. Further analysis should examine the best
combination of risk factors among contacts that predicts greater cost-effectiveness.
The NHS England/PHE national TB screening programme for migrants from high-TB-burden countries
recommends a single IGRA as the optimal screening strategy. Our results suggest that a combination
of the TST and IGRA would provide better value for money. Data from this cohort should be used to
investigate the cost-effectiveness of the national screening programme, taking into account subsequent
transmission and baseline active TB cases detected. As the current analysis focuses primarily on the
comparison of the testing strategies using the entire cohort, it would be appropriate to examine various
thresholds; this could include limiting CEA to those arriving in the last 2 years or 5 years.
The global effort to expand LTBI screening to high-risk groups should take into account the relative
cost-effectiveness of screening in various populations. Low-TB-incidence countries, in which risk-group-
based screening is currently recommended by WHO, should examine which groups are most likely to
benefit from treatment to inform national testing policy.
Implications for research
Our results suggest that the probability of cases arising as a result of new infection in this low-incidence
setting, the absolute risk of progression in IGRA- or TST-positive individuals and the discriminatory power
of these tests are all low. Further research to develop new markers with better predictive ability utilising
transcriptomics, new antigens and cytokines, metabolomics and proteomics are ongoing.
Our results indicate that the need for tests with improved predictive value remains. Ongoing work with
the PREDICT biobank will probably result in better biomarkers for progression and the development of
new assays. The cost-effectiveness of these new assays, using progression data from this study, should
be assessed.
It is also likely that the future risk of TB and, therefore, the ability of biomarkers to correctly predict who
will develop active TB, is influenced by subsequent changes that are not apparent at baseline. For example,
exogenous events such as a new HIV infection after the time of the IGRA or TST or the development
of other immunocompromising conditions or treatment that suppresses immunity will alter the risk of
progression to active TB. The follow-up data collected should inform analysis that takes into account these
changing risks in predictive models.
The low probability of progression to active TB, based on IGRAs and the TST, limits the value of latent TB
screening and treatment, making the development of an affordable vaccine that will prevent progression
to active TB in those already exposed to TB more important. The widespread treatment of populations in
which people may have a positive IGRA or TST result is unlikely to be cost-effective if it is not focused on
the highest-risk groups.
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Appendix 1 List of participating sites
l Royal Free London NHS Foundation Trust.
l Imperial College Healthcare NHS Trust.
l Homerton Hospital.
l North Middlesex University Hospital NHS Trust.
l Whittington Hospital.
l Barnet and Chase Farm NHS Hospitals Trust.
l Barts Health NHS Trust.
l Charing Cross Hospital.
l Northwick Park Hospital.
l Central Middlesex Hospital.
l Ealing Hospital.
l St George’s Hospital.
l Whipps Cross University Hospital.
l Newham General Hospital.
l Tower Hamlets PCT.
l City and Hackney PCT.
l University College London Hospital.
l Newham PCT.
l Westminster PCT.
l Lambeth PCT.
l Hillingdon Hospital NHS Trust.
l Croydon Health Services NHS Trust.
l Chelsea and Westminster Hospital NHS Foundation Trust.
l King’s College Hospital NHS Foundation Trust.
l South London Healthcare NHS Trust.
l West Middlesex University Hospital.
l Guy’s and St Thomas’ NHS Foundation Trust.
l Heart of England NHS Foundation Trust.
l Barking, Havering and Redbridge University Hospitals NHS Trust.
l NHS Brent (PCT).
l NHS Harrow (PCT).
l NHS Hillingdon (PCT).
l Leicester PCT.
l Greenwich Teaching PCT.
l Heart of Birmingham PCT.
l NHS Hounslow (PCT).
l NHS Birmingham.
l South Birmingham PCT.
l Solihull PCT.
l Kingston PCT.
l Croydon PCT.
l Sutton and Merton PCT.
l Wandsworth PCT.
l Sandwell PCT.
l Manchester University NHS Foundation Trust.
l Barnet PCT.
l Camden PCT.
l Enfield PCT.
l Haringey Teaching PCT.
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l Hammersmith and Fulham PCT.
l Ealing PCT.
l Sandwell and West Birmingham Hospitals.
l University Hospitals of Leicester NHS Trust.
l Coventry and Warwickshire Partnership NHS Trust.
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Appendix 2 Supplementary results
TABLE 44 Full cross-tabulation of results with TSTa; values are (progressors) total numbers
QFT-GIT result
T-SPOT.TB result
TotalPositive
Borderline
positive
Borderline
negative Negative Indeterminate Error Missing
TSTa positive
Positive (39) 745 (2) 52 24 (3) 225 11 16 (3) 40 (47) 1113
Negative (7) 124 (1) 49 41 (13) 1750 (1) 34 27 80 (22) 2105
Indeterminate 18 0 1 (1) 30 2 1 (1) 20 (2) 72
Error 6 0 1 9 0 0 0 16
Missing (2) 21 5 0 16 0 3 (4) 162 (6) 207
Total (48) 914 (3) 106 67 (17) 2030 (1) 47 47 (8) 302 (77) 3513
TSTa negative
Positive (2) 170 (2) 25 8 222 4 7 14 (4) 450
Negative (2) 56 (7) 34 29 2966 54 89 145 (1) 3373
Indeterminate 0 (1) 0 0 33 1 1 19 (1) 54
Error 3 0 1 30 0 1 0 35
Missing 20 4 4 121 1 0 (1) 258 (1) 408
Total (4) 249 (6) 63 42 3372 60 98 (1) 436 (15) 4320
TSTa missing
Positive (1) 174 10 6 46 (1) 3 27 63 329
Negative 26 10 7 (2) 795 8 84 232 1162
Indeterminate 5 0 3 10 2 0 17 37
Error 2 0 0 8 0 3 1 14
Missing 11 1 1 27 1 1 (1) 193 235
Total (1) 218 21 17 (2) 886 (1) 14 115 (1) 506 (5) 1777
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TABLE 45 Full cross-tabulation of results with TSTb; values are (progressors) total numbers
QFT-GIT result
T-SPOT.TB result
TotalPositive
Borderline
positive
Borderline
negative Negative Indeterminate Error Missing
TSTb positive
Positive (36) 585 35 12 (2) 112 6 8 (3) 27 (41) 785
Negative (6) 68 (1) 21 19 (7) 636 (1) 16 8 32 (15) 800
Indeterminate 14 0 0 10 1 0 (1) 11 (1) 36
Error 6 0 1 0 0 0 0 7
Missing (2) 12 2 0 5 0 2 (1) 80 (3) 101
Total (44) 685 (1) 58 32 (9) 763 (1) 23 18 (5) 150 (60) 1729
TSTb negative
Positive (5) 317 (1) 39 20 (3) 325 8 15 25 (9) 749
Negative (3) 111 60 50 (13) 3976 71 107 188 (16) 4563
Indeterminate 4 0 1 (2) 52 2 2 28 (2) 89
Error 3 0 1 38 0 1 0 43
Missing 29 7 4 131 1 1 (4) 323 (4) 496
Total (8) 464 (1) 106 76 (18) 4522 82 126 (4) 564 (31) 5940
TSTb missing
Positive (1) 187 (1) 13 6 56 (1) 4 27 65 (3) 358
Negative 27 12 8 (2) 899 9 85 237 (2) 1277
Indeterminate 5 0 3 11 2 0 17 38
Error 2 0 0 9 0 3 1 15
Missing 11 1 1 28 1 1 (1) 210 (1) 253
Total (1) 232 (1) 26 18 (2) 1003 (1) 16 116 (1) 530 (6) 1941
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TABLE 46 Cross-tabulations of test results for progressors
QFT-GIT
Test result, n (%)
TSTa positive TSTa negative TSTa missing
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
Positive 41 (53.2) 3 (3.9) 3 (3.9) 47 (61.0) 2 (13.3) 2 (13.3) 0 (0.0) 4 (26.7) 1 (20.0) 0 (0.0) 1 (20.0) 2 (40.0)
Negative 8 (10.4) 13 (16.9) 1 (1.3) 22 (28.6) 2 (13.3) 7 (46.7) 0 (0.0) 9 (60.0) 0 (0.0) 2 (40.0) 0 (0.0) 2 (40.0)
Missing 2 (2.6) 1 (1.3) 5 (6.5) 8 (10.4) 0 (0.0) 1 (6.7) 1 (6.7) 2 (13.3) 0 (0.0) 0 (0.0) 1 (20.0) 1 (20.0)
Total 51 (66.2) 17 (22.1) 9 (11.7) 77 (100.0) 4 (26.7) 10 (66.7) 1 (6.7) 15 (100.0) 1 (20.0) 2 (40.0) 2 (40.0) 5 (100.0)
TABLE 47 Cross-tabulations of test results for non-progressors
QFT-GIT
Test result, n (%)
TSTa positive TSTa negative TSTa missing
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
Positive 756 (22.0) 246 (7.2) 64 (1.9) 1066
(31.0)
193 (4.5) 228 (5.3) 25 (0.6) 446 (10.4) 183 (10.3) 52 (2.9) 92 (5.2) 327 (18.5)
Negative 165 (4.8) 1778
(51.7)
140 (4.1) 2083
(60.6)
88 (2.0) 2988
(69.4)
288 (6.7) 3364
(78.1)
36 (2.0) 800 (45.1) 324 (18.3) 1160
(65.5)
Missing 48 (1.4) 56 (1.6) 183 (5.3) 287 (8.4) 27 (0.6) 188 (4.4) 280 (6.5) 495 (11.5) 19 (1.1) 49 (2.8) 217 (12.2) 285 (16.1)
Total 969 (28.2) 2080
(60.5)
387 (11.3) 3436
(100.0)
308 (7.2) 3404
(79.1)
593 (13.8) 4305
(100.0)
238 (13.4) 901 (50.8) 633 (35.7) 1772
(100.0)
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TABLE 48 Cross-tabulations of test results for progressors
QFT-GIT
Test result, n (%)
TSTb positive TSTb negative TSTb missing
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
Positive 36 (60.0) 2 (3.3) 3 (5.0) 41 (68.3) 6 (19.4) 3 (9.7) 0 (0.0) 9 (29.0) 2 (33.3) 0 (0.0) 1 (16.7) 3 (50.0)
Negative 7 (11.7) 7 (11.7) 1 (1.7) 15 (25.0) 3 (9.7) 13 (41.9) 0 (0.0) 16 (51.6) 0 (0.0) 2 (33.3) 0 (0.0) 2 (33.3)
Missing 2 (3.3) 0 (0.0) 2 (3.3) 4 (6.7) 0 (0.0) 2 (6.5) 4 (12.9) 6 (19.4) 0 (0.0) 0 (0.0) 1 (16.7) 1 (16.7)
Total 45 (75.0) 9 (15.0) 6 (10.0) 60 (100.0) 9 (29.0) 18 (58.1) 4 (12.9) 31 (100.0) 2 (33.3) 2 (33.3) 2 (33.3) 6 (100.0)
TABLE 49 Cross-tabulations of test results for non progressors
QFT-GIT
Test result, n (%)
TSTb positive TSTb negative TSTb missing
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
T-SPOT.TB
positive
T-SPOT.TB
negative
T-SPOT.TB
missing
T-SPOT.TB
total
Positive 584 (35.0) 122 (7.3) 38 (2.3) 744 (44.6) 350 (5.9) 342 (5.8) 48 (0.8) 740 (12.5) 198 (10.2) 62 (3.2) 95 (4.9) 355 (18.3)
Negative 82 (4.9) 648 (38.8) 55 (3.3) 785 (47.0) 168 (2.8) 4013 (67.9) 366 (6.2) 4547 (77.0) 39 (2.0) 905 (46.8) 331 (17.1) 1275 (65.9)
Missing 32 (1.9) 16 (1.0) 92 (5.5) 140 (8.4) 43 (0.7) 225 (3.8) 354 (6.0) 622 (10.5) 19 (1.0) 52 (2.7) 234 (12.1) 305 (15.8)
Total 698 (41.8) 786 (47.1) 185 (11.1) 1669 (100.0) 561 (9.5) 4580 (77.5) 768 (13.0) 5909 (100.0) 256 (13.2) 1019 (52.7) 660 (34.1) 1935 (100.0)
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TSTa
Negative
Positive
Total
3410
2893
6303
13
64
77
3423
2957
6380
No TB TB Total
T-SPOT.TB
Negative
Positive
Total
1987
906
2893
16
48
64
2003
954
2957
No TB TB Total
      QFT-GIT
Negative
Positive
Total
1908
985
2893
21
43
64
1929
1028
2957
No TB TB Total
IGRA
Negative
Positive
Total
1745
1148
2893
13
51
64
1758
1199
2957
No TB TB Total
FIGURE 12 Two-step strategies with TSTa as the first test.
TSTb
Negative
Positive
Total
4870
1433
6303
25
52
77
4895
1485
6380
No TB TB Total
T-SPOT.TB
Negative
Positive
Total
767
666
1433
9
43
52
776
709
1485
No TB TB Total
      QFT-GIT
Negative
Positive
Total
727
706
1433
14
38
52
741
744
1485
No TB TB Total
IGRA
Negative
Positive
Total
645
788
1433
7
45
52
652
833
1485
No TB TB Total
FIGURE 13 Two-step strategies with TSTb as the first test.
DOI: 10.3310/hta22560 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 56
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Abubakar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
T-SPOT.TB
Negative
Positive
Total
5120
1183
6303
25
52
77
5145
1235
6380
No TB TB Total
TSTa
Negative
Positive
Total
277
906
1183
4
48
52
281
954
1235
No TB TB Total
TSTb
Negative
Positive
Total
517
666
1183
9
43
52
526
709
1235
No TB TB Total
      QFT-GIT
Negative
Positive
Total
250
933
1183
10
42
52
260
975
1235
No TB TB Total
FIGURE 14 Two-step strategies with T-SPOT.TB as the first test.
TABLE 50 Sensitivity analysis: IRs and IRRs when excluding those with assumed BCG vaccination status
Progression measure
TSTb result
TSTb result (assumed BCG
vaccination status excluded)
Positive Negative Positive Negative
Progression (n/N) 52/1485 25/4895 44/1320 23/4273
Years at risk 4674.8 15,896.6 4173.9 13,882.2
IR (per 1000 participants per annum) 11.1 1.6 10.5 1.7
95% CI 8.3 to 14.6 1.0 to 2.3 7.7 to 14.2 1.1 to 2.5
IRR (per 1000 per annum) 7.1 6.4
95% CI 4.4 to 11.4 3.8 to 10.5
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TABLE 51 Sensitivity analysis: IRs and IRRs for each single test when excluding less-certain progressors
Progression measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
No exclusions
Progression (n/N) 52/1235 25/5145 47/1444 30/4936 64/2957 13/3423 52/1485 25/4895
Years at risk 3926.2 16,645.3 4649.9 15,921.6 9416.8 11,154.6 4674.8 15,896.6
IR (per 1000 per annum) 13.2 1.5 10.1 1.9 6.8 1.2 11.1 1.6
95% CI 9.9 to 17.4 1.0 to 2.2 7.4 to 13.4 1.3 to 2.7 5.2 to 8.7 0.6 to 2.0 8.3 to 14.6 1.0 to 2.3
IRR (per 1000 per
annum)
8.8 5.4 5.8 7.1
95% CI 5.5 to 14.2 3.4 to 8.5 3.2 to 10.6 4.4 to 11.4
Excluding less-certain progressors
Progression (n/N) 49/1232 23/5143 44/1441 28/4934 60/2953 12/3422 48/1481 24/4894
Years at risk 3925.5 16,644.9 4649.2 15,921.2 9415.9 11,154.5 4673.9 15,896.5
IR (per 1000 per annum) 12.5 1.4 9.5 1.8 6.4 1.1 10.3 1.5
95% CI 9.2 to 16.5 0.9 to 2.1 7.7 to 14.2 1.2 to 2.5 4.9 to 8.2 0.6 to 1.9 7.6 to 13.6 1.0 to 2.2
IRR (per 1000 per
annum)
9.0 5.4 5.9 6.8
95% CI 5.5 to 14.8 3.4 to 8.6 3.2 to 11.0 4.2 to 11.1
TABLE 52 Sensitivity analysis: IRs and IRRs using all available test data (for participants with study time data)
Progression measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
Must have data for all tests (n = 6380)
Progression (n/N) 52/1235 25/5145 47/1444 30/4936 64/2957 13/3423 52/1485 25/4895
Years at risk 3926.2 16,645.3 4649.9 15,921.6 9416.8 11,154.6 4674.8 15,896.6
IR (per 1000 per annum) 13.2 1.5 10.1 1.9 6.8 1.2 11.1 1.6
95% CI 9.9 to 17.4 1.0 to 2.2 7.4 to 13.4 1.3 to 2.7 5.2 to 8.7 0.6 to 2.0 8.3 to 14.6 1.0 to 2.3
IRR (per 1000 per
annum)
8.8 5.4 5.8 7.1
95% CI 5.5 to 14.2 3.4 to 8.5 3.2 to 10.6 4.4 to 11.4
All available data for each test
Progression n/N 56/1566 29/6402 53/1888 33/6624 77/3510 15/4315 60/1726 31/5935
Years at risk 4633.6 19,506.8 5605.5 19,541.2 10,831.2 13,365.2 5285.7 18,372.6
IR (per 1000 per annum) 12.1 1.5 9.5 1.7 7.1 1.1 11.4 1.7
95% CI 9.1 to 15.7 1.0 to 2.1 7.1 to 12.4 1.2 to 2.4 5.6 to 8.9 0.6 to 1.9 8.7 to 14.6 1.1 to 2.4
IRR (per 1000 per
annum)
8.1 5.6 6.3 6.7
95% CI 5.2 to 12.7 3.6 to 8.6 3.6 to 11.0 4.4 to 10.4
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TABLE 53 Sensitivity analysis: IRs and IRRs using data for new entrants who were followed up for 2 years
(no exclusions)
Progression measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
Progression (n/N) 11/280 3/994 9/318 5/956 11/588 3/686 9/283 5/991
Years at risk 940.9 3321.8 1075.9 3186.8 1967.9 2294.7 948.4 3314.2
IR (per 1000 per
annum)
11.7 0.9 8.4 1.6 5.6 1.3 9.5 1.5
95% CI 5.8 to 20.9 0.2 to 2.6 3.8 to 15.9 0.5 to 3.7 2.8 to 10.0 0.3 to 3.8 4.3 to 18.0 0.5 to 3.5
IRR (per 1000 per
annum)
12.9 5.3 4.3 6.3
95% CI 3.6 to 46.4 1.8 to 15.9 1.2 to 15.3 2.1 to 18.8
TABLE 54 Sensitivity analysis: IRs and IRRs using data from contacts of patients with pulmonary TB (no exclusions)
Progression measure
Test and result
T-SPOT.TB QFT-GIT TSTa TSTb
Positive Negative Positive Negative Positive Negative Positive Negative
Progression (n/N) 9/171 4/804 8/212 5/763 13/509 0/466 10/264 3/711
Years at risk 584.5 2752.4 741.8 2595.1 1725.2 1611.6 885.2 2451.6
IR (per 1000 per
annum)
15.4 1.5 10.8 1.9 7.5 0.0 11.3 1.2
95% CI 7.0 to 29.2 0.4 to 3.7 4.7 to 21.3 0.6 to 4.5 4.0 to 12.9 0.0 to 2.3 5.4 to 20.8 0.3 to 3.6
IRR (per 1000 per
annum)
10.6 5.6 N/A 9.2
95% CI 3.3 to 34.4 1.8 to 17.1 N/A 2.5 to 33.5
N/A, not available.
TABLE 55 Combinations of TST results
Progression measure
TSTa/TSTb results
Positive/positive Positive/negative Negative/negative
Progression (n/N) 52/1485 13/3423 12/1472
Years at risk 4674.8 4742.0 11,154.6
IR (per 1000 per annum) 11.1 2.5 1.2
95% CI 8.3 to 14.6 1.3 to 4.4 0.6 to 2.0
Note
It is not possible to be TSTa negative and TSTb positive.
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Used a 1.5% discount rate for quality-adjusted life-years while retaining
a 3.5% discount rate for costs
Maintaining the base-case discount rate of 3.5% for costs, we adjusted the discount rate for effects to
1.5% and, when necessary, we applied an instantaneous rate (the natural log of 1.5%). Compared with
the base case, the three most cost-effective strategies maintain their positions in both subgroups, with
similar probabilities of cost-effectiveness. There is, however, a notable increase in the number of discounted
QALYs in both subgroups.
TABLE 56 The modelled costs and effects based on a discount rate of 3.5% for costs and 1.5% for QALYs: contacts
(mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test) £20,000 per QALY
Cost (£) QALYs Cost (£) QALYs INB* (£) Probability† (%)
0: TSTa 301.33 32.43492 272.38 0.00046 263.18 0
3: TSTa+ IGRA 242.07 32.43482 213.12 0.000359 205.93 0
4: TSTb 224.36 32.4349 195.40 0.000441 186.58 0
2: TSTa+ T-SPOT.TB 213.28 32.43477 184.32 0.000315 178.01 0
9: T-SPOT.TB 204.38 32.43476 175.42 0.000302 169.39 0
1: TSTa+QFT-GIT 204.75 32.43478 175.79 0.000323 169.34 0
7: TSTb + IGRA 205.34 32.43482 176.39 0.000356 169.27 0
6: TSTb + T-SPOT.TB 191.39 32.43476 162.43 0.000303 156.37 0
8: QFT-GIT 187.69 32.43474 158.73 0.000279 153.15 40
5: TSTb +QFT-GIT 184.99 32.43478 156.03 0.000324 149.55 60
10: no test 28.96 32.43446 0.00 0 0.00 0
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
TABLE 57 The modelled costs and effects based on a discount rate of 3.5% for costs and 1.5% for QALYs: new
entrants (mean of 500 PSA iterations)
Strategy
Mean per patient (discounted) Incremental (vs. no test) £20,000 per QALY
Cost (£) QALYs Cost (£) QALYs INB* (£) Probability† (%)
0: TSTa 273.49 30.55115 246.11 0.00046 236.92 0
3: TSTa+ IGRA 233.27 30.55111 205.89 0.000418 197.54 0
9: T-SPOT.TB 218.04 30.55114 190.66 0.000449 181.69 0
2: TSTa+ T-SPOT.TB 211.33 30.55108 183.95 0.000393 176.09 0
4: TSTb 205.62 30.55108 178.25 0.000394 170.37 0
1: TSTa+QFT-GIT 201.82 30.55105 174.44 0.00036 167.25 0
7: TSTb + IGRA 198.08 30.55109 170.70 0.000401 162.68 0
8: QFT-GIT 192.83 30.55112 165.46 0.000433 156.80 7
6: TSTb + T-SPOT.TB 187.57 30.55107 160.19 0.00038 152.59 2
5: TSTb +QFT-GIT 182.55 30.55103 155.17 0.000346 148.25 91
10: No test 27.38 30.55069 0.00 0 0.00 0
*Incremental net benefit at a cost-effectiveness threshold of £20,000 per QALY, compared with ‘no test’.
†Probability that strategy is the most cost-effective of the LTBI test strategies (at £20,000 per QALY).
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TABLE 58 The modelled costs and effects allowing for transmission: contacts (mean of 5000 PSA iterations)
Strategy
Original cohort (contacts) Secondary contacts of index cases
Mean costs (£)
combined
(discounted)
Mean number of
QALYs combined
(discounted)
Number
of TB
cases
Number
in cohort
TB incidence
per 10,000
patients
Mean number
of discounted
QALYs
Number
of TB
cases
Number of
secondary
contacts
TB incidence
per 10,000
patients
Mean number
of discounted
QALYs
0: TSTa 60 4162 145 22.13163 4 250 150 22.11595 302 22.13084
1: TSTa+QFT-GIT 67 4162 160 22.13151 5 278 166 22.11877 204 22.13082
2: TSTa+ T-SPOT.TB 67 4162 161 22.13150 5 279 166 22.11905 213 22.13083
3: TSTa+ IGRA 65 4162 156 22.13155 4 271 162 22.11736 242 22.13080
4: TSTb 63 4162 152 22.13160 4 263 158 22.11746 224 22.13087
5: TSTb+QFT-GIT 67 4162 162 22.13151 5 280 167 22.11921 185 22.13084
6: TSTb+ T-SPOT.TB 67 4162 161 22.13150 5 280 166 22.11915 191 22.13083
7: TSTb+ IGRA 66 4162 158 22.13155 4 274 163 22.11805 205 22.13084
8: QFT-GIT 65 4162 157 22.13154 4 271 162 22.11755 187 22.13080
9: T-SPOT.TB 66 4162 158 22.13152 4 273 162 22.11852 204 22.13085
10: no test 79 4162 189 22.13122 6 330 195 22.12407 29 22.13076
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TABLE 59 The modelled costs and effects allowing for transmission: new entrants (mean of 5000 PSA iterations)
Strategy
Original cohort (contacts) Secondary contacts of index cases
Mean costs (£)
combined
(discounted)
Mean QALYs
combined
(discounted)
Number
of TB
cases
Number
in cohort
TB incidence
per 10,000
patients
Mean number
of discounted
QALYs
Number
of TB
cases
Number of
secondary
contacts
TB incidence
per 10,000
patients
Mean number
of discounted
QALYs
0: TSTa 51 3795 135 21.04275 3 212 150 22.11809 275 21.09962
1: TSTa+QFT-GIT 55 3795 145 21.04265 4 230 166 22.11829 202 21.10401
2: TSTa+ T-SPOT.TB 55 3795 145 21.04265 4 229 166 22.11728 211 21.10384
3: TSTa+ IGRA 54 3795 142 21.04270 4 224 162 22.11736 234 21.10249
4: TSTb 54 3795 141 21.04274 4 223 157 22.11721 206 21.10220
5: TSTb+QFT-GIT 56 3795 146 21.04266 4 232 167 22.11816 182 21.10445
6: TSTb+ T-SPOT.TB 55 3795 146 21.04266 4 231 167 22.11774 187 21.10430
7: TSTb+ IGRA 54 3795 143 21.04271 4 226 163 22.11729 198 21.10307
8: QFT-GIT 53 3795 139 21.04269 4 219 162 22.11858 193 21.10139
9: T-SPOT.TB 53 3795 138 21.04270 4 219 163 22.11843 217 21.10130
10: No test 68 3795 179 21.04237 6 285 194 22.12137 27 21.11764
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